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Abstract
Infectious Mononucleosis (IM) is one of the most common serious illnesses in young
adults, and is caused by delayed primary infection with Epstein-Barr Virus (EBV).
The characteristic clinical features are thought to be due to extensive T cell
activation, and cytokine production, but the molecular mechanisms underlying this
are unclear. SAP (Surface Lymphocyte Activation Marker (SLAM) associated
protein), is mutated in X-linked lymphoproliferative disease (XLP), in which fatal
IM occurs, and is a key regulator of lymphocyte activation via signals from cell
surface 2B4 (CD244) and SLAM. Our aim was to monitor T cell activation via this
SAP/SLAM/CD244 pathway, and analyse whether the scale of activation was related
to the severity of clinical features in a cohort of 26 cases of IM. In addition, 10 males
with fulminant IM were screened for XLP gene mutations but none were identified.
At diagnosis of IM, SAP, CD244 and SLAM were significantly upregulated,
compared to controls, on both CD4 and CD8 T cells in peripheral blood (p<0.01).
The expression fell over the course of IM, but CD244 and SLAM remained elevated
on CD8 cells at one month post diagnosis. The numbers of lymphocytes expressing
CD8, and CD244/CD8 were significantly higher in cases with severe compared to
mild sore throat (p<0.05). Both expression of CD8, and expression of CD244 on
CD8 cells correlated positively with increased viral load (p<0.05).
Time is required for this antigen specific immune response to develop. In contrast
innate immune responses, such as Natural Killer (NK) cells are thought to be vital
early in the infection process. We show that NK cell numbers are significantly
elevated at diagnosis of IM compared to controls (p<0.01) and in the first month
following diagnosis.
In healthy adults, 2 distinct populations ofNK cells have been identified by the
density of cell surface expression of CD56; these subsets of CD56b"ght and CD56dim
cells differ in their ability to produce cytokines and lyse target cells. We have
identified significant changes in NK cell phenotype and function during IM, with an
increase in the proportion of CD56bllght cells, and cells showing an enhanced ability
to kill an EBV infected cell line.
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We suggest that activated T cells expressing CD244 modulate the clinical features of
IM, but control of activation is maintained by concurrent increased expression of
SAP. However, before this occurs NK cells have a critical role in both eliminating
infected B cells and augmenting this antigen specific T cell response via release of
immunomodulatory cytokines. The magnitude of the NK cell response may
ultimately determine whether primary EBV infection has a subclinical or clinical
outcome.
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1 Aims
• To screen a series of 10 males with fulminant IM or unexplained severe primary
EBV infection for mutations in the XLP gene SAP/SH2D1A.
• To establish a cohort of young adults with IM, and to collect concurrent data on
the clinical course of the illness from diagnosis to recovery, and samples for
laboratory analysis (serum, viable PBMC, and DNA).
• To investigate the expression of the SAP/SLAM/CD244 lymphocyte activation
pathway, which is mutated in XLP, at diagnosis and during recovery from IM in
healthy young adults. To analyse the relationship between the scale of this
immune response and the clinical features of IM in this cohort.
• To investigate the scale, phenotype, and function of the innate natural killer cell
response at diagnosis and during recovery from acute IM.
Aims 16




Epstein Barr Virus (EBV) is a member of the herpes virus family; all herpes viruses
have a comparable structure, and typically this consists of a core of linear double
stranded DNA, surrounded by a protein tegument and an envelope with viral
glycoprotein spikes (Roizman B, 1996).
All herpes viruses have a similar life cycle exemplified by their ability to persist in
the host for life. In the vast majority of healthy carriers the viruses cause limited or
no disease. This is because a delicate balance is maintained between the host immune
system, which limits production of new virus, and the virus, which persists and is
successfully transmitted in the face of host anti viral immunity. Disruption of this
balance, due to primary or acquired abnormalities of the host's immune system, may
lead to the development of virus associated disease.
Three subfamilies of herpes viruses are recognised, alpha, beta and gamma, and this
division has been made on the basis of biological properties, such as host range and
site of latency (Roizman B, 1996). Eight different herpes viruses are recognised to
infect humans: these are herpes simplex virus (HSV) 1 and 2, varicella zoster virus
(VZV), human cytomegalovirus (HCMV), human herpes virus 6 and 7 (HHV6 and
7), EBV, and Kaposi's sarcoma associated herpes virus (KSHV). The clinical
conditions associated with both primary infection and reactivation are detailed in
Table 2-1 (page 18), additionally the subfamily to which the virus belongs is shown.
The chief characteristics of the gamma herpes viruses, of which EBV is a member,
are target cells of lymphoid and in some cases epithelial cell origin, and a site of
latency which is frequently lymphoid tissue.
The EBV genome was the first herpes virus to be sequenced; it consists of a linear,
double stranded 184-kilobase pair DNA (http://www.med.ic.ac.uk/ludwig/EBV.htm).
EBV has coding potential for about 70 proteins. The genomes of the herpes viruses
vary from 31-75 percent guanine or cytosine, and that of EBV is composed of 60
percent guanine or cytosine (Pritchett et ah, 1975).
Introduction 17
An analysis of the immune response to primary Epstein- Barr Virus infection and the association with
clinical events
The other herpes virus discussed in this thesis is VZV, which has a genome of
125000 base pairs (Davison and Scott, 1986). The early genes induce replication of
viral DNA, and include viral thymidine kinase, a key target of anti viral drugs. The
late genes encode structural components of the virion, the viral glyoproteins and
envelope. The viral glycoproteins, VZV gH and VZV gC are both thought to mediate
viral entry and are targets of neutralising antibody.
Table 2-1 Human herpes virus infections and associated diseases.
Virus Subfamily Disease Association
Primary infection Reactivation
Herpes simplex virus 1 Alpha Cold sore Cold sore
Herpes simplex vims 2 Alpha Genital herpes Genital herpes
Varicella zoster vims Alpha Chicken pox
(varicella)
Shingles (Zoster)
Cytomegalovirus Beta IM - like illness Retinitis, Colitis,
Pneumonitis
Human herpes vims 6 Beta Exanthum subitum
(Roseola infantum)
Unknown
Human herpes vims 7 Beta Exanthum subitum
(rarely)
Unknown












EBV is one of the most studied herpes viruses and has particularly attracted interest
because of its oncogenic potential. Indeed, EBV was first identified in cultures from
biopsies of Burkitt's lymphomas from Africa (Epstein MA, 1964); and shortly
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afterwards was reported to transform B cells to long lived lymphoblastoid cell lines
(Pope et al., 1968a).
The link between EBV and infectious mononucleosis (IM) was also quickly
established. EBV was identified as the culprit virus when a female technician
working in a laboratory studying EBV developed IM, and was found to have
developed EBV antibodies during the course of the acute illness (Henle et al., 1968).
Subsequently, a serological study was undertaken of new students at Yale University,
and thus delayed primary EBV infection was confirmed to be the most common
aetiology underlying acute IM (Niederman et al., 1970). These studies are discussed
in more detail later in the section on IM (Section 2.6.1 page 28). Over the next ten
years it also became apparent that very occasionally primary EBV infection could
cause a severe, often fatal illness, known as fulminant IM (Purtilo et al., 1975). The
recognition that this occurred in maternally related male children led to the
identification of the X linked lymphoproliferative syndrome (XLPS).
Interest in EBV has continued over the subsequent 35 years with the recognition that
the virus plays a central role in the development of a number of lymphoid and
epithelial cell-derived cancers. Many EBV linked tumours show marked
geographical variation. China and South East Asia have the highest prevalence;
where both the majority of nasopharngeal carcinomas (Wolf et al., 1973; zur et al.,
1970) and up to 15 percent of stomach cancers are linked to EBV (Shibata and
Weiss, 1992). EBV is linked with childhood Burkitt's lymphoma in Africa (Epstein
MA, 1964) and throughout the world is recognised to have an important role in the
aetiology of Hodgkin's disease (Weiss et al., 1989). Other groups of tumours occur
in the immunosuppressed, and these include AIDS related non-Hodgkin's lymphoma
(NHL) (Boshoff and Weiss, 2002), and B cell lymphoproliferative disease (BLPD)
(Crawford et al., 1980). EBV related tumours are not discussed any further, however.
Table 2-2 (page 20) and Table 2-3 (page 21) provide a summary of EBV associated
diseases.
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Table 2-2 EBV associated diseases of lymphocyte origin
Disease Population at risk EBV association








HIV infection- primary central nervous




Burkitt's lymphoma (BL) African children 97-100%
HIV infection >25%
Hodgkin's disease (HD) Children -developing countries
Young adults- high socioeconomic
groups and history of IM
40-80% depending
on type
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Table 2-3 EBV associated disease of epithelial cell origin
Disease Population at risk EBV association
Oral hairy leukokplakia HIV and other immunodeficiencies 100%
Nasopharyngeal carcinoma S.Chinese and Inuit races- high
incidence




Gastric carcinoma Not identified Adenocarcinoma
5-15%
Leiomyosarcoma HIV and immunodeficiency Not known
2.3 Epidemiology of EBV
Primary infection with EBV is commonly sub-clinical, occurs predominately in early
childhood, and gives rise to a lifelong carrier state (Fleisher et al., 1979). In most
populations seropositivity increases with age, and over 90% of adults have persistent
infection. However, the rate of seroconversion varies according to economic status.
Over 90% of children over 2 years in developing countries have evidence of
persistent infection (Biggar et al., 1978; Haque et al., 1996), whereas seroconversion
may be delayed until adolescence in high socio-economic groups in industrialised
countries (2.6.1 page 28). The virus is present in saliva (Gerber et al., 1972), and it is
thought that close family contact is the main route of spread in young infants, and
therefore large family size and close proximity of living conditions are likely to aid
spread. In the west 5-10 % of people remain EBV negative for life, whereas in Africa
over 97% of the population carries the virus (Essers et al., 1991). The reasons for
this difference remain unclear.
2.4 Virus subtypes
Most healthy hosts carry only one of the two major virus subtypes of EBV, 1 or 2
(also called A and B respectively). The subtypes have 70-80% sequence homology,
and differ mainly in the genes which encode EBV nuclear antigens (EBNA)-2, -3A, -
3B and -3C (Rickinson and Kieff, 2003). Type 1 is the most common throughout the
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world; type 2 is rare, but is more prevalent in Africa and the Far East than the West
(Zimber et ah, 1986). In addition to the subtypes, minor sequence variants are
classified as strains and are usually unique to one individual, although recent data
suggest even healthy individuals may harbour more than one strain (Sitki-Green et
al., 2003). There is no evidence that variation of either strain or type affects clinical
pathogenesis.
2.5 EBV life cycle and patterns of viral latency
2.5.1 Cellular events of primary infection
EBV infects B cells via binding of the major viral envelope glycoprotein (gp 350)
(Tanner et al., 1987) to the CD21 receptor on resting B cells (Nemerow et al., 1986).
There has been a long standing debate as to additional cell types targeted in healthy
carriers; viral colonisation of B cells is well defined but whether infection also occurs
in epithelial cells is still under debate (Faulkner et al., 2000). Several histological
studies of IM tonsils have identified infected B cells around the tonsillar crypts, but
did not find any evidence of infection of epithelial cells (Niedobitek et al., 1989).
Additionally, a study on individuals with X-linked agammaglobulinaemia, who lack
B cells, found no evidence of either past or present EBV infection. This suggests
EBV colonisation can not occur in the absence of normal B cells (Faulkner et al.,
1999).
On the other hand EBV can be detected in and definitively linked to the pathogenesis
of epithelial cell diseases. These include oral hairy leukoplakia (Greenspan et al.,
1985), a benign infection of squamous epithelial cells on the tongue that occurs in the
immunosuppressed, and malignant nasopharyngeal carcinoma (Raab-Traub, 1992).
One possible explanation for the difficulties in identifying EBV infection in
epithelial cells from healthy virus carriers is that the infection is a transient event.
Borza and Hutt-Fletcher identified differences between the viral progeny of epithelial
and B cells in vitro, and showed that these changes identified in the viral envelope
were associated with changes in viral tropism. They suggest that epithelial cells are
transiently infected in primary infection, but that virus produced at this site is
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particularly effective at infecting B cells, and thus establishing viral persistence
(Borza and Hutt-Fletcher, 2002).
2.5.2 Three stages of viral life cycle
EBV, like all herpes viruses, establishes lifelong infection within the human host.
One of the particularly interesting features of EBV is that the site of viral persistence,
the B cell, is a key component of the host immune system. Recently progress has
been made in understanding how the virus exploits physiological pathways of B cell
differentiation in order to maintain this life long infection (Thorley-Lawson, 2001).
Three different stages of viral life cycle can be recognised. The first is viral entry
into and induction of proliferation of the host B cell. The second is viral persistence,
when the virus remains latent in B cells (viral latency). The third stage is viral
reactivation, and production of viral progeny to infect both new cells within the host
and allow transmission to naive hosts (lytic infection). (Bornkamm and
Hammerschmidt, 2001) have emphasised the importance of understanding that these
three processes occur simultaneously within the healthy seropostive host .
Historically, our understanding of the molecular events underlying gene expression
during the viral life cycle has been from in vitro studies.
2.5.3 Patterns of viral latency
The ability of EBV to induce B cell proliferation, in vitro, was established over 35
years ago; following infection, the resting B cell is transformed into an activated
phenotype capable of long term growth, known as a lymphoblastoid cell line (LCL)
(Henle et al., 1967; Pope et al., 1968b). Studies of the genetic events underlying B
cell transformation have aided our understanding of the processes underlying viral
persistence in vivo and the role of EBV in tumour pathogenesis.
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Table 2-4 EBV latent antigen expression
EBV Function known/postulated Expressed in vivo in
antigen PBM IM BL NPC HD BLPD TCL Ga Ca
EBNA 1 Genome maintenance ? + + + + + + +
EBNA 2 Viral oncogene, transactivates
cellular and other viral genes
- + - - + - -
EBNA
3A
Activates cellular genes - + - - + - -
EBNA
3B











- + - - + - -
LMP 1 Viral oncogene, induces B cell
activation and adhesion,
inhibits apoptosis
- + (+) + + (+) ?
LMP 2 Repression of lytic cycle,
enhances B cell survival
+ + + + + + +
PBM- peripheral blood mononuclear cells, IM-infectious mononucleosis, BL- Burkitt's
lymphoma, NPC- nasopharngeal carcinoma, HD-Hodgkin's Disease, BLPD- B cell
lymphoproliferative disease, TCL- T cell lymphoma, Ga Ca- gastric lymphoma. + -
expressed, - not expressed
Three dominant patterns of latent gene expression are recognised from these in vitro
studies, and are known as latency 1, 2 and 3 (Rickinson and Kieff, 2003). Latency 3
is also known as the growth program (Thorley-Lawson, 2001). In latency 3, all 9
latent genes are expressed and these are EBNA -1, -2, -3A,- 3B, -3C, and - LP(leader
protein), Latent membrane proteins (LMP) 1, 2A, and 2B, and two small
nonpolyadenylated RNAs (EBERs) (Dorothy H Crawford, 2001). EBNA -3A, -3B,
and 3C are also known as EBNA 3, 4 and 6, respectively. In addition in latency 3, the
BamHI A RNAs are transcribed, but little is known about their function (Epsten MA
Crawford DH, 1996). In latency patterns 1 and 2, a much more limited pattern of
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gene expression occurs. This classification of viral latency is useful, but it should be
recognised that some overlap between the patterns of gene expression occurs in vivo.
Table 2-4 (page 24) summaries the pattern of gene expression that occurs in EBV
linked conditions of both lymphocyte and epithelial cell origin.
2.5.4 Virus induced proliferation of B cells
Following EBV infection of a naive B cell, all 9 latent viral genes are expressed,
(latency 3) and these induce the B cell to enter cycle and proliferate (Bornkamm and
Hammerschmidt, 2001). The first gene to be transcribed is EBNA-2 (Allday et al.,
1989; Henkel et al., 1994; Rooney et al., 1989), which in co-ordination with EBNA
LP (Harada and Kieff, 1997), provides critical transactivation of both the cellular and
viral genes required for this process to occur. EBNA-3A and EBNA-3C are all
required for initiation of transformation and subsequent activation of cellular genes.
LMP-1 is essential for the proliferation of B cells (Peng and Lundgren, 1992). EBNA
-1 is able to attach to cellular chromosomes and so ensures the maintenance of EBV
in daughter cells (Yates et al., 1984).
LMP-1, EBNA-2 and EBNA- 3C are all recognised as viral oncogenes (Bornkamm
and Hammerschmidt, 2001). LMP-1 can transform rodent fibroblasts, and induce
tumours in transgenic mice (Wang et al., 1985), and is widely expressed in EBV
linked tumours such as Hodgkin's lymphoma (Pallesen et al., 1991) and NPC (Chen
et al., 1992; Liebowitz, 1994; Niedobitek et al., 1992). EBNA-2 can regulate the
cellular c-myc gene (Kaiser et al., 1999) and also viral LMP-1 (Abbot et al., 1990).
EBNA-3C also regulates LMP-l(Allday et al., 1993), and can functionally inactivate
the retinoblastoma gene (Canned et al., 1996), a cellular tumour suppressor gene.
The two small non-polyadenylated RNAs (EBERs) are the most highly expressed
RNAs in latently infected cells (Howe and Steitz, 1986). The demonstration of
EBERs expression by in-situ hybridisation on histological sections is often used as a
marker of EBV infection of a cell. However, their function is less clear although
recent data suggest they may also have a role in oncogenic transformation, via the
upregulation of Bcl-2 (Nanbo and Takada, 2002).
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2.5.5 Viral persistence
The second stage of the viral life cycle is viral persistence and the resting memory B
cell is thought to be the major site of viral persistence (Miyashita et al., 1995). In
healthy seropositive adults, 0.5-50 cells per million B cells in the peripheral blood
are infected with EBV (Wagner et al., 1992). Thorley-Lawson has suggested that in
order to enter a state of viral persistence, changes in viral gene expression must occur
which allows the B cell phenotype to change from a proliferating B cell blast into
long lived memory cells (Thorley-Lawson, 2001). EBV is thought to be able to
mimic, via changes in latent gene expression, the physiological signals that occur
after B cell activation via antigen, and which normally induce this change in B cell
phenotype.
Normally antigen activated B cells migrate to lymph nodes and proliferate in the
germinal centre. Depending on the specificity of the antibody produced and its ability
to bind antigen, the cell will either die by apoptosis, or survive as a resting B
memory or plasma cell. The signals that allow transition to a resting cell phenotype
and avoidance of apoptosis are ligation of CD40 and signalling via the B cell
receptor. The latent viral genes LMP1 and LMP2A are thought to substitute for these
signals in an EBV infected B cell and thus allow the cell to differentiate to a long
lived B cell with latent EBV infection (Gires et al., 1997). B cells found in the
peripheral blood of healthy carriers express very limited numbers of viral genes.
Normally only EBERs (Tierney et al., 1994) and LMP2A (Qu and Rowe, 1992) can
be detected; LMP2A prolongs cell survival by suppression of viral reactivation and
entrance to the lytic cycle (Miller et al., 1994; Miller et al., 1995). For the B cell to
exit the proliferation stage EBNA 2 must be switched off, and it is not clear what
signals this change in gene expression.
The limited number of genes expressed in circulating B cells is thought to serve two
ends towards maintaining viral persistence. Firstly the growth promoting genes are
switched off, and so reducing the chance of oncogenic transformation. Secondly,
minimal viral antigens are exposed to the immune system so avoiding recognition by
cytotoxic lymphocytes (CTL) (Bornkamm and Hammerschmidt, 2001). In addition,
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latently infected B cells do not express the co-stimulatory molecules expressed by
proliferating cells, such as CD21 and CD23, which promote immune activation.
2.5.6 Viral reactivation and entry to the lytic cycle
The third stage of the viral life cycle is reactivation and entry into the lytic cycle with
production of viral progeny. Expression of the BZLF1 gene is associated with the
switch from latent to lytic cycle (Countryman and Miller, 1985), however it is not
clear what signals this change in gene expression.
The EBV lytic cycle genes, like other herpes viruses, are described as immediate
early, early and late genes. The immediate early and early genes are expressed before
viral DNA is synthesised and the late genes after DNA synthesis. The late genes
products include gp350/220, the major virus envelope glycoprotein (Thorley-Lawson
and Poodry, 1982), which binds to CD21 (Tanner et al., 1987) and is an important
target of antibody mediated immunity.
In a proportion of healthy carriers virus is continually shed in saliva allowing
transmission to a new host and over time replacement of the pool of EBV infected B
cells in an individual. Lytic virus has been detected in the tonsil (Ikeda et al., 2000),
and it appears that circulating memory cells may return to the tonsil on reactivation
and thus allow these processes to occur.
Thus in the normal host the virus maintains a dynamic equilibrium between
persistent and lytic infection, and continually replenishes the pool of infected B cells.
2.6 Infectious Mononucleosis
IM is one of the most common causes of prolonged illness in university students in
the West, with 5-10% affected annually (Niederman et al., 1970; Sawyer et al., 1971;
Anonymous, 1971; Hallee et al., 1974), IM is most frequently caused by delayed
primary infection with EBV, although delayed CMV results in similar clinical
features, but only EBV infection will be discussed. Typical clinical features of IM
include fever, lymphadenopathy, sore throat and prolonged fatigue. Full recovery in
6-8 weeks is the norm; however the severity and duration of symptoms are highly
variable, with rare but well recognised chronic and fatal outcomes (Cohen, 2000).
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In this section the epidemiology and clinical features of IM are discussed. This is
followed by the immune response to both primary and persistent infection, as much
of this work stems from studies of acute IM (see 2.6.8 page 34). This is followed by
a review of XLP and associated syndromes in which severe primary EBV occurs
(See 2.7 page 39).
2.6.1 Seroepidemiology of IM
In the late 1960's, shortly after identification of the link between primary EBV
infection and IM, at least five serological studies were undertaken of both young
army recruits and university students in the USA and UK (Niederman et al., 1970;
Sawyer et al., 1971; Anonymous, 1971; Hallee et al., 1974; Brodsky and Heath, Jr.,
1972).









Yale University Freshmen (Niederman
1970)
424 26% 44%
Yale University Freshmen (Sawyer
1971)
355 51% At least 74%
Students entering English Universities
(P.H.L.S 1971)
1457 57% 50%
USA Military Academy (Hallee 1974) 1401 63.5% 26-35%
Range 26-63.5% 26-74%
All groups measured EBV antibodies in serum on arrival at university (or army
academy) and at a time point between 9 months and 4 years later. Notably, only the
UK study included female cases. In addition, Brodsky and Heath collated data from
the American College Health Association and found an incidence of IM of around
10%, and this study included both male and female students (Brodsky and Heath, Jr.,
1972). Thus the studies provided useful data on EBV seroprevalence in young adults,
and their subsequent risk of IM (See Table 2-5 page 28).
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In addition, the studies investigated the link between an individual's social and
geographical status, and EBV seroprevalence. As well as studying US university
students, Niederman et al measured prevalence of antibodies in other groups of
young adults of comparative age with a range of social backgrounds. They found
markedly higher rates of antibody positivity (75-77%) in students at universities in
the Philippines, and also in military recruits in Columbia (87%), than in the US
institutions (Niederman et ah, 1970). Hallee et al found that military cadets from low
income families, had significantly higher EBV antibody prevalence at arrival at the
academy compared to those from high income families (Elallee et al., 1974).
In summary, the results confirmed that EBV seroconversion is linked to IM, and
identified those at high-risk for IM as affluent groups in the West, especially new
university students. The range of those who developed symptomatic seroconversion
was wide, from 26-74%, and the reasons behind this are unclear. Interestingly the
study in the US military academy noted a peak incidence of IM in February, about 6
weeks after the cadets Christmas leave presumably because the cadets were more
likely to be sexually active while on holiday (Hallee et al., 1974).
By their mid twenties the majority of adults will be seropositive, although some,
around 10%, will remain seronegative throughout adult life (Henle and Henle, 1980).
2.6.2 Transmission of EBV
IM is colloquially known as the 'Kissing Disease', and it is presumed that the
initiation of sexual activity in adolescence places seronegative individuals at risk of
contact with infectious virus in saliva (Gerber et al., 1972). In fact kissing was
suggested as a mode of transmission even before isolation of EBV (Hoagland, 1975).
Infectious virus is present in genital secretions of both male and female
asymptomatic carriers (Sixbey et al., 1986; Israele et al., 1991), as well as in the
saliva, so primary infection may occur when the virus is transferred to naive cells
either in the oropharynx or genital tract of the new host.
Current data, although limited, suggest that EBV is more commonly found in saliva
compared to sexual secretions. Around 50% of healthy seropositives secrete EBV in
their saliva (Haque and Crawford, 1997), whereas around 10% of seropositive
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women who were found to have EBV present in cervical secretions (Enbom et al.,
2001).
2.6.3 The incubation period of IM
At present most authorities describe a time lag of between 30-50 days after
exposure to the virus before the onset of clinical IM. This time scale probably stems
from the original studies of Hoagland who suggested that IM was contracted from
kissing another person with IM (Hoagland, 1975). Having developed this hypothesis,
he then questioned cases about their sexual activity, and calculated an incubation
period of 33-49 days. We now know that his theory was partially correct, but also
that primary EBV infection can be acquired from asymptomatic carriers. Additional
data on the incubation period are available from case histories in which the likely
date of transmission has been documented; an incubation period of 38 days was
suggested in one case (Svedmyr et al., 1984) and 90 days in the other (Chang, 1975).
IM can also be transmitted through blood transfusion, and studies on this mode of
transmission suggest an incubation period of 21-35 days (Gerber et al., 1969). It
remains difficult to establish any more accurate data on the length of the incubation
period, or why it should be so prolonged.
2.6.4 Diagnostic criteria of IM
The clinical syndrome of IM was described as early as 1940, long before primary
infection with EBV was identified as the most common aetiology, and the diagnostic
criteria used at this time are still useful today (Hoagland, 1975):-
1. 'Clinical. The patient should present with a history of insidious onset of malaise,
fever, and sore throat, and on physical examination we should find cervical
lymphadenopathy and hyperplasia of pharyngeal lymphoid tissue, usually
accompanied by pharyngitis.
2. Haematological. There should be an absolute lymphocytosis (4,500/mm3), at
least 51% lymphocytes on differential count, the presence of atypical
lymphocytes, and the persistence of lymphocytosis for at least two weeks.
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3. Serological. Heterophil (Paul-Bunnell-Davidsohn [PBD]) antibody, absorbable
by ox erythrocytes but not by guinea pig kidney powder, must appear in the
serum during illness'.
Current practice would continue to rely on these characteristic clinical features for
making a diagnosis, but supported by EBV serology. The gold standard for the
diagnosis of IM is detection of IgM antibodies to viral capsid antigen (VCA). Anti-
VCA IgM is present for 1-2 months and subsequently anti- VCA to IgG appears and
then remains. Most laboratories use an ELISA as a screening method, but may
supplement this with an indirect immunofluorescence assay as a more sensitive test.
The test described by Hoagland, the heterophile antibody test, which forms the basis
for the rapid monospot test, is still used for diagnostic screening. This is positive in
85% of acute IM cases, but may be absent in young children (Sumaya and Ench,
1985). On occasions auto antibodies such as cold agglutinins, cryoglobulins,
antinuclear antibodies or rheumatoid factor arise. It should be noted that although the
majority of individuals with IM have a profound lymphocytosis, with 'atypical'
lymphocytes (activated CD8+ T cells) in the peripheral blood, the presence of these
cells is not diagnostic of IM. Atypical lymphocytes are also found to a lesser extent
in other infections, including HIV seroconversion illness, CMV, viral hepatitis,
toxoplasmosis, influenzae and mumps.
EBV DNA viral load is not routinely measured in IM, and the relationship between
severity of illness and EBV DNA levels is not clear at present. Several investigators
have compared EBV DNA viral load in healthy seropositive controls with those
found in IM, and identified both a higher rate of detection and higher values in those
with IM (Berger et al., 2001; Hopwood et al., 2002). In addition, the authors of a
case report have suggested it is useful to monitor viral load in those with fulminant
IM, in order to assess response to treatment (van Laar et al., 2002).
2.6.5 The characteristic clinical features of IM
IM normally occurs in young adults and the majority of patients experience fever,
lymphadenopathy, sore throat and fatigue. Although the data are several decades old,
the clinical manifestations documented in the early studies are still pertinent. The 6
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key features emphasised are listed below, followed by the frequencies of occurrence
as documented by (Chang r s, 1980) as originally described in (S C Finch, 1969).
1. Onset of illness is invariably insidious.
2. Headache is generally mild except in a few patients who may have severe
headache (occurs in 40-70% cases).
3. Sore throat is the most common presenting symptom; it varies from mild to
severe. In some patients, it may be sufficiently severe to cause pain on
swallowing (occurs in 80-85% of cases).
4. About 90% of IM patients have fever, which may last up to 6 weeks (occurs in
80-95% of cases).
5. Virtually all patients have enlarged cervical lymph nodes which vary in size from
that of a pea to a hazlenut, which show no sign of acute inflammation, and which
are not matted together (occurs in 100% of cases).
6. Pharyngitis varies greatly in severity from mild pharyngeal injection to follicular
tonsillitis or exudative pharyngitis (occurs in 65-85% of cases).
In addition, generalised lymphadenopathy often occurs accompanied by
splenomegaly. A degree of hepatomegaly and mildly abnormal liver function tests
are also common, but jaundice is rare (-5%). Fatigue occurs in 90-100% of cases (S
C Finch, 1969). Urticarial skin rashes can occur, most commonly associated with the
use of ampicillin. The aetiology of this is unclear, however a small investigation has
suggested the rash is linked to a specific sensitisation to amoxicillin. Clinically this is
important as this implies a long term allergy to amoxicillin, rather than a reaction
limited to the inter-current viral illness (Renn et al., 2002). Rare complications
include acute liver necrosis, splenic rupture, pharyngeal or tracheal obstruction, and
haematological disorders, including thrombocytopenia and haemolytic anaemia
(Table 2-6 page 33). Again, the majority of these features were described in the early
studies on EBV (S C Finch, 1969). The aetiology of many of these complications is
unclear, but the nature of the conditions (such as thrombocytopenia or
glomerulonephritis) suggests either an auto immune or antibody mediated pathology.
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Rare cases of IM have also been documented in children, middle-aged adults and the
elderly (Auwaerter, 1999). The illness tends to be milder in young children, and
more severe in older adults; the rarity and atypical presentation of IM in these age
groups may make diagnosis more difficult.
Table 2-6 Complications of IM (Macsween and Crawford, 2003)
Organ/system Complication
Liver Jaundice (5%), abnormal liver function (-90%),
fulminant hepatitis (rare)
Respiratory Respiratory tract obstruction due to tonsillar
enlargement, interstial pneumonitis (rare).
Neurological Guillan Barre syndrome
Spleen Splenomegaly and rupture
Haematological Thrombocytopenia and haemolytic anaemia
Secondary infection Streptococcal sore throat
Psychological Depression and prolonged fatigue
Renal Haematuria, interstial nephritis, glomerulonephritis
Cardiac Myocarditis, pericarditis, arrythmia
Immunological Depressed cell mediated immunity
2.6.6 Clinical course and treatment
In the vast majority of cases IM is a benign and self-limiting disease with prolonged
fatigue being the most disabling symptom, and full recovery after 6-8 weeks is the
norm. Treatment is supportive, with advice to avoid both alcohol (particularly if
hepatitis is present) and vigorous exercise, the latter because of the risk of splenic
rupture. Steroids are reserved for serious complications and, if required, a short
reducing course is usually adequate (McGowan, Jr. et al., 1992). Aciclovir inhibits
viral replication but is ineffective in altering the clinical course of IM (Tynell et al.,
1996). This is because the clinical symptoms are not due to viraemia, but to the
marked immune response to EBV, which is well established by the time of clinical
presentation.
Relapses can occur in the first 6-12 months following infection, and IM may be
linked, in the short term, with the development of a prolonged fatigue syndrome and
depression (White et al., 1998). The risk of these complications seems to be higher in
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those with pre-morbid psychological and social problems and lower physical fitness
(White et ah, 2001). However, there is no evidence that the chronic fatigue syndrome
is caused by abnormal immunological response to EBV (Swanink et ah, 1995).
Little data are available on the severity or length of fatigue in the immediate period
following acute IM, although this may be one of the most disabling symptoms.
Assessment of fatigue in an objective manner is difficult; particularly as the majority
of fatigue scales described in the literature are pertinent to either an older age group
or a specific condition such as post chemotherapy or pregnancy (Monga et ah, 1999).
2.6.7 Conditions associated with life threatening primary EBV Infection
A number of conditions have been linked to severe or fatal EBV infection, and X
linked proliferative disease (XLP) is the most well known. XLP, and the other
conditions are discussed in detail following the section on immune response to
primary EBV infection (See section 2.8 page 50).
2.6.8 Immune response to primary EBV infection
The key feature of the immune response to IM is the marked expansion of atypical
lymphocytes, and much progress has been made in characterising the scale,
phenotype and epitope specificity of these cells. Moreover, this work in IM has
provided a useful model for studying the immune response to other persistent viral
infections in humans. Much of this progress has been made by studying, ex vivo
peripheral blood mononuclear cells (PBMC) from young adults with IM, and
accepting this is a good model of primary infection. However it should be
recognised that there are some fundamental limitations to this work. Studies on silent
seroconvertors, either as adults or young children are very limited, but silent
seroconversion is the most common mode of EBV acquisition. The other caveat is
that very limited data are available on immune responses in the tissues and lymph
nodes where much of the pathology of IM occurs.
2.6.8.1 A CD8+ lymphocytosis dominates the immune response to IM
The majority of PBMC found in the peripheral blood in IM are activated
lymphocytes and typically the majority (over 70%), are CD8+ T cells, which express
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the activation markers HLA-DR+ CD45RO+CD45RA (Tomkinson et al., 1987;
Callan et al., 1996; Hoshino et al., 1999). This dramatic CD8+ T cell response is
thought to both control the infection by lysis of proliferating EBV infected B cells,
and cause the symptoms of IM by excess cytokine release.
The dramatic scale of this CD8+ lymphocytosis has promoted debate as to whether
these cells are superantigen driven, or are a large clonal response to a specific viral
antigen (Sutkowski et al., 1996). Recent work is widely accepted as identifying the
majority of these cells as antigen specific, both by analysis of T cell receptor (TCR)
diversity and use of tetramer technology (Callan et al., 1996; Callan et al., 1998).
Firstly IM patients were shown to have expansions of CD8 cells that used a variety
of T cell receptor (TCR) variable region beta chains (VP) (Callan et al., 1996),
whereas the response to a superantigen would predict selective use of VP chains
(Sutkowski et al., 1996). Moreover, TCR VP chains selected by the same antigenic
peptide in the groove of the MHC molecule would tend to show sequence
conservation in the VP chains. Analysis of the sequence of the expanded TCR VP
chains in individuals with acute IM showed such sequence conservation. Again, this
confirmed the oligoclonal nature of the expansions, consistent with an antigen
specific response. Subsequently, the advent of tetramer technology allowed the
detection of CTL specific to antigenic epitopes of the investigator's choice. Studies
in acute IM showed dramatic expansions of antigen specific CTL; in one case 44%
of the total CD8+ cells within the peripheral blood were specific for a single lytic
epitope of EBV (Callan et al., 1998).
Further work studying the antigen specificity of CTL in acute IM, has shown that the
immunodominant epitopes used are predominantly from immediate early (BZLF1
and BRLF1), with some from early proteins (BMLF1, BMRF1, and BALF2) of the
lytic cycle (Silins et al., 1996; Elliott et al., 1997; Steven et al., 1997; Hislop et al.,
2002). CTL responses to the late proteins which encode the structural antigens gp350
and gp85 are much weaker (Khanna et al., 1999b). In addition, these studies showed
that the frequency of antigen specific cells fell following recovery from IM; however
these cells continued to be detectable up to three years after infection (Silins et al.,
1997). The frequency of CD8+ T cells reactive to the latent antigens appears to be
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much lower. Callan et al found 1-2 percent of the total CD8+ T cell population was
directed against the EBNAs (Callan et ah, 1998), whereas in a further study Hislop et
al, found responses against LMP-2 were very rare (Hislop et ah, 2002).
The role of CD4 + T cells in the control of primary infection is less well understood.
The most detailed investigation of CD4+ T cells responses in IM identified cells
specific to both lytic and latent antigens. Like CD8+ T cell responses, the most
frequently detected CD4+ cell responses were also to the lytic antigens, (in this case
BZLF1), compared to the latent antigens studied (EBNA -1 and EBNA- 3A)
(Precopio et al., 2003). One other study identified CD3+CD4+CD8+ lymphocytes
which were reactive against the lytic cycle antigen BHRF-1 (White et al., 1996).
Data are limited on the response of other lymphocyte subsets during primary
infection, although expansions of both NK (Tomkinson et al., 1987), and y5 cells
have also been identified (Hassan et al., 1991; De Paoli et al., 1990).
2.6.8.2 The cytokine response is critical to the pathogenesis of IM
Cytokines are thought to be critical to the pathogenesis of IM, and the release of
excessive T helper 1 type cytokines is thought to cause the typical clinical features.
The best evidence to support this derives from studies of cytokine gene expression in
tonsil from IM patients: expression ofmRNA for lymphotoxin, tumour necrosis
factor a (TNF a), and Interleukin (IL)- 6 have all been detected (Foss et al., 1994).
In addition, several investigators have found elevated levels of IL-2, IL-6, TNF a and
IFN y in the peripheral blood at diagnosis of IM (Biglino et al., 1996; Andersson et
al., 1984), and the same cytokines have been identified after in vitro infection of
PBMC with EBV (Andersson et al., 1984).
It remains difficult to ascertain how this cytokine network evolves in vivo, however
it is probably reasonable to postulate that the earliest events are the release of IL-6
and TNF a either from monocytes or infected B cells. IL-6 can act on both B and T
cells; it induces the differentiation of B cells, and both proliferation by T cells and
release of IL-2 by T cells (Hirano et al., 1990). In addition, TNF a is an important
activator of NK cells (Cooper et al., 2001a). In terms of symptom causation, both NK
cells and activated T cells are an important source of INF y, a key candidate,
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alongside IL-6 and TNF a for causing the systemic features of IM such as fever
(Dinarello, 1999).
2.6.8.3 The humoral immune response to EBV
During primary infection antibodies are generated to both lytic and latent viral
antigens. Neutralising antibody to gp 350, the main viral envelope glycoprotein, and
also gp85 another glycoprotein on the viral envelope prevent binding to the CR2
receptor on B cells in vitro (Tanner et al., 1987). It is not clear whether these
antibodies have a role in limiting primary infection, but are thought to prevent re¬
infection. Currently EBV vaccines based on the generation of neutralising antibody
are being developed (Jackman et al., 1999). For further details of vaccines see 2.9
page 52.
2.6.8.4 Symptomatic versus asymptomatic primary EBV infection
Despite our increased understanding of immune response to EBV, it is not clear why
the manifestations of primary infection are different between age groups and
individuals, and how the scale of the immune response relates to clinical features. It
is likely that milder forms of the syndrome occur without detection, and a spectrum
of clinical features exists ranging from mild sore throat to full blown IM. Some
insight has been gained into the mechanisms of silent infection, as 3 cases of
asymptomatic seroconversion have been fortuitously identified during a phase 1
vaccine study in Australia (Silins et al., 2001). In contrast to those with IM, the
silent seroconvertors did not develop the lymphocytosis or increased CD8+ cells
count typical of IM. The use of T cell repertoire was also analysed and there was no
change in usage between primary and persistent infection in the symptomatic group,
whereas the IM cases showed marked expansions in the spectrum of T cell receptors
used. The authors suggest that that this identified expansion of T cells in acute IM
supports the hypothesis that the pathology of IM is modulated by the T cell response.
In addition although the numbers studied were small, EBV load was compared
between the 2 groups, and 2 out of 3 of the asymptomatic cases showed levels equal
or higher to the 3 symptomatic cases.
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Additionally it has been suggested that infants are more likely to silently seroconvert
as they receive a lower dose of infecting virus than young adults (Epsten MA
Crawford DH, 1996). This is because transmission in infants is likely to be from
close family contact, such as sharing toys or cups, compared to sexual contact by
young adults. The other important factor is potential differences in the immune
response to infection between children and young adults. This is likely to be relevant
as children manifest different clinical responses to a number of other infectious
agents such as VZV and parvovirus.
These hypotheses are difficult to investigate in vivo in humans, and an animal model
would be useful in investigating the pathogenesis of IM. One such model is the
murine gamma herpes virus, MHV-68 (gamma HV-68) infection of mice in which
the virus establishes latency in B cells (Nash et al., 2001). However, a primate may
provide a better model for vaccine studies and rhesus monkeys are infected by EBV-
like lymphocryptovirus. This results in an IM like syndrome following primary
infection, and importantly the virus is secreted in the oropharynx (Wang, 2001).
2.6.9 The immune response to persistent infection
After acute infection a state of viral persistence is established with long term cellular
immunity provided by EBV-specific CD8 + cytotoxic T lymphocytes. These cells
can be detected in the circulation in all healthy seropositive individuals, and normally
have a resting phenotype (HLA DR-CD38-CD62+) (Tan et al., 1999).
As suggested by the studies during recovery from IM, the CTL detected in latency
are directed against both lytic (BZLF1 and BMLF1) (Steven et al., 1997), (BRLF1)
(Pepperl et al., 1998) and latent viral epitopes (EBNA3A, EBNA3B, and EBNA3C)
(Murray et al., 1992) and reviewed in detail by (Khanna and Burrows, 2000).
CD4+ T helper cells have a central role in the maintenance of antigen specific
immunity and in mouse models are important in resistance to both virus infection and
cancer (Bickham et al., 2001). Like studies during acute infection, studies on
persistent infection in healthy virus carriers have focused on identification of CD8+
T cell responses, rather than CD4+ T cells. This may be due, in part, to the
difficulties of identifying CD4+ T cells specific for EBV antigens; tetramer
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technology is not yet well established for the identification of CD4+ T cell responses
(Nepom et ah, 2002).
However several groups have identified EBNA-1 responses in the majority of
donors, and additionally one group found a minority of donors, around 10%, to have
responses to LMP-1 and LMP-2 (Munz et ah, 2000; Bickham et ah, 2001) .
Of particular interest is the identification of EBNA-1 specific cells, as EBNA-1 (Gly-
Ala) repeat interferes with processing and presentation by CD8+ T cells (Levitskaya
et al., 1995). Although EBNA 1 specific CD8+ T cells can be recognised in vivo,
they require exogenous antigen to allow for presentation in the context of HLA1
(Blake et al., 1997).
2.7 X-linked lymphoproliferative disease (XLP)
2.7.1 Duncan's syndrome and the XLP registry
In 1998, two groups, taking quite different approaches, identified the genetic defect
underlying the rare X linked lymphoproliferative disease XLP (Coffey et al., 1998;
Sayos et al., 1998). The syndrome was first described by Purtilo and colleagues in
1975, although both Bar and Purtilo had previously identified similar cases (Bar et
al., 1974; Purtilo et al., 1974; Purtilo et al., 1975; Bar et al., 1974). Purtilo recognised
that a novel X linked genetic defect was likely to be the cause of the severe and fatal
lymphoproliferation, which had been documented in 6 out of 18 male members of
the Duncan family. In at least 3 of the 6 boys, IM had occurred during or prior to
death, and 2 of the 6 boys also developed lymphoma. Purtilo called the syndrome
Duncan's Disease, and correctly suggested EBV or other viral agents were the trigger
for the syndrome.
In 1976, with the identification of further cases the syndrome was named X-linked
lymphoproliferative syndrome (XLPS) (Schuster et al., 1993) and in 1978 a registry
was established (Hamilton et al., 1980). The name was changed to X-linked
lymphoproliferative disease (XLP) in 1990 when a single XLP gene locus on Xq25
was identified (Wyandt et al., 1989b). In 2002 data had been recorded from 309
males from 89 families, and XLP was reported to affect around one in a million
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males (Sumegi et al., 2000). The collection of data by the registry has allowed
important analysis of the spectrum of clinical features that occur in XLP, and
diagnostic criteria to be established. The registry now maintains a website at
www.hta.fi/imt/bioinfo/idr/Diag_XLP.html.
2.7.2 Clinical Manifestations of XLP
The mean age of onset of XLP is 2.5 years, however cases have been observed as
young as 5 months and up to 40 years. Three major clinical phenotypes are
recognised (Seemayer et al., 1995) (Table 2-7 page 40), however individuals may
suffer from a combination of these phenotypes.
Table 2-7 Common clinical phenotypes of XLP (Seemayer et al., 1995).
Phenotype Frequency Mortality of each
phenotype
Fulminant IM 58% 96%
Lymphoma (mostly
extranodal B cell origin)
30% 69%
Hypogammaglobulinemia 31% 45%
The most common phenotype is fulminant IM, which occurs in around two thirds of
cases, and has the worst prognosis with a mortality rate of over 90%. In response to
primary EBV infections the affected boys rapidly develop large numbers of EBV
infected B cells which in turn stimulate a dramatic proliferation of cytotoxic T cells.
At post mortem large numbers of EBNA positive cells have been found in the blood
and infiltrating the tissues (Crawford et al., 1979). Unlike the normal response to
EBV, the T cells are apparently unable to limit the proliferation of B cells, and this
dysregulated cytotoxic T cell response and subsequent cytokine release leads to
extensive organ damage (Purtilo et al., 1975; Seemayer et al., 1995). Bone marrow
failure remains the most common cause of death in XLP (Schuster and Kreth, 1999).
The second most common phenotype is hypogammaglobulinemia, which is found in
a third of cases. Again the aetiology is likely to be immune mediated with subsequent
necrosis of the lymphoreticular system. Affected individuals have low IgG and IgA,
and low to normal IgM (Grierson et al., 1991; Seemayer et al., 1995). T and NK cell
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numbers may also be low, and have defective function (Sullivan et al., 1980; Harada
et al., 1982; Argov et al., 1986; Masucci et al., 1981). Boys suffering from
hypogammaglobulinemia may be treated with regular immunoglobulin infusions and
in isolation this phenotype carries the most favourable prognosis. Since identification
of the gene, a number of men with common variable immunodeficiency have been
found to, in fact, have mutations in the XLP gene (Gilmour et al., 2000; Soresina et
al., 2002).
The other major phenotype is lymphoma and these are normally of B cell origin
(Grierson and Purtilo, 1987). The most common site is the terminal ileum, but also
hepatic, renal and central nervous system lymphomas have been described. A small
number of cases of Hodgkin's disease and T cell lymphomas have also been reported
(Harrington et al., 1987). Of note, lymphomas of different subtypes have occurred
within the same family (Hamilton et al., 1980). The tumours may respond to standard
paediatric chemotherapy protocols, but the mortality remains high at 69% (Gaspar et
al., 2002).
It is not clear what proportion of lymphomas in XLP contain EBV, although there is
evidence that lymphoma may develop without serological evidence of prior EBV
infection (Brandau et al., 1999).
Other manifestations of XLP include systemic vasculitis (Dutz et al., 2001), aplastic
anaemia (Poy et al., 1999; Seemayer et al., 1995), and pulmonary lymphomatoid
granulomatosis (Gaspar ct al., 2002).
2.7.3 Immunodeficiency prior to EBV exposure
Affected boys are typically reported as being well until encountering EBV, but there
is some debate as to whether immunological abnormalities occur prior to EBV
infection. This is a difficult area to study, firstly asymptomatic cases can only be
identified through screening family members of affected individuals, and secondly
there is growing evidence that XLP is not only precipitated by EBV infection.
However, immunological studies on XLP cases in the 1980's suggested that boys
with XLP frequently do not develop full antibody memory, characterised by an
inability to switch from IgM to IgG isotype (Ochs et al., 1983). This is especially
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interesting, as recent work on a mouse model of XLP has confirmed this finding
(Crotty et ah, 2003), and this is reviewed in the discussion (See section 9.4 page
172).
In 1995 Seemayer reported on 32 cases from the registry who had been identified as
carrying the mutated gene by restriction fragment length polymorphism but whom
had no serological evidence of EBV infection. Of the 32 cases identified, 17 in fact
fulfilled diagnostic criteria for XLP as they had dysgammaglobulinemia, with raised
IgA and IgM and/or defects in IgG, IgGl or IgG3 production (Seemayer et al.,
1995).
2.7.4 Treatment of XLP
The treatment of XLP remains difficult, and the only curative option is allogeneic
haemopoietic stem cell transplantation (Vowels et al., 1994; Pracher et al., 1994;
Gross et al., 1996). The most common presentation, fulminante EM remains the
most difficult to treat; use of the anti-histiocyte agent, etoposide may induce
remission prior to bone marrow transplant. The rarity of the condition and diverse
clinical spectrum of presentations makes any comparative analysis of treatment
options difficult, and survival rates remain extremely variable (Gaspar et al., 2002) .
Genetic screening ofmale family members is now possible, and regular
immunoglobulin infusions may protect those identified as at risk of developing
clinical XLP.
2.7.5 Identification of the XLP gene
The first breakthrough in the search for the gene was in 1989, when the locus for
XLP was linked to the long arm of the human X chromosome in Xq24-q27 (Skare et
al., 1989a; Skare et al., 1989b). Lurther deletions at this site in other XLP cases
provided confirmatory evidence that this was the XLP locus, and narrowed it down
to Xq25 (Wyandt et al., 1989a). Coffey et al working with an international
consortium, identified the gene using a positional cloning strategy with XLP patients
with known deletions as reference points (Coffey et al., 1998). The critical region
was localised to an approximately 3Mb region, and a yeast artificial chromosome
contig was established to provide a physical map of the region. Pour candidate genes
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were identified using exon trapping and sequencing techniques. Only two of these
genes were candidates, as the other two were found to lie partly outside the critical
region. Further refining of the critical region led to the identification of the likely
candidate as a gene which encoded a SH2 domain. This gene, subsequently named
SH2D1A, was mutated in 9 out of 16 unrelated XLP cases, but not in healthy
controls.
The SH2D1A gene contains 4 exons. It encodes a protein of 128 amino acids, which
contains a 5-amino acid N terminal sequence, an SH2 domain, and a 25-amino acid
C terminal tail (Coffey et al., 1998; Poy et al., 1999).
Sayos et al cloned the XLP gene serendipitously, when they identified a signalling
protein for the cell surface lymphocyte activation marker termed SLAM (Sayos et
al., 1998). This novel SH2 domain containing protein was called SLAM associated
protein (SAP). SLAM/CD150 is a T/B/dendritic cell cell surface glycoprotein, and is
a costimulatory molecule involved in cellular activation. The mouse homologue of
SAP was found on the mouse X chromosome, at a point corresponding to human
Xq25. Mutations in SAP were subsequently detected in 3 XLP patients, but not in
over a hundred healthy controls. Moreover, the mutant SAP proteins where unable to
bind to SLAM. Identification of these mutations, in a novel T cell activation
pathway provided the first insight into the molecular pathophysiology of XLP.
Morra and colleagues have suggested the XLP gene should be called SAP/ SH2D1A
and the gene product SAP (Morra ct al., 2001).
2.7.6 The relationship between mutations identified in XLP and clinical
phenotype
Since the identification of the gene a number of groups have looked for mutations in
the gene in clinically diagnosed cases of XLP. Sumegi and colleagues have screened
the largest number of affected families, 35 from the XLP registry, for mutations in
the SAP gene, and looked for any relationship between genotype and clinical
phenotype (Sumegi et al., 2000). They identified 28 different mutations and
classified them as large genomic deletions of the entire gene or part of the coding
region, splice-site mutations and nucleotide substitutions, both nonsense and mis-
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sense. The most common mutations were large genomic deletions. No relationship
was found between genotype and phenotype, and in particular those with large
genomic deletions did not appear to have worse disease than those with single
nucleotide substitutions. It was also noted that among families with the same
mutation very variable clinical presentations may occur, providing further evidence
that additional environmental or virological factors must contribute to the clinical
outcome.
At least another nine series of mutation analysis of XLP patients have been published
(Coffey et al., 1998; Nichols et al., 1998; Yin et al., 1999; Strahm et al., 2000;
Brandau et al., 1999; Nistala et al., 2001; Arico et al., 2001; Gilmour et al., 2000;
Sumazaki et al., 2001). All groups used PCR based sequencing techniques.
Mutations have most frequently been identified in exon 2, particularly nucleotide
substitutions or deletions. This is functionally significant as it is exon 2, which
encodes the central portion of the SH2 domain, which is critical to the function of
SAP. One hot spot has been identified, at nucleotide position 462 resulting in an
Arg55stop transition. 3 different groups have described the same mutation, however
it is possible that more than one investigator has inadvertently analysed DNA from
the same affected individual. Otherwise mutations are sporadic throughout the four
exons. In most series around 50-60 % of those with a clinical diagnosis of XLP have
been found to have mutations in SAP/SH2D1A. Predictably, more mutations have
been identified in cases with a strong family history compared to sporadic cases of
fulminant IM.
Several investigators have looked for mutations in SAP in other conditions in which
severe EBV infection occurs. Two groups have looked for mutations in a total of 26
cases of chronic active EBV (CAEBV) (Sumazaki et al., 2001; Sumegi et al., 2000)
and no mutations in SAP/SH2D1A were found. In a study of 25 cases of
hemophagocytic lymphohistiocytoses (HLH), 2 out of 25 cases were found to have
mutations in SAP (Arico et al., 2001).
2.7.7 Cellular and tissue distribution of SH2D1 A/SAP
SAP is predominantly expressed in T lymphocytes (Sayos et al., 1998), and NK cells
(Tangye et al., 1999). The T cell subsets include both CD4+ and CD8+ cells, and the
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CD8+ subsets were also noted to express CD45RO+ and CD45RA+. Although SAP
is detected in resting lymphocytes, expression is increased on activation (Nagy et al.,
2002). Nagy et al cultured PBMC either with EBV or PHA and found increased
expression of SAP in the cultured cells compared to ex vivo PBMC. In addition
tumour cell lines derived from both T lymphocytes and NK cells were found to
express SAP, like their cellular counterparts (Kis et al., 2003).
Coffey et al found expression of SAP mRNA in B cell subsets (Coffey et al., 1998),
however other investigators have not confirmed this finding, and the consensus
opinion is that B cells do not express SAP protein (Sayos et al., 1998; Nichols et al.,
1998; Gilmour et al., 2000). It is possible that the B cell subset tested by Coffey et al
was not an entirely pure population of cells, as no comment is made on the cell
separation method used. B cell derived LCL's have also been found to be
consistently negative, though Nagy et al have found expression of the protein in a
number of EBV positive BL derived cell lines, though not EBV negative BL lines
(Nagy et al., 2000). The reasons for the expression in BL derived lines is unclear. A
limited survey has been carried out of SAP/SH2D1A expression in lymphoma tissue;
Hodgkin's and non-Hodgkin's lymphoma of both T and B cell origin expressed the
gene (Nichols et al., 1998).
Both Coffey and Sayos who identified the SAP/SH2D1A gene surveyed human
tissue for expression of SAP, using Northern blotting (Coffey et al., 1998; Sayos et
al., 1998). Both groups found the highest expression of SAP in the thymus, but the
gene was also expressed in the spleen, the lungs and liver. SAP expression was not
identified in prostate, testis, ovary, intestine, colon or brain. This pattern of gene
expression in the tissues is consistent with a T cell protein.
2.7.8 SAP and regulation of cell surface lymphocyte activation molecules
SLAM and CD244
SAP is a small protein in which the first three exons encode the SH2 domain and
exon 4 encodes the tail sequence. Immediately upstream of exon 1 are putative
binding sites for transcription factors involved in T cell development and function
(Sayos et al., 1998; Sayos et al., 2000). The crystal structure of SAP has been
published (Poy et al., 1999).
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SAP was first identified as a cytoplasmic signal transduction protein for cell surface
SLAM (Sayos et al., 1998), and its function is now thought to be as a cytoplasmic
regulator of cellular activation by at least a further 4 cell surface receptors (Tangye et
al., 1999). The structure of the protein, which lacks signalling domains, predicts that
it functions as a blocking molecule (Poy et al., 1999). By binding to phosphorylated
SLAM, SAP prevents signalling by other SH2 domain containing proteins (such as
SHP-2), which do have down stream signalling capacity (Figure 2-1 page 46). As
well as SLAM, SAP binds 2B4/CD244 (Tangye et al., 1999), CD84 and Ly-9 (Sayos
et al., 2001), and NTB-A (Bottino et al., 2001). All are members of the













Figure 2-1 SAP transduction pathway
2.7.8.1 SLAM/CD150
SLAM is primarily expressed on lymphocytes and expression has been documented
on resting T cells, B cells and dendritic cells; expression is rapidly upregulated on
both CD4 + and CD8+ subsets following activation in vitro (Aversa et al., 1997).
Engagement of SLAM by specific antibody leads to T cell proliferation, and
preferential production of TH1 type cytokines including IFN y (Garcia et al., 2001).
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SLAM is also expressed on B lymphocytes and in vitro studies have suggested that
signalling through SLAM leads to proliferation of B cells and immunoglobulin
synthesis, of IgM, IgG and IgA subclass (Punnonen et al., 1997). In addition to the
membrane bound form of SLAM, activated lymphocytes express mRNA for a
secreted form (Punnonen et al., 1997). Studies in human disease have documented
increased expression of SLAM in lymphocytes from synovial fluid of patients with
both rheumatoid arthritis and reactive arthritis compared to lymphocytes from the
peripheral blood (Isomaki et al., 1997). SLAM can function as a self ligand, however
other ligands have not yet been identified.
Also of interest, SLAM has been identified as a receptor for wild type measles virus
(Tatsuo et al., 2000), and this finding may eventually provide some insight into the
pathogenesis of measles associated immunosuppression.
2.7.8.2 2B4/CD244
Like SLAM human CD244 is a cell surface lymphocyte receptor which is
phosphorylated following activation and recruits SAP (Tangye et al., 1999). Human
CD244 is expressed on all NK cells and on around 50% of CD8+ lymphocytes. It is
not expressed on resting B cells or CD4+ lymphocytes (Nakajima et al., 1999; Kubin
et al., 1999). Cross linking of CD244 on NK cells results in enhanced cytotoxicity
and cytokine production including IFN y (Nakajima et al., 1999).
There has been particular interest in the role of CD244 in the pathogenesis of XLP as
CD244 is the counter receptor for the B cell activation molecule CD48 (Latchman et
al., 1998). CD48 is expressed at ten times higher levels on EBV infected B cells than
EBV negative cells (Thorley-Lawson et al., 1982). Therefore this interaction between
CD48 and CD244 may provide a important mechanism by which both CD8+ T cells
and NK cells recognise EBV infected B cells in vivo.
Four groups have shown that NK cells from XLP patients maintain normal
expression of CD244, but fail to initiate cytotoxicity via this receptor (Parolini et al.,
2000; Benoit et al., 2000; Tangye et al., 1999; Nakajima et al., 2000). NK cell
activity via other receptors such as CD 16, which does not associate with SAP, was
found to be normal. Of particular interest, Parolini and colleagues showed that NK
Introduction 47
An analysis of the immune response to primary Epstein- Barr Virus infection and the association with
clinical events
cells from XLP patients were unable to kill either autologous or allogeneic LCL.
However, killing was restored by simultaneous disruption of 2B4-CD48 and NK
receptor-MHC 1 interactions. Parolini, unlike the other investigators, did not only
find that NK cells from XLP patients failed to kill via CD244, but that engagement
of CD244 actually inhibited killing by NK cells. This failure of CD244 mediated
killing in XLP may explain the defects in NK cell killing previously identified in
XLP patients (Argov et ah, 1986; Harada et ah, 1982; Masucci et al., 1981; Sullivan
et al., 1980; Sullivan et ah, 1980). A further receptor, NTB-A, also binds to SAP and
has a very similar function to CD244. NTB-A is expressed on NK and T cells, but
unlike CD244 is also expressed on B lymphocytes (Bottino et ah, 2001).
2.7.8.3 Ly-9 and CD84
Ly-9 (CD299) and CD84, two further cell surface receptors, have also been found to
bind SAP via their cytoplasmic tails (Sayos et ah, 2001). Like the other receptors in
the family, Ly-9 and CD84 are expressed on both T and B lymphocytes.
2.7.8.4 SAP transduction pathways
Identification of the XLP gene product SAP has generated a great deal of interest in
the role of SAP in controlling T and NK cell activation pathways. Much of this work
has focused on a role for SAP as a natural inhibitor of T cell activation, initiated by
ligation of the SLAM family of TCR co-receptors (Sayos et ah, 2000; Morra et ah,
2001). On the other hand, work by Latour and colleagues, suggests SAP is not just an
inhibitory molecule but may facilitate recruitment of FynT tyrosine kinase to the
phosphorylated cytoplasmic domain of SLAM (Nichols et ah, 2001; Latour et ah,
2001). The recruitment of FynT leads to a signaling cascade which subsequently
inhibits secretion of IFN y by activated T cells. The cytokine response in activated T
cells, which lacked either SAP or SLAM was particularly interesting. In cells that
expressed both SLAM and SAP, TCR ligation inhibited INF y secretion, but did not
affect IL-2 production. This finding highlights the importance of SAP expression to
the control of INF y, a cytokine that is thought to be critical to the pathogenesis of
both IM and XLP. However, the results of this in vitro work should be interpreted in
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the context of our knowledge that normal individuals without defects in SAP or
SLAM can express INF y from activated T cells.
In contrast, ligation of CD244 and CD84, both expressed on NK cells, and also
acting via SAP, results in secretion of INF y. This activation cascade is thought to
involve signalling via phospholipase Cy and linker for activation of T cells. In
summary, SAP controls several distinct signalling pathways in T and NK cells, all of
which may modulate cytokine production (Engel et al., 2003).
Mouse models of XLP, in which mice with defects in SAP expression have been
generated, have corroborated the immunological findings which have been
documented humans with XLP (Czar et al., 2001). In response to lymphocytic
choriomeningitis virus (LCMV) increased numbers of CD4+ and CD8+
lymphocytes, which produced INF y, were observed. Interestingly, even prior to virus
infection, a skewing of the lymphocyte cytokine profile towards a TH1 phenotype,
and defective IgE antibody production was observed (Czar et al., 2001).
2.7.9 Improved screening for XLP and Diagnostic Criteria (Defined by the
XLP Registry)
The identification of the XLP gene has allowed a definitive diagnosis to be made in
putative XLP cases. New criteria for the diagnosis of XLP have been proposed by the
European Society for Immunodeficiencies (ESID) and Pan American Group for
immunodeficiencies (PAGID) and are documented below (Conley et al., 1999).
2.7.9.1 Definitive XLP
Male patient with lymphoma/Hodgkin's disease, fatal EBV infection,
immunodeficiency, aplastic anemia or lymphohistiocytic disorder who has a
mutation in SH2D1A/SAP/DSHIP.
2.7.9.2 Probable XLP
Male patients experiencing death, lymphoma/Hodgkin's disease, immunodeficiency,
aplastic anaemia or lymphohistiocytic disorder following acute EBV infection and
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maternal cousins, uncles or nephews with a history of similar diagnosis following
acute EBV infection.
2.7.9.3 Possible XLP
Male patients experiencing death, lymphoma/Hodgkin's disease, immunodeficiency,
aplastic anaemia or lymphohistiocytic disorder following acute EBV infection. This
is sometimes described as sporadic XLP.
2.8 Other conditions associated with severe primary EBV
infection
The identification of the XLP gene, as well as improved techniques in
immunophenotyping and molecular genetics, has increased our understanding of the
spectrum of conditions in which primary EBV infection is life threatening. A
number of syndromes are recognised which occur in previously immunocompetent
individuals (Table 2-8 page 50). These include sporadic fulminant IM, which may be
linked with EBV associated haemophagocytic syndrome, fulminant EBV+ T-cell
lymphoproliferative disorder, and chronic active EBV (CAEBV). Both EBV
associated haemophagocytic syndrome (Imashuku, 2002), and fulminant EBV+ T -
cell lymphoproliferative disorder (Quintanilla-Martinez et ah, 2000) are pathological
classifications which present as fulminant IM, whereas CAEBV is recognised as a
distinct clinical entity (Kimura et al., 2001).
Table 2-8 Conditions associated with life threatening EBV infection
Disease or syndrome Clinical Presentation Key diagnostic feature






Life threatening IM Haemphagocytosis in bone marrow
Sporadic fulminant IM Life threatening IM No mutations in SAP/SH2D1A
Fulminant EBV+ T -cell
lymphoproliferative disorder
Life threatening IM Clonal expansions of EBV infected T
cells.
CAEBV Recurrent severe IM Minimum of 6 month course
Very high viral load
T or NK cells infected with EBV
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Fulminant IM occurs sporadically, in both males and females, as well as in those
with defects in SAP/SH2D1A underlying XLP.
2.8.1 EBV associated haemophagocytic syndrome
The diagnosis of this syndrome is made histologically and is characterised by the
presence of phagocytosis of blood cells in the bone marrow. EBV infection is
thought to be one of the most common virological causes of haemophagocytosis,
particularly in childhood (Ohshima et al., 1999). However a number of other viruses
have been implicated including hepatitis A (Ishii et al., 2003), as well as non viral
causes such as malignancy.
Clinically haemophagocytosis presents in a similar manner to fulminant IM and
haemophagocytosis has been described in XLP (Arico et al., 2001).
2.8.2 Fulminant EBV+ T-cell lymphoproliferative disorder
Fulminant EBV+ T-cell lymphoproliferative disorder is a very rare disorder, which
may present following primary infection, but also occurs in association with CAEBV
(Quintanilla-Martinez et al., 2000). The key pathological feature is clonal expansion
of EBER+CD3+T cells, which typically infiltrate the liver and spleen. A recent case
series and review has helped define the syndrome and suggests the prognosis is
extremely poor; of a total of 16 cases described in the literature 15 were dead within
a year. The sudden clinical onset with rapid deterioration, and presence of large
numbers of EBV positive T cells, is suggestive of acute infection, however
surprisingly EBV serology may not be typical of primary infection.
2.8.3 Chronic Active EBV (CAEBV)
CAEBV is characterised by chronic or recurrent IM-like symptoms which are life
threatening. Typically, the clinical course is less acute than fulminant IM, but the
longterm prognosis is poor. The disease is most common in Japan, and a recent
national survey carried out by Kimura and colleagues has helped to clarify the key
features (Kimura et al., 2001; Kimura et al., 2003). The diagnostic criteria for
CAEBV used in the survey, included a greater than 3 month duration of EBV related
illness, a very high number of EBV genome copies in the peripheral blood or a
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grossly abnormal antibody profile. In total, they identified 82 patients who fulfilled
these criteria and had been diagnosed since 1990.
Like XLP, CAEBV predominately occurs in children, and Kimura found the mean
age of onset was 11 years with a range from 9 months to 53 years. The mortality was
high, at over 40%, with a mean survival of only 4.3 years from onset. The causes of
death included hepatic failure, complications of transplant, lymphoma and
hemaphagocytic syndrome. Kimura also made an important observation that unlike
healthy virus carriers, T and NK peripheral blood lymphocytes are infected with
EBV, and the type of cell infected could be linked to prognosis. Those with T cell
CAEBV had a shorter survival time than those with NK cell disease. Another
prognostic feature was the EBV DNA viral load in PBMC, with higher viral loads
found in those with severe disease. This data may be useful in guiding treatment
options. Bone marrow transplant may be successful (Okamura et al., 2000; Kawa et
al., 2002), but should be reserved for those with a poor prognosis as the risk of
transplant is substantial. Another new treatment option is infusion of EBV specific
CTL (Savoldo et al., 2002).
2.9 Vaccine Development
Both primary and persistent EBV infections are associated with significant pathology
and this has led to interest in the development of an EBV vaccine. An ideal vaccine
would prevent the complication of late primary infection, IM, and prevent viral
persistence, thereby potentially eradicating EBV driven cancers. At present there are
two main approaches to vaccine development (reviewed by (Khanna et al., 1999a).
First, induction of neutralizing antibody to gp 350 should prevent virus binding to
CD21, the key B cell receptor, and thus prevent infection. Gp 350 vaccines are
under trial, but it is not clear yet whether induction of an antibody response, possibly
with induction of cytotoxic T cells to the same viral epitope, will provide sterile
immunity (Khanna et al., 1999b). The first trial to be reported was a small Chinese
trial of 19 children, 9 who whom received a live recombinant vaccinia virus
expressing Gp350 (Gu et al., 1995). Of these 9 children, 6 remained anti-VCA
negative sixteen months after vaccination, compared to the 10 controls who all
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seroconverted during this period. Although these results are promising, use of live
vaccinia virus vaccines is generally considered unacceptable by the licensing
authorities.
The second approach to vaccination is the induction of cytotoxic T cells specific to
EBV by vaccination with synthetic peptides (Moss et al., 1998). As cytotoxic T cells
are critical to controlling primary infection, this mechanism may limit early viral
replication. This in turn may significantly attenuate the immune response to primary
infection, and the associated clinical features of IM, but probably would not prevent
establishment of viral persistence. The major difficulty with this type of vaccine is
the need for multiple CTL epitopes to be combined within the vaccine. This is
because each MHC allele presents a different viral epitope, and so a cocktail of
epitopes must be included to cover the diversity of MHC alleles within a population.
However we now know that certain groups ofMHC class 1 molecules bind very
similar peptides (Thomson et al., 1995), thus exploitation of these MHC 'supertypes'
may allow a significant proportion of the population to be covered by a relatively
small number of peptides.
CTL based vaccines are also being developed as therapeutic vaccines against EBV
linked tumours (Duraiswamy et al., 2003). Recent work has focused on the
development of an LMP1 specific vaccine, as LMP-1 and LMP-2 are the key latent
antigens expressed in EBV- associated nasopharngeal carcinoma and Hodgkin's
disease (Lee et al., 1997; Duraiswamy et al., 2003; Meij et al., 2002).
Even if an ideal vaccine is developed there will be considerable difficulties in
deciding when to use it and in whom to use it. As previously discussed the data on
the epidemiology of IM is several decades old, and up to date information is required
in order to identify the target population, and the appropriate age to offer vaccination.
Perhaps with the recent advent of vaccines to human papilloma virus and herpes
simplex virus (Koutsky et al., 2002), vaccination against sexually transmitted disease
prior to puberty will become more acceptable. Other small target populations are
likely to be seronegative transplant recipients and possibly boys with mutations in
SAP/SH2D1A prior to infection with EBV.
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2.10 Human NK cells
CTL are recognised as the major cytotoxic cell in defence against viral infection
(Appay et al., 2002), however the acquired immune system takes up to a week to
develop (Parham, 2003). On the other hand the innate immune system is able to
provide an immediate response to infection and thus is likely to be critical early in
the infective process. NK cells are part of the innate immune system, and have a
central role in early defence against infectious agents particularly viruses, and control
of tumour growth. New evidence is emerging for a critical role played by NK cells,
in the control of herpes virus infection, and this is discussed in more detail at the end
of this section (See section 2.10.6 page 61).
2.10.1 Key characteristics of NK cells
Human NK cells comprise approximately 10% of the peripheral blood lymphocytes,
and are also present in the lymph nodes, spleen, bone marrow and placenta. NK cells
develop in the bone marrow from CD34+ progenitor cells. NK cells express CD56
and/or CD 16 but are CD3/aP TCR negative, they are thymus independent and do not
undergo germ line rearrangements of their receptors (Farag et al., 2002). NK cells are
cytotoxic cells and lyse target cells by the release of perforin which allows the
subsequent traffic of cytotoxic granzymes to the target cell (Russell and Ley, 2002).
In addition they can mediate antibody-dependent cellular cytotoxicity via CD 16 (Fcg
RIII), and are an important source of both antiviral and immunoregulatory cytokines.
NKT cells share some characteristics with both NK cells and T cells, they express
NK cell receptors but also an invariant CD3/aP TCR (Godfrey et al., 2000).
Recently much progress has been made in our understanding of the mechanisms that
regulate NK cell activation and in particular recognition of virus infected and
malignant cells. It is hoped this progress will eventually allow NK cells to be utilised
in clinical immunotherapy of cancers and possibly infections (Farag et al., 2002).
2.10.2 NK cell subsets - CD56bright and CD56dim cells
In healthy adults, two distinct populations of NK cells have been identified by the
density of cell surface expression of CD56 (Lanier et al., 1986), and these subsets
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differ in their ability to produce cytokines and lyse cellular targets (Cooper et al.,
2001a). Around 90% of resting NK cells are CD56dim, and this subset is cytotoxic
and expresses high levels of CD 16. The remaining 10% of cells are CD56bnght and
resting CD56bnght cells show less cytotoxic activity than the CD56d'm subset.
However, after stimulation with 1L 2, CD56bllghl cells produce high levels of
immunoregulatory cytokines, and also show enhanced cytotoxic activity (Cooper et
al., 2001b; Cooper et ah, 2001a). At present it is not clear whether the two subsets
represent different stages ofNK development or have different roles in the
pathogenesis of human disease.
2.10.3 NK cell function is controlled by opposing signals.
In 1986 Karre and colleagues predicated that NK cells recognize and target
autologous cells, which have either down regulated or altered major
histocompatibility complex (MHC) class 1 expression (Karre et ah, 1986). This was
known as the "missing self' hypothesis. Since then it has become clear that NK cells
express a number of both inhibitory and activating receptors which operate in concert
to control NK cell function (Figure 2-2 page 56). Broadly speaking NK cells do not
kill cells which express a full set of autologous MHC 1 molecules, but may be able to
lyse allogeneic cells which express certain combinations of MHC1 (Valiante et ah,
1997). NK cell receptor biology is a rapidly advancing field, and the nomenclature is
complex; receptors can be classified both by their function; inhibitory or activating,
and by their structural characteristics. As our knowledge grows it is evident that the
expression of a number of these receptors is promiscuous with much overlap in
expression of receptors between NK, NKT and CD8+T cells. As there are marked
differences between the nomenclature and function of the mouse and human NK cell
receptor systems, only the human system will be discussed.
Three major groups of receptors are recognized based on their structural
characteristics, Killer Immunoglobulin Receptors (KIRs), Natural Cytotoxicity
Receptors (NCR), and the C-type Lectin Domain family (Moretta et ah, 2000;
Moretta et ah, 2002; Lanier, 2001). KIRSsbelong to the immunoglobulin superfamily
and recognize different groups ofMHC including MHC-A, MHC-B and MHC-C.
The NKG2 family is characterized by a C-type lectin domain, and is a heterodimer of
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a common subunit, CD94, and a unique unit encoded by the NKG2 family. The
NCRs also belong to the immunoglobulin gene superfamily but have little homology
with known human cell surface molecules. The KIR family and the CD94/NKG2
family include both inhibitory and excitatory receptors, whereas currently all
members of the NCR family identified are activating type receptors.
Figure 2-2 NK cell activation is controlled by inhibitory and activating
receptors
2.10.3.1 Inhibitory Receptors
NK cells express a series of cell surface inhibitory receptors, which recognize MHC
l expression on the cell surface of autologous cells. This recognition of normal MHC
l on healthy cells is believed to protect against damage to self. On the other hand
alteration ofMHC 1, either on virus infected or malignant cells precludes this
inhibitory interaction, allowing activating receptors to dominate, and trigger NK cell
mediated lyses. For example, NK cells are able to lyse a MHC 1 negative LCL
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known as 721-221 (Shimizu et al., 1988). However, transfection ofMHC 1 genes
into a previously NK cell susceptible target inhibits NK cell killing (Litwin et al.,
1993).
At least 3 groups of inhibitory receptors have been identified in humans, KIRs,
members of the NKG2A/CD94 family, and CD85j and CD85d based motifs (Lanier,
1998) (Table 2-9 page 57). The KIR group of receptors recognizes different alleles
ofMHC-A, MHC-B, or MHC-C molecules. Each type of KIR, is expressed by only a
subgroup ofNK cells, though all mature NK cells will express at least one receptor
for self MHC 1, and this allows recognition of even minor changes in selfMHC. KIR
expression is not limited to NK cells, but also occurs on subsets of activated CD8+
apTCR+ T cells (Mingari et al., 1998). NKG2A/CD94 also recognizes MHC
molecules, but class E (Lanier, 2001).
Table 2-9 Inhibitory NK cell receptors
Inhibitory receptors Family Ligands
KIR2DL KIR MHC-C
KIR3DL KIR MHC-B MHC-A
CD94/NKG2A (CD 159a) C type lectin domain MHC-E
CD85j, CD85d C type lectin domain MHC class I
2.10.3.2 Excitatory receptors
NKG2D, is an activating NK receptor, which is part of the C type lectin domain
family and again its expression is not limited to NK cells but it is present on
%8TCR+T cells and CD8+ a(3TCR+ T cells (Bauer et al., 1999). A number of
ligands have been recently recognized including the human MHC, MHC- class-I-
chain related A and B antigens, (MICA and MICB), and UL-16 Binding Proteins
(ULBPs). The MICA antigens have been the focus of much interest as they are
expressed at low levels in healthy tissues, but are frequently over expressed in
tumours, and virally infected tissues (Jamieson et al., 2002).
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The NCR family of receptors includes, NKp46, NKp30 and NKp44 (Moretta et al.,
2000). NKp46 was the first to be identified, and cross linking of the receptor leads to
calcium mobilization, target cell cytotoxicity and cytokine release (Sivori et al.,
1997; Sivori et al., 1999; Pessino et al., 1998). Interestingly, NKp46 expression
appears to be limited to NK cells, and expression is high in the majority of donors
(Moretta et al., 2000), so the receptor may prove to be a useful means of identifying a
pure NK cell population. NKp30 is also expressed by all NK cells, however is
thought to co-operate with both NKp46 and NKp44 in the lysis of target cell lines
(Pende et al., 1999). NKp44 is not expressed by resting cells but is expressed in vitro
following NK cell activation with IL-2, and again is thought to cooperate with
NKp46 in the lysis of target cell lines (Vitale et al., 1998). Inhibition of NKp46
activity by a blocking antibody has reduced the lysis of a number of cell lines
including EBV transformed LCL and tumour lines (Parolini et al., 2000), however
the targets ligands for the NCR receptors have yet to be identified.
Working in concert with the NCRs are a number of co-receptors, which are
structurally different, but in vitro studies suggest cooperation is required with the
NCRs to signal cell activation. CD244/2B4, and NTB-A, are included in this group;
CD244 is only able to trigger activation on cells with a high surface density of
NKp46 and requires simultaneous engagement of NKp46 for activation to occur. For
example, NK cell clones with high surface density of NKp46 were triggered by
engagement of CD244 by antibodies, whereas NK cells with low cell surface
expression of NKp46 were not (Sivori et al., 2000). As previously discussed CD244
may be important in the recognition of EBV infected cells as it is able to ligate CD48
and of note signals via SAP (Figure 2-2 page 56).
The KIR group of receptors is encoded on chromosome 19, by a family of genes
known as the leukocyte receptor complex. Interestingly, the KIR genes are very
polymorphic; within a population individuals have highly diverse NK cell repertoires
and unless related almost always have different KIR types (Uhrberg et al., 1997). In
addition the KIR group of genes appear to be rapidly evolving. Substantial
differences were found between human and chimpanzees KIRs despite the fact that
we diverged from chimpanzees 5 million years ago (Khakoo et al., 2000), a relatively
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short time in evolutionary terms. Of note, the genes encoding CD94 and NKG2 do
not show the same degree of genetic diversity (Shum et ah, 2002).
Table 2-10 Activating NK cell receptors (Adapted from Cerwenka and Lanier,
2001).






CD244/2B4 NCR co-receptor CD48





NKG2D C type lectin domain MIC, ULBP
MIC-MHC-class-1 -chain-related molecules. ULBP-UL16-binding protein.
2.10.4 Cytokines acting on NK cells
As explained, the outcome ofNK cell interaction with a possible target cell is the
result of a concert of signals from activating and inhibitory receptors. How this is
influenced by other mechanisms such as chemokine and cytokine networks is not yet
clear. However, NK cells express cytokine receptors and are themselves an important
source of immunoregulatory cytokines. At present, most of our knowledge of NK
cell cytokine networks derives from in vitro tissue culture systems.
NK cells are the target of cytokines and monokines which are expressed by bystander
cells following viral infection, in particular a/|3 interferons are released following
viral infection and are potent inducers of NK cell mediated cytotoxicity (Cerwenka
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and Lanier, 2001; Orange and Biron, 1996; Nguyen et al., 2002). NK cells also
express receptors for monocyte-derived cytokines (monokines) including IL-1, IL-
• 10, IL-12, IL-15 and IL-18 (reviewed by Biron et al., 1999). IL-12 and Tumour
Necrosis Factor (TNF) are both able to stimulate the production of INF y by NK cells
(Tripp et al., 1993; Hunter et al., 1994; Paya et al., 1988; Paya et al., 1988).
The response of CD56bnght and CD56dim cell subsets to IL-2 in vitro has been studied
in detail (Cooper et al., 2001a). All NK cells express a functional heterodimeric IL-2
receptor with intermediate affinity for IL-2, however it is the CD56bnght subset which
has constitutive expression of a high affinity IL-2 receptor, and a high proliferative
response to low dose IL-2 in vitro. In contrast, CD56dim cells have a very limited
proliferative response to IL-2 (Cooper et al., 2001b). Other differences between the
bright and dim subsets have been identified, including the expression of a functional
CC-chemokine receptor 7(CCR7), and expression of high levels of functional L-
selectin- adhesion molecule on the CD56bnght cell subset (Kim et al., 1999). Both of
these receptors are involved in cell trafficking and it has been suggested that
CD56bnghl cells are able to traffic to secondary lymphoid organs. Indeed CD56bnght
cells have recently been identified as the dominant NK cell in human lymph nodes,
and may provide an important point of contact with the acquired immune system
(Fehniger et al., 2002).
The end result of NK cell activation is initiation of the cells effector functions.
However, we are now beginning to recognize that NK cells may be 'primed' before
activation occurs, indeed initially the cells must migrate to the site of the target, be it
infection or malignancy. Our knowledge of NK cell priming and migration is limited;
recent studies have suggested that bi-directional cross talk between dendritic cells
and NK cells may be important (Piccioli et al., 2002). In addition, co-stimulatory
molecules, engaged by NK cells (such as intracellular adhesion molecules or CD58)
alongside the cytokine networks discussed above, may have a role in cell priming
before cell activation occurs (Zitvogel, 2002).
2.10.5 NK cells are a source of immunoregulatory cytokines
NK cells are known to produce a number of pro inflammatory cytokines, including
IFN y, TNF (3, granulocyte/macrophage colony stimulation factor and beta
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chemokines, macrophage inflammatory protein la and macrophage inflammatory
protein 1(3 (Orange and Biron, 1996). Again differences have been identified
between the CD56b"ght cell and CD56dimcell subsets. In studies on human NK cells,
the CD56bnght cell population, either stimulated with monokines or phorbal 12-
myristate 13-acetate (PMA) and ionomycin, are the major source of the cytokines
detailed above (Cooper et al., 2001b).
2.10.6 NK cells and control of viral infection
The strongest evidence for the role of NK cells in control of herpes virus infections
remains the case histories of individuals with NK cell defects who have developed
recurrent herpes virus infections (Biron et al., 1989 and reviewed in Orange, 2002).
Isolated NK cell defects are rare, but defective NK cell responses have also been
documented in several other syndromes in which severe EBV infection occurs, these
include CAEBV (Joncas et al., 1989), EBV linked viral haemaphagocytic syndrome
(Kogawa et al., 2002) and Chediak-Higashi syndrome (Merino et al., 1983).
Chediak -Hiagashi is a rare autosomal recessive lysosomal storage disorder in which
hypopigmentation and NK cell defects occur. The important role of NK cells in the
pathogenesis of XLP has been discussed (see section 2.7.8.2 page 47).
Earlier studies on the immune response to EBV have identified raised NK cell
numbers during IM (Tomkinson et al., 1989). Previous investigators have also
documented a decreased ability of ex vivo PBMC from IM patients to kill the NK
target cell line K562 (Williams et al., 1989). However, when this work was carried
out NK cell separation methods were limited. Since then, much progress has been
made in our ability to both identify NK cells in the peripheral blood, and isolate them
from the PBMC population either by use of magnetic beads or FACS methodology.
Recently, it has become clear that certain NK receptors are able to directly recognise
viral antigens on infected cells. For example, NK cells expressing NKp46, one of the
major human activating receptors, bind to and lyse cells expressing the
haemagglutinins of both influenza and parainfluenza viruses (Mandelboim et al.,
2001). Furthermore, susceptibility to mouse cytomegalovirus has been linked to
deletion of an activating NK cell receptor (Daniels et al., 2001; Brown et al., 2001;
Lee et al., 2001), which recognises the viral protein Ml57 (Arase et al., 2002).
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Interestingly, Lanier has noted that individuals with NK cell defects do not appear to
be at risk of severe influenzae infection, therefore the relevance of the interaction
between Nkp46 and haemagglutinins to the control of influenzae infection in humans
remains unclear (Cerwenka and Lanier, 2001).
Viral infection may lead to reduced expression of MHC 1 on the surface of a cell,
and this is thought to be associated with evasion of CTL recognition by the virus. On
the other hand, this is likely to render the cell susceptible to recognition by NK cells.
However a number of viruses also have mechanisms which may allow them to
escape detection by NK cells (Farrell et al., 1997, and reviewed in Orange et al.,
2002). For example, human CMV encodes a class 1 homologue on the cell surface,
which is thought to block NK cell activity by ligation of inhibitory NK cell receptors
(Beck and Barrell, 1988). In addition, in mice, the CMV Ml52 encoded gp40
glycoprotein has been shown to downregulate ligands for NKG2D (Lodoen et al.,
2003). Following human CMV infection, intracellular sequestration of ligands for
NKG2D occurs, again allowing the virus to evade detection by NK cells (Dunn et al.,
2003). Other mechanisms of viral evasion of NK cells are well recognized, such as
virus encoded cytokine binding proteins (Orange et al., 2002), which would inhibit
NK cell recruitment and activation. At present it is not known if EBV utilities any of
these mechanisms.
Following the unraveling of the interaction between NK cells and mouse CMV
infection, Lanier and Arase have suggested that a key evolutionary pressure on NK
receptor development may be viral infection (Arase and Lanier, 2002).
2.11 Varicella Zoster Virus
Varicella zoster virus (VZV) is an alpha herpes virus, which is solely a human
pathogen. Unlike the other herpes viruses, primary infection in childhood is normally
symptomatic, (chicken pox), although only mild illness occurs in the majority of
cases. Primary infection in adults, tends to be much more severe, particularly in
pregnancy. After primary infection, the virus establishes latency in sensory nerve
ganglia. Reactivation of the virus is common, particularly in the elderly and causes
Introduction 62
An analysis of the immune response to primary Epstein- Barr Virus infection and the association with
clinical events
Herpes Zoster (shingles). Host immunosuppression can lead to both severe primary
infection and life threatening systemic disease associated with reactivation.
2.11.1 Primary infection- Chickenpox
Primary VZV infection, or chicken pox, is normally a mild illness characterised by a
febrile illness and vesicular rash, and no significant complications. In temperate
climates over 95% of the population is infected under the age of 10. The incubation
period is 10-21 days, and the virus is highly infectious with 70-90% of seronegative
household contacts contracting the virus (Arvin and Gershon, 1996).
Antiviral therapy is appropriate in severe cases, though should ideally be used within
24 hours of the onset of disease. Aciclovir and the newer pro drugs such as
valaciclovir, inhibit the viral DNA polymerase; they are selective for the virus as
only the viral thymidine kinase phosphorylates and activates the drugs.
2.11.1.1 Immune response to primary VZV infection
As demonstrated by the severity of infection in children with defects in cellular
immunity, the T cell response is critical to the control of primary VZV infection. In
comparison, those with B cell defects appear to be at less risk of disseminated
disease (Cohen et ah, 1999).
Studies of ex-vivo T cells from individuals with primary VZV have enabled the
identification of a number of characteristics of the cell mediated response. As in
primary EBV infection, T cell populations are activated and express increased levels
MHC-2 (Arvin, 1992). Strangely, there appears to be a prolonged delay in the
development of VZV specific T cells, as they are not easily detected until 24-72
hours after the appearance of the rash. However, the majority of this work was done
before the advent of more sensitive techniques for detection of antigen specific cells
(such as tetramers) and use of these technologies may allow identification of VZV
specific cells earlier in the disease course. Both virus specific CD4+ and CD8+ cell
subsets have been identified during primary infection. The CD4+ cells are mainly of
a TH1 phenotype and synthesis IL-12 and IFN-y (Asanuma et ah, 2000). At present
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there is no animal model of primary VZV infection in which to investigate the
pathogenesis further.
2.11.2 Live attenuated VZV vaccination
VZV was the first herpes virus for which a vaccine was available and widely used.
The vaccine is a live attenuated virus, based on the OKA strain. The vaccine was
licensed in the USA in 1995 (1996), and it is more widely used in the USA than the
UK. It is 85-90% effective in preventing primary infection, and in those who do go
on to develop chickenpox, the condition is usually mild (Wise et al., 2000). It may be
particularly useful in seronegative health care workers. Unfortunately a live
attenuated vaccine is not suitable for either pregnant women or the
immunosuppressed, both high risk groups for severe VZV infection. However, the
vaccine is indicated for leukaemia patients in remission, who seem to be especially
vulnerable to severe infection.
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3 Materials and Methods


















Applied Biosytems 850 Lincoln Centre Drive
Foster City, CA 94404
10975 Torreyana Road San Diego, CA
92121-1106
DAKO Corporation 6392 Via Real CA
93013 USA
Law Hospital Carluke Lanarkshire Scotland
ML85QZ
CAMR Salisbury Wiltshire SP4 OJG
20 Hampden Street Boston MA 02119
Fisher Scientific UK Ltd Bishop Meadow
Road, Loughborough,
Leicestershire LEI 1 5RG
3 Lancer court Astmoor Industrial Estate,
Runcorn, Cheshire WA7 1PN
Immunotech, Coulter, 13276 Marseille
Cedex 9 France
P O Box 520, Wembley, Middlesex, HA9
7YN, UK, Tel: +44 20 8385 0303
1 Admiralty Way, Camberley, Surrey, GUI5
3DT,
Miltenyi Biotech Friedrich-Ebert-Str 68
51429 Bergisch Germany
www.mwgbiotech.com
Molecular Probes Inc 4849 Pitchford avenue
Eugen Or 97402-9165, USA
45 William Street Wellesley, MA, 02481-
4078, USA
Boundary Court, Gatwick Rd, Crawley,
RH10 9AX
2161 Delaware Avenue, Santa Cruz,
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Sarstedt







68 Boston Rd, Leicester LE4 1 AW
Unit 17, Coatbridge Business Centre, 204
Main Street, Coatbridge, Lanarkshire ML5
3RB
Chadwick Rd, Runcorn, Cheshire WA7 1PR
Sigma-Aldrich Company ltd. Fancy Rd,
Poole, Dorset, BH12 4QH
www.genosys.co.uk
Vector Laboratories inc 30 Ingold Road
Burlingame, CA 94010 USA.
Zymed laboratories 561 Eccles Avenue So.
San Francisco, CA 94080
3.2 Laboratory consumables, chemicals, and kits
All laboratory consumables were supplied by Fisher Scientific UK or Scientific
Laboratory Supplies unless otherwise stated. All tissue culture consumables were
supplied by Fred Baker UK. All laboratory chemicals were supplied by Sigma unless
otherwise stated.
Amplitaq with 10X PCR buffer II & MgCl2
Solution
Big dye rapid reaction mix
Animal Serum- mouse, rabbit, horse, pig
Cell dissociation medium
Cytospin filters and cartridges
DAKO fluorescent Mounting Medium
DAKO antibody diluent with background
reducing components
DAKO ISH kit and EBERS probe











DAKO Protein Block Serum Free DAKO
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DAKO Ultramount aqueous permanent
Mounting Medium, Ready to Use
ImmunoEdge Pen
Infectious Mononucleosis absorption kit
(monospot)
Invitrogen Easy DNA kit
Haematoxylin Nuclear Counter Stain
MACS NK Cell Isolation Kit
MACS Separation Columns MS+ Columns
MACS Magnet cell separator
Methyl Green Counter stain
Perm/Wash Buffer
Primers for XLP PCR and EBV PCR
Qiagen quick gel extraction kit




























Vectastain ABC Kit Vector
VectorMount Mounting Medium Vector
Vector Red Alkaline Phosphatase Vector
Avidin Biotin Blocking Kit Vector
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3.3 Antibodies
Table 3-1 Details of antibodies used
Target Isotype/
species
Label Use Dilution Storage Source
CD244/
2B4
Mouse IgG! PE Flow lOul per sample 4°C Immunotech
EBV
LMP1
Mouse IgG| IHC 1:25 4°C DAKO
EBNA-
3B









IHC 1:20 4°C Kind gift Prof
Rowe Cardiff




CD56 Mouse IgG| IHC 1:30 4°C Zymed
Laboratories
CD3 Mouse IgG| IHC 1:50 4°C DAKO
Goat IgG Horse Biotin IHC 1:500 4°C Vector
SAP Rabbit IHC 1:20 4°C Santa Cruz
Diagnostics
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Goat Biotin IHC 1:500 4°C Vector
Rabbit
IgG
Goat Biotin IHC 1:500 4°C Vector
CD56 Mouse IgG| PE Flow lOul per sample 4°C BD
Pharmingen
CD 16 Mouse IgG) FITC Flow lOul per sample 4°C BD
Pharmingen
CD8 Mouse IgG, FITC
& PE
Flow 1 Oul per sample 4°C BD
Pharmingen




Flow lOul per sample 4°C BD
Pharmingen
CD19 Mouse IgGi FITC Flow lOul per sample 4°C BD
Pharmingen
CD4 Mouse IgGi FITC
& PE
Flow lOul per sample 4°C BD
Pharmingen
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IHC- immunohistochemistry, Flow- flow cytometry- no conjugate, FITC Fluorescein-5-
isothiocyanate, PE- R-phycoerythrin






Working solution 10 mM
Citrate Buffer
4.2 g Citric Acid 14.7 g Sodium Citrate 18 ml Stock A
20 mis ddFEO 500 mis ddFEO 82 ml Stock B
Fill to 1 litre with ddFEO
and pH to 6.0





Tris Buffered saline (TBS)
(made up in BS)
Tris HCL pH 8.0 lOmM
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Streptomycin lOOug/ml
Fetal calf serum 10%v/v
Made up in lx RPMI 1640.
Freezing medium store at 4°C, and use within 28 days
Fetal Calf Serum 90% v/v
DMSO 10% v/v
DNAase store at 4°C, and use within 2 days
Fetal Calf Serum 70%v/v
Heparin 100 units per ml
MgSOa 15mM
DNAase 2000 units per ml
Flow cytometry buffer, store at 4°C, and use within 28 days
Bovine Serum Albumin 1% w/v
Sodium azide 0.1%w/v
EDTA 0.02%v/v
PBS Made up in PBS
MACS Buffer, store at 4°C, and use within 24 hours
Bovine Serum Albumin 1% w/v
EDTA 0.02%v/v
PBS Made up in PBS
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10 X PCR Buffer 1 (autoclave before use as 10 x PCR buffer), store at
room temperature
Tris-HCL (ph 8.8) 670 mM
(NH4)2 S04 ( enzyme grade) 166 mM
MgCT 67 mM
1x Tris EDTA T(0.1)E, store at room temperature
Tris HCL(ph 8.00) lOmM
EDTA ImM
TCR-T.0.1.E with Creole red, autoclaved before use (28g sucrose and 8mg Cresol
red) in 100ml T.O.l.E
3.5 Cell Lines
Cell line Source Medium Reference
B958 LCL
Marmoset
Standard tissue culture medium (Miller et ah,
1972)










3.6 PCR and sequencing techniques
3.6.1 DNA extraction
Tissue specimens were snap frozen and stored at -70° C. Samples (3.5-100mg) were
thawed on ice and pulverised with a pellet mixer in 200 ul of PBS. The Invitrogen
Easy DNA kit was used, as per manufacturers instructions. 350 ul of solution A was
added to the cell suspension and the mixture was vortexed until evenly dispersed.
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The cell suspension was then incubated at 65° C for 10 minutes and briefly
centrifuged. 500ul of chloroform was added and again the tube vortexed until the
viscosity decreased and the mixture was homogenous. The suspension was then
centrifuged at 13,000rpm for 15 minutes at 4° C; two separate layers form, and the
upper layer was transferred into a clean microfuge tube. The DNA was then
precipitated by addition of 1ml of 100% alcohol, and freezing overnight at -20° C.
The DNA was then centrifuged at 13,000rpm for 15 minutes at 4° C, the ethanol
removed and the pellet allowed to air dry. The pellet was then resuspended in
molecular grade water, and stored at 4° C (short term) and -20° C (long term).
3.6.2 PCR reaction
Two PCR methods were used, the first followed the method of (Coffey et ah, 1998)
the second was adapted from (Yin et ah, 1999). A Biometra T3 thermocycler PCR
machine was used throughout.







Primer forward (lOOng/ul) 1.5
Primer reverse (lOOng/ul) 1.5
DNA(10ng/ul) 5
Made up in ultrapure water Total 50ul
Method 2 1 sample (ul)
Buffer (15mM Mg) 5
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DNTP (20mM) 0.5
Primer forward 0.1 nM/ul 0.5
Primer reverse 0.1 nM/ul 0.5
Taq polymerase 0.4
DNA (50ng) 4
Made up in ultrapure water Total 50ul
3.6.3 Cycling conditions
The cycling conditions were the same for both methods. The reaction started with 5
minutes denaturing at 94° C, followed by 35 cycles of three steps; 93° C for 30
seconds, primer specific annealing temperature for 30 seconds, and 72° C for 30
seconds. This was followed by an extension step of 5 minutes at 72° C.
3.6.4 Primer selection
The oligonucleotide primers used for the PCR were designed from the published
sequences for all 4 exons, and were chosen to amplify the whole coding exon. The
primer sequences were situated just outside the coding region for each exon (Coffey
et al., 1998). (See Table 2-1 page 18).
Table 3-2 Primers used for PCR and sequencing SH2DIA/SAP









F ACAGAAGCATTACTAAGC 60 568
R CCAGCTGCTGTTGCCCAC
Exon 2 F CAATGACACCATATACGTGT 60 341
R GCTTTCTTAATGATCCATGA
Exon 3 F CAAGTTACACAAATGTTTA 55 308
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R CTTGGACTCATAACTCTCTG
Exon 4 F TCATTGTGAGTTTTATGCAG 55 233
R GCTCACCGAACTGTATTA
3.6.5 Control Template
A positive and negative control was used with each PCR reaction, genomic DNA
was used as a positive control and molecular grade water was used to replace the
DNA as a negative control.
3.6.6 Gel separation
PCR products were separated on either 2.5 % or 4% agarose and visualised by
ethidium bromide (EB) staining; 2.5 ul of EB per 50 ml gel or buffer. TBE buffer
was used in the gel tank. The gels were run at 120 V for 40-80 minutes. A 1 Kb DNA
marker was used.
3.6.7 Gel products - cleaned before sequencing.
The PCR products were purified directly after separation on a gel. QIAGEN
QIAquick Gel Extraction Kit was used; instructions and reagents were supplied by
the company. Appropriate bands were cut from the agarose gel using a minimal
amount of UV exposure. The gel band was weighed, and 6 volumes of buffer QC
were added to the gel. (The volumes was calculated using the principal of
100mg=100ul). The gel and buffer were incubated at 50°C for 10 minutes, with
vortexing every 2 to 3 minutes. When the gel had dissolved completely 1 volume of
isopropranol was added to the mixture and mixed gently. The solution was applied to
a spin column, and centrifuged for 1 minute. The column was washed with 500ul of
Buffer QC, to remove excess agarose. 750 ul of Buffer PE was added and the column
centrifuged for 1 minute, twice. The DNA was eluted with the addition of 30 ul of
elution buffer (10 mM Tris-Cl, ph 8.5), and the product stored at 4°C.
3.6.8 Sequencing and ethanol precipitation
Sequencing was carried out using BIG DYE Terminator Ready Reaction kit. In brief
8ul of clean PCR product was mixed on ice with 2ul of primer (concentration of
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1.6pmole/ul), 8ul of Big Dye and 4ul of water. The reaction was 25 cycles of 95°C
for 30 seconds, 50°C for 20 seconds, and 60°C for 4 minutes, followed by a holding
step at 4°C.
A second sequencing service was also used, the commercial service MWG Value
Read. Clean PCR products were sent at a concentration of DNA = 20ng/100
nucleotides.
PCR and sequencing products were ethanol precipitated prior to use. Either lOul
purified PCR product (for MWG sequencing) or lOul of the sequencing reaction
were mixed with lul of 3M NaOAc and 200 ul of 100% Ethanol, at -20°C, vortexed
and left on ice for 20 minutes. The tube was then centrifuged at 15000rpm for 30
minutes at 4 °C, and then washed (once or twice) with 70% alcohol, and again
centrifuged at 15000rpm for 15 minutes.
3.6.9 BLAST search
Sequences were entered into the National Centre for Biotechnology (NCBI) BLAST
(standard nucleotide search engine http://www.ncbi.nlm.nih.gov/blast/) and
sequences were compared with the wild type sequence for the 4 XLP exons. The full
sequence is available on European Molecular Biology Laboratory (www-db, embl-
heidelberg.de) (EMBL) sequence data base (ID HSDSHP, accession number AL
023657), and this was used to verify the location of the sequence within the 4 exons.
3.7 Cell culture techniques
3.7.1 FICOLL- HYPAQUE Separation of PBMCs
50 ml Falcon tubes were filled with a volume of Ficoll equal to the volume of blood
to be separated. Using a sterile pipette an equal volume of blood was over-layed on
the Ficoll. The tubes were centrifuged at 2200 rpm at 20°C for 20 minutes. The
plasma was collected using a Pasteur pipette and stored at -20°C. A sterile pasteur
pipette was used to collect the mononuclear cell layer which were transferred to a
clean centrifuge tube. The tube was filled with HBSS and centrifuged at 1200 rpm
(330g) at 20°C for 7 minutes. The supernatant was discarded and the pellet
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resuspended in HBSS. The viable cells were counted using the trypan blue exclusion
test and a haemacytometer.
3.7.2 Cell culture
All cells were cultured in an humidified 5% CCF incubator at 37 0 C, and fed as
required, usually every 2-3 days with the appropriate tissue culture medium.
Adherent cell lines were split once the growth was 70-80% confluent; cell
dissociation medium and cell scrapers were used to remove adherent cells and the
cells were washed in tissue culture medium prior to resuspension. Cells grown in
suspension were split when the tissue culture flask was approximately one third full.
3.7.3 Cell wash
All cell washes were carried out in HBSS or RPMI at lOOOrpm for 5 minutes, in a
bench top centrifuge.
3.7.4 Cell counts
A 1 in 1 dilution of cell suspension was made by adding 10|il of cells to 10|dl of
trypan blue. lOpl of stained cells was applied to the haemocytometer. The number of
unstained cells (viable) in the 25 central squares was counted and divided by 5. This
number, divided by 10 is equal to cell count per ml of cell suspension.
3.7.5 Viable storage of cells
Cell lines were fed the day before freezing. Cells were counted and spun in a
centrifuge in culture medium at 1000 rpm (330g) for 5 min. Cells were resuspended
in freezing medium at 5xl06to 5xl07 cells per ml, and 1 ml was placed in a cyrovial.
Vials were frozen for 24-48 hours at -70°C, followed by storage in liquid nitrogen
Cryovials of cells were thawed at 37°C in a water bath for 1-2 minutes. Cells were
immediately transferred into a Falcon tube containing 10-30 ml of warm HBSS. The
tube was subsequently centrifuged at 1000 rpm (330g) for 5 minutes. The cells were
then counted and used as required.
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3.7.6 B958 virus preparation and titration
B958 cells were grown to 90% capacity in six 250 ml flasks, and then left covered in
parafilm without feeding for 10 days. The culture was then spun in a centrifuge at
1200rpm for 5 minutes at 4 °C, the supernatant was then filtered through 0.8 pm
filter and the cell pellet discarded. The supernatant (in Beckmann bottles) was then
spun in a centrifuge at 18000rpm for 2.5 hours at 4 °C. The cell pellets were then
resuspended in 1 ml of tissue culture medium, and lOOpl was stored and frozen at -
70°C in cryovials.
The virus was titrated by mixing EBV negative PBMC with a dilution series of virus
stock ranging from neat virus, through 101' 10 2' 10~3' 10"4' 10 s 10"6'to no virus. The
cells were incubated in a 96 well plate (5 wells of each dilution , for 4 weeks with
weekly feeding. At the end of four weeks the wells were scored for outgrowth under
an inverted microscope. The virus titre equalled the dilution showing 50% growth.
3.7.7 Generation of PHA blasts
PBMC were suspended at 106 cells/ml in standard tissue culture medium, and 20pl of
PHA per ml of cell suspension was added. Cells were placed at 2ml per well in a 24
well plate, and incubated at 37°C.
3.7.8 Generation of lymphoblastoid cell lines
PBMC were suspended at 106 cells/ml in standard tissue culture medium with 100-
200 ul of B95-8 virus and incubated for 10 minutes at 37°C. 0.5ml per well was
added to a 24 well flat bottomed plate. The plate was incubated at 37°C and fed with
standard tissue culture medium every 3-4 days. When growth was established wells
were split, and transferred to a flask as required.
3.8 Flow Cytometry
3.8.1 Antibody titration
The anti SLAM (A 12, IgGl) antibody was grown at the Sheffield University
Hybridoma Unit, and labelled with FITC at Scottish Antibody Production Unit.
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A series of titration experiments were undertaken to investigate the optimal amount
of SLAM antibody for staining 0.5-1 x 106 cells for flow cytometry. PBMC from 5
different donors were stimulated with PHA, and subsequently stained with varying
amounts of FITC labelled SLAM antibody.
In summary maximum SLAM expression occurred at 4-6 hours following PHA
stimulation and 5ug of labelled antibody per 0.5-1.0 x 106 cells, gave adequate
staining but minimal background. This amount of SLAM antibody was therefore
used for the flow cytometry experiments. All other antibodies were used at
concentrations recommended by the manufacturer.
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6 0-6 SLAM at Expression Maximum expression
5mcg maximal at 4 occurs between 4-6 hours
hours, stable at post PHA stimulation
6 hours.
3.8.2 Cell surface staining
0.25-0.5 x 106 cells were placed in plastic tubes, and spun for 5 minutes at lOOOrpm.
Appropriate quantities of stain were added to each tube (Table 3-1 Details of
antibodies used page 68) and incubated at 4°C for 15-30 minutes. The cells were
then washed in 1ml per tube, cold FACS buffer, and spun for 5 minutes at lOOOrpm.
The supernatant was aspirated and the cells resuspended in 0.25-0.5 ml of FACS
buffer and stored at 4°C. Tubes were analysed within 24 hours. The stained cells
were analysed on a FACScalibur (Becton Dickinson). Samples were analysed by
either 2 or 3 colour staining, plus TO-PRO. Cells were gated on forward and side
scatter to identify the lymphocyte population, and dead cells were identified by
staining for TO-PRO 3. In addition, in some analysis cells were further gated into a
CD3 positive and negative population. Unstained cells and cells stained with
appropriate isotype controls were used as negative controls. The data were processed
on CELLQuest program (Becton Dickinson).
3.8.3 Intracellular staining
SAP is an intracellular antigen, and therefore the cell membrane must be permeated
prior to the antigen staining, and flow cytometric analysis. Intracellular flow
cytometry is a well established technique; the cell is permeated using a chemical
such as saponin, and then stained with the appropriate antibody, followed by 2-3
wash steps to remove excess antibody.
The technique was established for analysis of antigens for which there is a labelled
monoclonal antibody such as INF y, an intracellular cytokine expressed in PHA
stimulated PBMC. However, when intracellular staining of SAP was carried out,
using an unlabelled polyclonal antibody, extensive non specific staining occurred and
acceptable results could not be obtained. A number of steps were undertaken to
reduce the non specific staining. These included use of a number of different
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fluorescent secondary antibodies, increased number of wash steps, use of acetone
absorption of the primary antibody, and use of alternative methods of cell




Fresh PBMCs were suspended at 1 x 106 cells/ml in PBS, and stored at 4° C. The
cytospin chambers, slides (pre-coated with polysine) and a filter card were loaded
into the cytospin, and the filters were pre wetted with 50ul of PBS. 50ul of PBMC
suspension was added to each cytospin chamber and spun at 150rpm for 3 minutes.
The slides were then fixed in acetone (at 4° C) for 10 minutes, and stored at -20° C.
3.9.2 Removing paraffin wax
Paraffin embedded sections were immersed in xylene for 5 minutes, followed by 5
minutes in 100% ethanol. The sections are rehydrated by sequential immersion for 3
minutes in 90%, then 70% then 30% ethanol, diluted in water. Finally slides were
washed in tap water.
3.9.3 Microwave Antigen Retrieval
Antigen retrieval was carried out after de-waxing. The slides were washed in running
water and immersed in citrate buffer in a plastic container, suitable for use in a
microwave. The slides in buffer were microwaved on high for 3 x 5 minutes, with
top up of buffer as needed. The slides were then washed in running tap water,
followed by PBS. It was found that use of citrate buffer and microwave heating gave
improved antigen retrieval compared to other systems tested including commercial
buffers. Antigen retrieval was not required for frozen sections.
3.9.4 Single colour staining using an avidin-biotin amplification system
Immunohistochemistry was carried out using an avidin-biotin amplification system.
In brief an unlabelled primary antibody of choice is use to target the designated
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antigen (e.g. SAP). This is followed by a biotinylated antibody against the species of
the primary antibody, and then followed by peroxidase conjugated avidin antibody.
Finally a peroxidase dependent colour substrate is added (eg DAB (3, 3' -
diaminobenzidine). Alternatively an alkaline phosphotase substrate may be used.
3.9.4.1 Single colour biotin- avidin peroxidase DAB (3, 3'-
diaminobenzidine)
Slides, either paraffin fixed tissue, frozen section or cytospins were rinsed with PBS
for 5 minutes. The slides were then incubated with 0.5% hydrogen peroxide for 10
minutes followed by a PBS wash. (All PBS washes were for 2 x 5 minutes). Next,
the slides were incubated with normal serum diluted 1:5 in PBS, determined by the
species of the secondary antibody. The slides were then incubated with the primary
antibody ( Table 3-1 Details of antibodies used page 68) followed by a wash then the
secondary antibody (biotinylated and diluted 1:500), followed by a further wash. All
antibody dilutions were carried out in DAKO antibody diluent. The slides were
subsequently incubated with the peroxidase substrate solution (for 30 minutes),
followed by a wash followed by DAB solution for 5 minutes in the dark. The slides
were counter stained with haematoxylin for 1-2 minutes, followed by clearing by a
rinse in 95% alcohol, 100% alcohol, 95% xylene, and 100% xylene. The slides were
mounted and covered with a glass cover slip.
3.9.5 Optimization and method for sequential staining techniques.
In order to identify the cell type and function of the cells which expressed SAP a
number of methods of visualizing 2 antigens in the same cell type were assessed
(Table 3.4 page 82). A combination of 2 fluorescent antibodies, or DAB (brown)
staining combined with Vector red failed to give satisfactory results. The problems
derived both from the background staining from the SAP polyclonal antibody and the
need for a good colour contrast to allow visualization of dual labeled cells. It was
found that a first step reaction using DAB, for an antigen which was expressed by a
small proportion of cells, followed by Vector Blue worked well.
For the double staining procedure the slides were stained with DAB as above, and
then incubated with avidin biotin block for 15 minutes are room temperature. The
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procedure was then followed as for single staining, except alkaline phosphatase
substrate solution was used, with Vector Blue substrate. Slides were not cleared in
xylene, but fixed with DAKO ultramount, which does not require a cover slip. In all
cases the primary and secondary antibodies were from different animal species.




























Good colour contrast, optimal
results using less common antigen
with primary substrate.
3.9.6 Counting
200 cells were counted on each slide in random fields. SAP/INF y dual positive slides
were graded as high (4+ dual positive cells per hundred cells), low (2 or less dual
positive cells per hundred cells), or negative (no dual positive cells).
All the figures of IHC are marked with the microscope magnification; as digital
photography was used, some of the figures were enlarged digitally.
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3.9.7 In situ hybridisation for RNA detection using EBER probe.
The working procedure was followed for the PNA ISH Detection Kit (DAKO). All
glass ware and water were washed to inactivate Rnase and double distilled water was
used throughout. The slides were immersed in 99% ethanol followed by 96%
ethanol, for 2 times 3 minutes at each concentration. The slides were incubated with
proteinase K (diluted 1:1000) for 10 minutes in a humid chamber at room
temperature. The slides were then washed in pure water (2x3 minutes) and then
dipped in 96% ethanol, and air dried. 1 drop of FITC-conjugated PNA probe was
added to the slide, and the slides were placed in a humid chamber at 55° C for 90
minutes. The slides were then immersed in the stringent wash solution (preheated to
55°C) and washed at 55°C for 30 minutes, followed by a brief immersion in TBS (
room temperature). The slides were then incubated with 2-3 drops of ANTI-
FITC/AP for 30 minutes at room temperature, and washed in TBS (2 x 3minutes),
followed by pure water (2 x 1 minute). Finally, the slides were incubated with
substrate solution for 30-60 minutes at room temperature, and washed in tap water,
and mounted.
3.10 NK cell separation
PBMC were separated from whole blood using Ficoll method as described
(3.7.1page76). The MACS beads separation method was followed as per the
manufacturers instructions. In brief, cells were suspended in fresh cold (4 °C) MACS
buffer at total volume of 80ul per 107 total cells. 30ul of hapten antibody cocktail
(containing anti: CD3, CD4, CD14, CD15, CD19, and CD36 antibodies) was added
per 107 cells and incubated for 15 minutes at 4 °C. Cells were washed in MACS
buffer, and re-suspended at 80ul per 107 total cells in MACS buffer and 30ul of anti-
hapten antibody cocktail was added per 107 cells and incubated for 15 minutes at 4
o
°C. The cells were washed in MACS buffer, re-suspended in 500ul of buffer per 10
total cells, and applied to an LS+ column in the magnetic field of the Midi MACS
magnet. The NK cells were eluted with 4 x 3ml of MACS buffer, and the retained
cells were the non NK cell fraction.
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The cell purity was checked by standard FACS analysis on 5 occasions, using
antibodies to CD56 and CD3, and found to routinely contain less than 0.5% CD3
positive cells on all occasions. Between 5-30% of the cells did not stain with
antibodies to either CD3 or CD56, and so were checked for expression of CD 14,
CD 19, and CD4, all of which were negative. On direct microscopy significant
numbers of red blood cells were noted, and therefore represented the unstained cells
in the NK cell fraction.
3.11 51Chromium release assay for cytotoxicity
0.5 x 106 of each target cell line was suspended in a minimal volume of medium and
incubated with 100 micro Ci of chromium^l at 37°C for 60 minutes. The cells were
then washed with RPMI 3x5 minutes at 1200 rpm in a centrifuge. NK cell effectors
were incubated for 4 hours, at ratios of 20:1, 10:1, and 5: 1 with the target cell line.
Chromium release was measured using a y counter. NK cell cytotoxicity was
calculated as percent lysis = [(experimental release- spontaneous release)/ (maximum
release-spontaneous release) ] x 100. Spontaneous release was calculated by
incubating target cells without effector cells and maximal release was calculated by
incubating target cells with 1% Triton X.
3.12 EBVDiagnostic Serology
EBV serological status was determined by EBV serology (IgG and IgM), to viral
capsid antigen (VCA) by indirect immunoflouresence. In addition acute diagnostic
samples were tested with the monospot test.
3.12.1 Monospot
A Microgen Bioproducts IM kit was used as per manufactures instructions. In brief,
25 ul of positive control or test serum was placed in each of 2 ovals of white glass
slide. 1 drop of guinea pig antigen was added to one oval, and 1 drop of ox cell
antigen to the other. 1 drop of horse cell suspension was added to each oval, and the
slide was gently rocked. A positive result is indicated by agglutination in the oval
containing guinea pig antigen, but not in the oval containing ox antigen.
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3.12.2 Immunoflourescence for EBV anti VCA
All tests were carried out on serum. The serum was heat inactivated prior to testing,
by heating for 20 minutes at 56°C. Test slides were prepared by placing 5 x 104 cells
of the P3HR1 cell line in the 12 wells of a microscope slide. The test sera were
diluted in PBS at 1:5 and 1:10, and were added to the slides along with control sera,
from known positives and negatives. The slides were incubated for 1 hour in a humid
chamber at 37°C. The slides were then washed in PBS, and incubated with lOul of
FITC conjugated rabbit anti human IgG (diluted 1:50 in PBS). The slides were
incubated for a further lhour at room temperature. The slides were washed in PBS,
and mounted in PBS: glycerol. The slides were read under an epiflourescent
microscope.
3.13 Quantitative EBV PCR
The EBV quantitative PCR was kindly carried out by K.McAulay following the
method described by (Stevens et al., 1999) by quantitative competitive PCR (Q-
PCR). The amplification reaction contained the following: 50mM KCL, 1.5mM
MgCl, lOmM Tris pH 8.5, 25 pmol of each primer, one of which was biotin labelled,
and 1U of taq. Cycling conditions were 4 min at 95°C; 40 cycles at 95°C, 55°C and
72°C for 1 min each; and finally 3 min at 72°C. Products were captured on a
streptavidin coated plate and probed with digoxigenin labelled wild type and internal
standard probes. Optical density was measured and used to calculate copy number.
3.14 Controls
3.14.1 Subjects with primary VZV infection
Four adults (2 male, 2 female, age range 28-40 years), with laboratory proven
primary VZV infection, 3 of whom required hospital admission and treatment with
acyclovir, were enrolled in the study. 3 cases were recruited from the Regional
Infectious Disease Unit at the Western General Hospital, Edinburgh. The other case
was the partner of a laboratory worker. In all cases, blood for this study was taken
before commencing antiviral therapy.
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3.14.2 Healthy Control Subjects
Blood was taken from 13 healthy volunteers (age range 22-30 years; 3 male, 10
female) and used for control experiments. All subjects were white Caucasian,
however the age range and male:female ratios were not identical for each of the
subject groups. These differences are minor and could not account for the findings in
this study. Additional control data were available from UK blood donors (n=14),
however Full blood counts (FBC) were not available. In addition NK cell counts
were available from an additional 8 healthy controls from studies carried out by Dr
Macsween.
3.15 Ethics
Ethical committee approval was obtained by the University of Edinburgh Research
Ethics Committee for both the IM and VZV studies. In addition consent was
obtained from the Edinburgh Students Ethics Committee for the IM study. All
individuals signed a consent form, both at time of recruitment to the study, and again
if they subsequently developed IM and became part of the IM cohort study
(5.3.2page 101).
3.16 Statistical analysis
The Mann Whitney U test was used to test for differences in the medians of
quantitative variables (e.g. CD8 counts between cases and controls). Spearman's
rank correlation was used to examine associations between 2 quantitative variables.
All significance tests are 2-tailed. All statistical analysis was carried out using
graphpad PRISM software, www.graphpad.com 1999.
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4 Results of XLP Mutation Screening
4.1 Clinical histories of cases screened for defects in the
XLP gene
Clinical material was available on 10 males who had suffered a severe IM-like illness
and in whom the diagnosis of XLP had been considered, on clinical grounds before
identification of the gene (Table 4-1 page 89). The majority of tissue was from post¬
mortem examination and had been stored at -70° C.
The age range of the cases was from 1- 34 years.
A positive family history was noted in 2 out of the 10 cases. In both cases this was
of a brother who had predeceased the proband, and had died of a similar illness.
In 3 of the 10 cases EBV serology showed primary EBV infection, with positive
anti VCA IgM. In addition one case may have seroconverted near the onset of the
illness, as the serology recorded was carried out 16 months after the onset of the
illness. Serology was not available in the other cases. In addition, EBNA positive
cells were found in a lymph node in one other case, which is consistent with primary
infection.
The outcome was known on 4 out of the 10 cases. Of these 3 cases were dead and
the other one had made an uncomplicated recovery.
1 case was placed on the XLP registry at the time of his death, case 7.
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Table 4-1 Clinical details of putative XLP cases
XLP 1
Age 8 years
16 month history of severe IM like illness with an enlarged liver, spleen and
lymphadenopathy.
IgM Anti VCA< 10 and IgG Anti VCA 1: 320 Anti EA 1:40.
Family history and outcome unknown.
XLP 2
Age n/a
Male with history of uncontrolled EBV infection.
No other clinical details available.
XLP 3
Age 4 years
3 day history of cold and sudden deterioration secondary to seizures, and subsequently died.
Family history of febrile illness and rapid deterioration in deceased brother who was aged 3
at time of death.
XLP 4
Age 1 year
Acute tonsillar enlargement leading to respiratory arrest, outcome unknown.
Family history of chromosomal abnormality.
EBNA positive cells in lymph node.
XLP 5
Age 17 years
History of acute onset severe IM complicated by abnormal liver function, treated with
acyclovir and died. No family history as adopted.
Positive Monospot, Anti VCA IgM and Anti VCA IgG VCA positive and 10% of PBMC
EBNA positive.
Lymphoma found at post mortem.
XLP 6
Age n/a
Male infant with high EBV viral DNA load in the PBMC.
XLP 7
Age 34 years
History of acute onset severe IM complicated by hepatic, renal failure and pancytopenia. No
family history of note. Treated with Fresh frozen plasma, died 13 days after admission.
IgM and IgG VCA 128 and 10% of PBMC EBNA positive.
At post mortem lymph node, liver, spleen, thymus, and tonsil EBNA positive.
Added to XLP registry.
Case history published (Crawford et al., 1979).
XLP 8
Age 14 years
History of immune dysfunction of unknown aetiology










Acute IM complicated by major gastrointestinal bleed requiring hemicolectomy, abnormal
liver function and impaired coagulation
IgM positive and IgG anti VCA 2560 & EBV genome PCR 6 x 10'Vug DNA
Full recovery made.
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4.2 PCR and sequencing on XLP material
A PCR assay based direct sequencing method, derived from (Coffey et al., 1998),
was used to screen for mutations in the 4 coding exons of the XLP gene (SAP/
SH2D1 A) in the 10 clinical cases described in Table 4-1 page 89. The method was
used as described (Section 3.6 page 72), and minimal alteration was required for
exons 2, 3 and 4. Figure 4-1 shows amplification of PCR products for exon 2, 3 and
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Figure 4-1 Gel picture of the 4 XLP exons.
Columns 1, 5, 9 and 13 are the negative control (water). Columns 2, 6, 10 and 14 are
the positive control (genomic DNA). Columns 3, 4, 7, 8, 11, 12 15 and 16 are XLP
cases. On this occasion exon 1 and exon 3 failed to amplify for an XLP case. The
size of the amplified product is indicated above.
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However, as exon 1 repeatedly failed to amplify a number of optimization steps were
taken, described in Section 4.2.1 below. Despite these steps the exon still failed to
amplify satisfactorily. Therefore a second method was used (Yin et al., 1999), as
described in the Methods (Section 3.6.2 page 72), which used the same primer





Figure 4-2 XLP exons 2, 3, and 4 after DNA bands cut for direct sequencing.
DNA was successfully amplified for exons 2, 3, and 4. The first column for each pair
is genomic DNA, the second is from a case. The bands were cut prior to direct
sequencing.
4.2.1 PCR optimization for exon 1
A number of optimization steps were undertaken including, alteration of annealing
temperature, alteration of DNA concentration in the PCR mix, and alteration of the
template concentration for the second round of the PCR (see section 4.2.1.1 page 92
onwards). Subsequently the second PCR method was used, and optimization of the
gel concentration, agarose grade and voltage speed allowed identification of exon 1
bands for direct sequencing (see Section 4.2.1.4 page 93).
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4.2.1.1 Annealing Temperature
The annealing temperature was verified for the exon 1 primer sets using a
temperature graded PCR machine, genomic DNA as a template, and a temperatures
range of 1° C between 56-65° C. Optimal bands were obtained between 60° C and
65° C (Figure 4-3 page 92). The annealing temperatures for exons 2, 3, and 4 were
used as described in the published data (Coffey et al., 1998).
Figure 4-3 Annealing temperature for exon 1 PCR (roundl).
The correct annealing temperature for exon 1 was verified using a temperature
gradient of 56-65°C. The temperature at which the PCR product was obtained is
shown above each band.
4.2.1.2 DNA Concentration
A range of DNA concentrations in the exon l PCR mix were tested, from 5ng, lOng,
20ng, 30ng, 40ng, to 50ng in 5ul of molecular grade water. Optimal bands were
obtained at concentrations of 20 & 30ng/5ul of water.
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4.2.1.3 Template Concentration for Second Round of PCR for exon 1
The original method described by (Coffey et al., 1998k), used a second round of PCR
for exon 1, to optimize sequencing results. Using this method a second set of primers
was used as described in the methods (3.6.4 page 74). A titration of the first round
PCR products of, 1/2, 1/8, 1/16, 1/50, 1/100, diluted in molecular grade water was
carried out. Optimal bands of 568bp, were obtained at dilutions of 1/50 and 1/100
(Figure 4-4 page 93). However, adequate sequence was not obtained. Using the
second PCR method derived, the same primers as for the first round of PCR were
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Figure 4-4 Titration of PCR template for exon 1 PCR round 2.
A gel picture is shown of a dilution series of first round PCR (568bp) products in
molecular grade water, the dilution used is shown above each band.
4.2.1.4 Gel concentration, agarose grade and voltage speed.
15 ul of PCR products, and a lkb DNA ladder were routinely run on a 2.5% agarose
gel at 80 V for 60- 90 minutes, and adequate band definition for cutting was obtained
for exons 2, 3 and 4. However for exon 1, 2 partially merged bands were obtained at
the correct bp (729bp) marker. A higher concentration gel (5% agarose) and lower
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voltage (40V) was used to increase resolution and allowed differentiation between
the two bands (Figure 4-5).
Figure 4-5 5% agarose gel showing separation of 2 bands of exon 1.
The gel picture shows the improved separation of the 2 bands obtained for exon 1
(729bp) using a high concentration gel and low voltage for running the gel.
In summary, method 2 derived from (Yin et al., 1999) allowed PCR amplification of
exon 1 for the 10 cases studied. The PCR products were then used for direct
sequencing as described (Section 3.6.8 page 75), with purification of gel products
prior to sequencing. However, poor sequence was obtained on numerous occasions,
and eventually the results were obtained in conjunction with Dr Coffey at the Sanger
Centre.
Nucleotide sequences were entered into the National Center for Biotechnology
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with wild type sequence for the 4 XLP exons (Figure 4-6 page 95). Coding lengths of
436 for Exon 1, 64 bp for exon 2, 145 bp exon 3 and 128 bp exon 4 were sequenced
as identified in (Coffey et ah, 1998; Sayos et ah, 1998). If the derived sequence
contained a number of unidentified nucleotides a visual survey was made of the
signal obtained using CHROMAS software, and on occasion a nucleotide could
clearly be designated which the automated sequence had been unable to verify. If the
sequence obtained contained nucleotides that differed from the standard BLAST
sequence, or un-designated nucleotides (n) the sequencing reaction was repeated. It
was decided an exon did not contain a mutation when a nucleotide sequence, which
aligned 100% with the wildtype sequence, was obtained for the entire coding region.
Figure 4-6 Example of blast search on XLP 5 exon 2
Human DNA sequence from clone 1052M9 on chromosome Xq25. Contains
the SH2D1A gene for SH2 domain protein 1A, Duncan's disease
(lymphoproliterative syndrome) (DSHP), part of a 60S Acidic
Ribosomal protein 1 (RPLP1) LIKE gene and part of a mouse D0C4 LIK>
Length = 134245
Score = 589 bits (297), Expect = e-166
Identities = 297/297 (100%)
a Strand = Plus / Plus
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4.2.3 Summary of XLP Mutation Screening Results
Nucleotide sequences which aligned with the known sequence for exon 1, 2, 3, and 4
were obtained from genomic DNA. No mutations were identified in the 10 cases
analyzed. Results were also available for genomic DNA from 3 healthy donors and
no mutations were identified.
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5 Medical Research Council seroepidemiological
study of Epstein-Barr Virus in the Edinburgh
Student population
5.1 Background
The ongoing seroepidemiological study of EBV in the Edinburgh student population
funded by the Medical Research Council of Great Britain (MRC) has allowed access
to the clinical samples and associated case histories used for the experiments and
analyses detailed in chapter 6 page 109, chapter 7 page 129 and chapter 8 page 140
(see Figure 5-1 page 99). The five-year study is being undertaken in order to address
the following key questions about the acquisition of primary EBV infection and the
mechanisms of clinically overt seroconversion (IM) compared to silent
seroconversion:
• Why do only 50% of those who seroconvert as young adults develop IM?
• Is sexual contact an important route of spread of EBV among young adults, and
can virus be transmitted in sexual secretions?
• What factors cause around 10% of healthy individuals to remain EBV
seronegative?
• What are the prevalence of EBV types in the community, and is each type linked
to IM?
A combination of epidemiological, genetic, virological and immunological
approaches have been used to answer these questions about the pathogenesis of
primary EBV infection and IM. The principal investigators are Dorothy Crawford
(Department of Medical Microbiology, University of Edinburgh), Anthony
Swerdlow (Section of Epidemiology, Institute of Cancer Research Sutton) and
Nadine Harrison, Edinburgh University Health Centre). The study is being
undertaken in the student population as university students are typically of the age
and social background to be at high risk of IM (see Section 2.6.1 page 28).
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Moreover, as the majority of students access healthcare through a university health
service, a robust mechanism for recruitment and follow up can readily be organised.
5.2 Recruitment to Seroepidemiological Study
Participants were lecruited at the beginning of their fiist university teim, in 1999 and
2000 (Figure 5-1 page 99). All new students who were due to study for 4 years or
longer at Edinburgh University and who enrolled at Edinburgh University Health
Centre were eligible to join the study. At recruitment participants were asked to give
a blood sample and answer a detailed anonymous questionnaire assessing possible
epidemiological risk factors for early or late acquisition of EBV. All participants
were also advised they would be contacted 3 years after recruitment to complete the
study by giving a further blood sample and completing a questionnaire. One of the
aims of rebleeding the cohort after 3 years would be to identify those who had
seroconverted without overt illness, and thus the rate of silent seroconversion
compared to symptomatic seroconversion with IM.
All blood samples were tested for EBV status using IgG antibodies to VCA and, if
this test was inconclusive, a screening test for anti EBNA IgG was used. All tests
were read by 2 independent observers, and repeated if a definitive result could not be
obtained. All seronegatives were also negative by PCR testing.
All participants were subsequently informed of their serological status, and thus if
they remained at risk of developing IM. All seronegative participants were advised
of the symptoms of IM, including prolonged sore throat, swollen glands, fever, and
fatigue, and asked to contact Edinburgh University Health Centre if they were
concerned that they had developed IM. Our laboratory carries out all routine
diagnostic testing of EBV serology for Edinburgh University Health Centre, and thus
all seronegative participants developing IM were readily identified.
This prospective study on IM has enabled the establishment of a large IM cohort
with detailed data on the clinical sequelae of IM, both at diagnosis and over the
course of the illness. Alongside the clinical assessment, there has been concurrent
collection of clinical samples including viable PBMC, DNA, serum and throat
washings. At present the study has focused on 2 aspects of the pathogenesis and
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clinical outcome of IM: firstly a detailed case control study reassessing the clinical
course of IM, in particular in relation to fatigue, and impact on outcome of university
studies (Dr Macsween); secondly, an assessment of immune activation in IM, both at
diagnosis and during convalescence, and in particular how immune activation
correlates with clinical illness. Figure 5-1 below gives a visual overview of the MRC
study.
Figure 5-1 (a, b and c) Overview ofMRC study and IM cohort
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5.3 Study Design for IM Cohort
5.3.1 Criteria for Inclusion in the IM Cohort
All students (including both those previously registered with the MRC study and
those who have not) who attend the Edinburgh University Health Centre with
symptoms suggestive of IM undergo EBV serological testing (IgM and IgG
antibodies to VCA and monospot). In addition, at the GP's discretion, a full blood
count (FBC) and Liver Function Tests (LFT) are sent for routine diagnostic testing.
All those with positive IgM antibodies to VCA were suitable for inclusion in the IM
Cohort and were contacted by a study doctor. The diagnostic criteria for IM was a
positive EBV VCA IgM antibody test, +/- a positive monospot; those who were only
monospot positive were excluded. In addition, a number of the participants in the
MRC Seroepidemiological study developed IM, which was diagnosed outwith the
University Health Service. These people were asked to contribute to the study on
return to Edinburgh, and a retrospective assessment of the illness was made.
However, only cases in whom concurrent clinical samples and data were available at
the time of acute illness were included in the immune activation cohort which is
defined in the following section.
5.3.2 Definition of the IM cohort, immune activation cohort & longitudinal
cohort
In order to clarify the relationship between the cases recruited with acute IM, and the
subset in whom more detailed investigation were carried out, including immune
activation studies, each cohort has been defined. The demographic and clinical
features of the IM cohort and Immune activation cohort are recorded in Table 5-1
(page 102, and see Figure 5-1 page 99).
5.3.2.1 IM Cohort
The IM cohort consists of all participants recruited with acute IM from September
1999 to December 2002. 56 cases were included in this study.
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5.3.2.2 Immune Activation Cohort
The immune activation cohort is a subgroup of 26 cases from the IM cohort in whom
viable cells were available at diagnosis with concurrent record of clinical features,
and in whom immune activation studies could be carried out.
5.3.2.3 Longitudinal Cohort
The longitudinal cohort is a subgroup of 7 cases from the immune activation cohort
in whom, in addition to the analysis made at diagnosis, samples were available for
immune activation studies with concurrent clinical details during recovery and at
around 6 months after diagnosis.
Table 5-1 Demographic features of cohorts
Number of cases IM cohort 56
Immune activation cohort 26
Age IM cohort Range 18-26 years
Immune activation cohort Range 18-26 years
Sex IM Cohort Male 29 Female 27
Immune activation cohort Male 12 Female 14
5.4 Clinical assessment of the IM Cohort.
After recruitment to the IM Cohort Study all participants were followed up by the
study doctor, and the clinical assessment was carried out as detailed in Table 5-2
(page 103). A clinical proforma was designed in order to record the same clinical
information, in an objective manner, in each case and monitor the course of the
illness. In order to standardise data collection, the date on which blood was drawn for
EBV serology was recorded as the date of diagnosis, and subsequent study visits
were recorded as visit 1, visit 2 etc. The first study visit was made as soon as possible
after diagnosis. When possible, cases were followed up at 2 weeks and 1 and 2
months, or until they had returned to their pre illness activity level, normally defined
by return to full time studies. All patients were recalled at around 6 months.
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However, not all time points were met, often due to individuals returning to full-time
study or to their parental home.
Table 5-2 Schedule of Follow up and investigations in the IM Cohort
Diagnostic blood (20 ml EDTA) Monospot and IgM and IgG to VCA
Storage of viable PBMC, serum and DNA
First follow up visit Information sheet and consent
Questionnaire (confidential) - family, social, work,
travel and sexual risk factors for EBV acquisition
Clinical proforma- details of worst point in illness and
current point
Examination proforma and Fatigue scale - fatigue at
worst point in illness, current point and when well.
Blood FBC& LFT
EBV serology & viral load
Storage of viable PBMC,
serum and DNA
Throat washings EBV strain analysis
Second and subsequent follow up
visits




Blood as visit one
5.5 Results of clinical assessment of IM
In order to examine the relationship between illness severity and immune activation
we needed to develop a robust and objective measurement of clinical features. The
clinical proforma in the appendix shows which features of the illness were recorded
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in each case. From these data we identified clinical parameters that were both
objective and reflected the variation in illness severity experienced in the cohort.
Therefore only the parts of the clinical assessment which were used in the immune
activation study (Chapter 6 page 109 and Chapter 8 page 140) are discussed below.
Results are shown for both the IM cohort (56 cases) and the immune activation
cohort (26 cases). The number of visits per case ranged from 1 -7.
5.5.1 Time to first follow up and definition of worst symptoms
The typical course of IM consists of a short prodrome, followed by an acute phase,
followed by a variable period of recovery. We found that participants tended to visit
the GP around the time of the acute phase, and this is when the diagnostic blood was
taken. However, at the time an individual was seen by the study doctor at visit one,
the most acute symptoms may have resolved, and therefore both the most severe
symptoms experienced and the current symptoms were recorded.
The first follow up was carried out as soon as possible after diagnosis, and for the
immune activation cohort the range was 2-16 days, with a mean of 9 days. With
three exceptions, the worst point of the illness was within 6 days of diagnosis.
5.5.2 Definition and analysis of sore throat
Sore throat is one of the hallmarks of IM, and severe tonsillar swelling and
obstructive symptoms is one of the most common causes of hospital admission. Mild
sore throat was defined as being able to swallow a normal diet at the worst point of
illness, and severe as unable to swallow normal diet or more extreme symptoms. The
results are shown in Table 5-3 (page 104), the data were available in all cases.
Table 5-3 Analysis of sore throat in acute IM
Symptoms of Sore throat Number of
cases
% of cases
IM Cohort Severe 21 38
Mild 35 64
Immune Activation Cohort Severe 12 46
Mild 14 54
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5.5.3 Definition and analysis of fever, lymphoadenopathy and rash
Participants were able to clearly and consistently identify whether they had
experienced a number of physical symptoms including fever (measured without
using a thermometer), swollen glands, rash, anorexia and headache. The results are
shown in Table 5-4 (page 105) the number of cases who experienced the symptom is
shown over the total number in which data were recorded.
Table 5-4 Analysis of clinical features of IM
Clinical Feature Cohort Number of
cases
% of cases
Cases with fever IM Cohort 42/56 75
Immune Activation Cohort 21/26 81
Cases with Headache IM Cohort 37/56 66
Immune Activation Cohort 15/26 57
Cases with Anorexia IM Cohort 44/56 78
Immune Activation Cohort 22/26 85
Cases with Swollen glands IM Cohort 53/56 95
Immune Activation Cohort 26/26 100
Cases with Rash IM Cohort 5/51 10%
Immune Activation Cohort 5/26 19%
5.5.4 Assessment of fatigue
Fatigue is a common symptom of IM, and prolonged fatigue is a frequent
complication. Moreover, there has been considerable interest in the relationship
between IM and chronic fatigue syndromes, and in our cohort the impact residual
fatigue has on an individual's ability to complete their university studies.
Ideally, the assessment of fatigue should be objective and allow comparison over
time in an individual, and also comparison between cases with very different pre
illness levels of activity and work patterns. A detailed review of the literature did not
identify any fatigue scales that fulfilled these criteria and were suitable for use in this
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cohort (Monga et al., 1999; Behrenz and Monga, 1999). We therefore devised a
fatigue scale that assessed 3 parameters of fatigue (see appendix).
• Physical function, such as ability to dress or leave home
• Impact on university attendance and studies
• Individuals subjective feeling of fatigue
• All parameters were compared to an individual's function when well. As there is
a strong psychological element to the impact an illness has on an individual's
ability to function, it would be difficult to investigate correlations between these
parameters and immune function. We therefore focused on the relationship
between physical function at worst point in illness, e.g. ability to leave home, and
correlated this with parameters of immune response. The results are shown in
Table 5-5 (page 106).
Table 5-5 Analysis of Fatigue in IM
Number of cases % of cases
Cases able to leave home at worst point
of illness










5.5.5 Definition of recovery and long term follow up
Recovery from illness was defined as when an individual could return to their pre -
morbid level of function, and this usually meant return to full time studies. We
recalled all participants at around 6 months to obtain a blood sample and to monitor
recurrence of symptoms. Of the 26 cases in the immune activation cohort, the
prodrome was a median of 6 days with a range of 0-31 days. The severe period was a
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median of 7 days with a range of 2-14, and the overall length of illness was a median
of 32 days with a range of 5 days to over 6 months.
A summary of the clinical features of the 26 cases in the immune activation cohort is
provided in Table 5-6.
Table 5-6 Summary of clinical details for 26 cases of IM in the immune
activation cohort









1 22 F Part time Severe Yes No No 4554
2 20 F Part time Mild Yes Yes Yes 5841
3 19 F Full time Mild No No No 82
4 22 M Part time Severe Yes No No 3498
5 22 F Part time Severe Yes Yes No 14982
6 20 M Full time Mild No Yes No 2376
7 20 M Full time Severe Yes Yes No NK
8 25 F Part time Mild Yes Yes Yes 867
9 20 M Part time Mild No Yes No 3036
10 20 M Full time Severe Yes No No Na
11 24 M Part time Mild Yes Yes Yes 14982
12 26 M No attendance Mild Yes Yes Yes 2673
13 21 F No attendance Severe Yes Yes No 2409
14 21 F Part time Severe Yes No No 11913
15 20 M Part time Severe Yes Yes No Na
16 20 F Part time Mild Yes No No 2771
17 18 F Part time Mild Yes No No 12886
18 218 M Full time Mild Yes Yes No 8007
19 19 M Full time Severe Yes Yes No 16422
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20 20 M On holiday Severe Yes Yes No 6868
21 19 F Part time Severe Yes No No 4420
22 19 F Part time Mild No Yes No 7514
23 22 F On holiday Mild No Yes No 646
24 19 F Part time Mild Yes Yes Yes 0
25 22 M On holiday Mild Yes Yes No 2550
26 21 F Part time Severe Yes No No 49249
Na = data unavailable F= female. M= Male
* = able to leave home at worst point in illness
**=EBV genome copies per 106 PBMC
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6 Immune activation and clinical events in Infectious
Mononucleosis
It is well established that there is a dramatic lymphocytosis in acute IM, principally
consisting of CD8 positive T cells. However, it is not clear what changes occur in
other lymphocyte subsets, how long the lymphocyte numbers remain raised, and how
this relates to the severity of illness. We analysed lymphocyte subsets by flow
cytometry in 26 cases at the time of diagnosis of acute IM (Table 5-6 page 107). Data
were compared with results from healthy controls, but as total lymphocyte counts
were not available on all controls, only the first 14 cases were used for analysis when
lymphocyte counts were required for comparison purposes. Ranges and medians are
shown in the text; further data are included in the appendix.
6.1 Analysis of lymphocyte subsets in acute IM
6.1.1 Total lymphocyte counts, CD3, and CD8 cell counts were all
significantly elevated at diagnosis of IM
The total lymphocyte count, CD3 and CD8 counts were significantly elevated at
diagnosis of IM (p< 0.01 for all subsets, for ranges see Table 6-1 page 110). The
median value for total lymphocyte counts was 7.19 x 106 per ml for cases and 1.67 x
106 per ml for controls; for CD3 counts the median value was 5.07 x 106 per ml for
cases and 1.00 x 106 per ml for controls; and for CD8 counts the median was 4.40 x
106per ml for cases and for controls 0.48 x 106 per ml. Neither CD4 nor B cell
counts were significantly altered.
The spectrum of lymphocytosis was wide, which may reflect the variable clinical
course of IM.
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Table 6-1 Lymphocyte subsets in acute IM
Cell Counts x 106 per ml
Cell type At diagnosis of
acute IM
At first review of
IM
Control Subjects
Total Lymphocyte 1.98-12.65 ** 1.45-2.33 1.23-2.41
CD3+ Lymphocyte 0.89-9.62 ** 0.96-1.62 0.49-1.79
CD4+ Lymphocyte 0.31-0.78 0.35-0.52 0.11-0.90
CD8+ Lymphocyte 0.58-9.43 ** 0.46-0.62 0.31-0.89
B Cell 0.30-0.90 0.13-0.54 0.17-1.54
** median values were significantly different to control values (p<0.01)
6.1.2 Acute IM causes significant activation of the SAP/SLAM/CD244
activation pathway
The clinical features of IM have been attributed to the CD8 lymphocytosis. However,
the activation status of the cells has not been fully investigated. The expression of
the lymphocyte activation molecules CD244 and SLAM was analysed by flow
cytometry in the same 26 cases (Table 5-6 page 107).
6.1.2.1 At diagnosis of acute IM numbers of T cell subsets expressing
CD244 were significantly elevated
At diagnosis of acute IM numbers of CD3, CD4 and CD8 T cell subsets expressing
CD244 were all significantly elevated; (p< 0.01 for all subsets and for ranges see
Table 6-2 page 111). The median number of CD3 positive cells expressing CD244
was raised at 3.95 x 106 per ml for cases compared to 0.27 x 106 per ml for controls.
The median values for CD4/CD244 double positives, was 0.2 x 106 per ml for cases
and 0.04 x 106 per ml for controls, and the median value for CD8/CD244 double
positives was also markedly raised at 3.17 x 106 per ml for cases compared with 0.22
x 106 per ml for controls (Figure 6-1 page 113). The median percentages of CD3
(median 77%), CD4 (median 30%) and CD8 (median 82%) cells expressing CD244
in IM cases were also increased over control median values of 14%, 9% and 51% for
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CD3, CD4, and CD8 respectively (p<0.001) for all percentage data sets (Figure 6-2
page 114, Figure 6-3 page 115 and Figure 6-4 page 116). As previously reported,
CD244 was not expressed on B cells, and was constituently expressed on NK cells
(Nakajima et al., 1999).
Table 6-2 Expression of CD244 in acute IM


















CD3 0.40-9.33** 35-97*** 0.09-0.81 0-33 21-47**
CD4 0.05-0.48** 8-80*** 0.02-0.07 1.75-17 7-75*
CD8 0.45-8.77*** 25-97*** 0.14-0.67 33-77 50-71*
*** median values were significantly different to control values (p<0.001)
** median values were significantly different to control values (p<0.01)
* median values were significantly different to control values (p<0.05)
6.1.2.2 At diagnosis of IM, numbers of CD3, and CD8 T cells
expressing SLAM were all significantly elevated
At diagnosis of IM, median numbers of CD3, and CD8 T cells expressing SLAM
were all significantly elevated (p< 0.01 and for ranges Table 6-3 page 112 and see
Figure 6-1 page 113).
The median number of CD3 cells expressing SLAM was 2.17 x 106 per ml for cases,
compared to 0.06 x 106 per ml for controls. For CD8/SLAM double positive cells,
f\ fs
the median value for cases was 1.86 x 10 per ml compared to 0.06 x 10 per ml for
controls. The percentage of IM CD8 cells (median 60%) expressing SLAM was also
significantly different from controls (median 41%) (p<0.001) (Figure 6-4 page 116).
The number of CD4 cells expressing SLAM in IM cases was not significantly
elevated (median value of 0.21 x 106 per ml compared to a control value of 0.09 xlO6
per ml), but the percentage of CD4 cells expressing SLAM, and thus an activated
phenotype, was significantly increased (median 60% compared to a control median
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of 31%) (p<0.05) (Figure 6-3 page 115). As CD4 cells are central to the TH1/TH2
balance of the immune response, the change in activation status (despite minimal
changes in total cell numbers) may be an important influence on the balance of
cytokine release in EBV infection.
Table 6-3 Expression of SLAM in acute IM


















CD3 0.77-5.6*** 11-100 0.0-0.68 0-92 27-85
CD4 0.07-0.48 17-100* 0.0-0.38 3-92 31-91
CD8 0.3-4.53*** 26-92** 0.0-0.35 0-92 35-70*
*** median values were significantly different to control values (p<0.001)
** median values were significantly different to control values (p<0.01)
* median values were significantly different to control values (p<0.05)
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Figure 6-1 Upregulation of SLAM/CD244 on peripheral blood lymphocytes
during acute IM.
I The number of peripheral blood CD8 cells expressing either SLAM (median 1.86
xlO6 per ml) or CD244 (median 3.17 x 106 per ml) in acute IM was significantly
higher (p<0.001) compared to control values. Bars show median values.
II The number of peripheral blood CD4 cells expressing CD244 (median 0.2 x 106
per ml) was significantly higher in acute cases of IM, (p<0.01) compared to controls.
The median number of CD4 cells expressing SLAM (median 0.21 x 106 per ml) was
not significantly different from the control values. Bars show median values.
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Figure 6-2 (I, II and III) Percentages of CD3 lymphocyte subsets are higher in
acute IM compared to healthy controls
In each plot, bars show the median values, and the difference between the 2 medians
was statistically significant in plots where the p value is shown. All values refer to
peripheral blood. The same format is followed in Figure 6-3 (page 115) and Figure
6-4 (page 116).
I Shows the percentage of lymphocytes expressing CD3. The median for healthy
controls was 66% and for cases was 76%.
II Shows the percentage of CD3 lymphocytes which express CD244. The median for
healthy controls was 14% and for cases was 77%.
III Shows the percentage of CD3 lymphocytes which express SLAM. The median
for healthy controls was 27% and for cases was 54%.
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Figure 6-3 (I, II and III) Percentage of CD4 lymphocyte subsets expressing
CD244 or SLAM is higher in acute IM than in healthy controls
I shows percentage of CD4 lymphocyte subsets in both healthy controls and cases of
acute IM. The median for healthy controls was 39% and for cases was 15%.
II shows the percentage of CD4 lymphocytes which express CD244. The median for
healthy controls was 9% and for cases was 30%.
III shows the percentage of CD4 lymphocytes which express SLAM. The median for
healthy controls was 31% and for cases was 60%.
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Figure 6-4 (I, II and III). Percentages of CD8 lymphocyte subsets expressing
SLAM or CD244 are higher in acute IM compared to healthy controls
I Shows the percentage of lymphocytes expressing CD8. The median for healthy
controls was 24% and for cases was 64%.
II Shows the percentage of CD8 lymphocytes, which express CD244. The median
for healthy controls was 51% and for cases was 82%
III Shows the percentage of CD8 lymphocytes, which express SLAM. The median
for healthy controls was 41% and for cases was 60%.
6.2 Longitudinal analysis of IM immune response
We carried out a longitudinal study in a group of 7 patients, (cases 1, 4, 5, 9, 10, 11
and 12 from Table 5-6 page 107) during the course of IM in order to relate the
clinical symptoms to changes in lymphocyte subsets in the peripheral blood. Cases
were followed up until they had returned to their pre-morbid activity level.
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6.2.1 Lymphocytosis in acute IM falls rapidly despite ongoing clinical
symptoms
At diagnosis 86% of IM patients had raised lymphocyte counts. In contrast, at the
first review 9-16 days later, and despite features of ongoing clinical illness, all of the
total lymphocyte counts and all the CD3 and CD8 subsets had returned to within the
range established for controls and remained within this range for the duration of the
illness in all subjects (Table 6-1 page 110). Thus the prolonged clinical features of
IM were not simply a reflection of a sustained elevation in lymphocyte numbers in
the peripheral blood.
6.2.2 CD8 cells maintain an activated phenotype over the duration of
clinical illness
In order to investigate why clinical features such as lymphadenopathy remained
when absolute lymphocyte counts rapidly return to normal following diagnosis, the
level of activation molecules expressed on T cell subsets was examined. At the time
of first follow up total numbers of CD3 and CD8 cells expressing CD244 had fallen
in each case. However, the median percentages of CD3, CD4 and CD8 cell subsets
expressing CD244 remained significantly elevated above that of controls (p < 0.05)
The median percentage of CD3 cells expressing CD244 was 40% for cases, and 14%
for controls, the median percentage of CD8 cells expressing CD244, was 64% for
cases and 51% for controls, and for CD4/CD244 double positives was 14% for cases
and 9% for controls (Table 6-2 page 111, Figure 6-5 page 119 and Figure 6-6 page
120 for data on case 9).
Both the number of CD8 cells expressing SLAM (median 0.32 x 106 per ml) and the
percentage (median 59%) of cells expressing SLAM at first follow up, were
significantly elevated above controls, (p< 0.05, Table 6-3 page 112). Neither the
numbers of CD4 cells expressing SLAM (median 0.23 x 106 per ml) nor the
percentage of SLAM/CD4 double positive cells (median 46 %) were significantly
different from controls at this time point.
At follow up closest to 1 month, (range 20-42 days) 5 out of 5 cases studied
remained unwell with ongoing fatigue in all subjects. In addition 2 cases had
physical signs; one had enlarged tonsils and the other enlarged glands. The
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percentage of SLAM/CD8 double positives and CD244/ CD8 double positive cells
remained elevated in 4 out of the 5 cases. This prolonged expression of CD244 and
SLAM on CD8 cells indicates that T cells remain activated over the course of the
clinical illness, which may explain the extended clinical symptoms.
At the final follow up (range 59-80 days following diagnosis of IM), 6 cases had
made a full recovery, but 1 case still suffered fatigue (Case 4). In all cases
lymphocyte counts and CD3, CD8 and CD4 subsets were within the range for
controls. Interestingly, expression of both CD244 and SLAM on CD8 cells had fallen
in all cases, except in the case with sustained fatigue in whom levels of CD244 and
SLAM remained high with 60% of CD8 cells expressing CD244 and 71% of CD8
cells expressing SLAM.
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Figure 6-5 (a-d) Flow cytometric analysis of lymphocytes showing increased
expression of CD244/CD8 on lymphocytes. In the above plots the cells were gated
on lymphocytes. However, when the analysis was carried a further CD3 positive gate
was used in addition.
The data shown are from case 9 from Table 5-6 page 107.
(a) At diagnosis VL= 3036
(b) 16 days after diagnosis VL=78
(c) 42 days after diagnosis VL= 1
(d) 6 months after diagnosis VL=241 (VL = viral load in EBV genomes /106
PBMC.)
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Figure 6-6 Expression of CD244 & SLAM is elevated during recovery from IM
The percentage of CD8 cells expressing CD244 (filled squares) and SLAM (filled
triangles) are shown for case 9 (Table 5-6 page 107). Data are compared to median
control values for CD244 (open squares), and SLAM (open triangles).
6.3 Extent of immune activation at diagnosis is significantly
linked to severity of illness
We hypothesised that if the clinical symptoms of IM are caused by activated T cells
rather than direct cytopathic effects of the virus, the extent of immune activation
should predict clinical severity of IM. We therefore analysed the relationship
between physical symptoms and function, and degree of immune activation in our
cohort of 26 IM cases (Table 5-6 page 107).
The severity of sore throat was recorded in 26 cases and classified as either mild (14
subjects) or severe (12 subjects). The median percentage and number of lymphocytes
expressing CD3, CD244/CD3, CD8, and CD244/CD8 at diagnosis were all
significantly higher in the severe compared to the mild group (p <0.05 Figure 6-7
page 123). The median total lymphocyte counts were higher in the severe compared
to the mild group, however changes were not significant. Other immune parameters
investigated at time of diagnosis, including CD4 + cells and T cell subsets expressing
SLAM, were not significantly linked to severity of sore throat (Table 6-4 page 122).
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Of note, there was no significant difference in length of illness prior to diagnosis in
those experiencing mild compared to severe sore throat.
Experience of fever was also recorded at the point in the illness at which the
individual felt most unwell; 21 individuals experienced fever, the other 5 did not.
There was a higher percentage of CD8+ T cells in the group with fever, median
percentage of CD8+ T cells in the febrile group was 70% and in afebrile group was
44%, (p<0.05, Figure 6-8 page 124). For the other parameters measured, median
expression was also higher in the febrile compared to the afebrile group. These
included CD3, CD244/CD3, CD244/CD8 percentage expression, and CD3,
CD244/CD3, CD8, and CD244/CD8 cell counts (Table 6-4 page 122). However
median values were not significantly different between the 2 groups, possibly due to
the small numbers of afebrile cases.
Lymphadenopathy was experienced by all cases, and so could not be linked to level
of immune activation. Rash is another common symptom of IM, however the
aetiology of the rash is unknown. Interestingly the percentage of the lymphocytes
expressing CD3 was significantly lower in the 5 cases with rash, compared to the 20
cases without rash, (data unavailable in one case) with a median value of 60%
compared to a median value of 79% respectively (p<0.01). None of the other
immune parameters investigated were significantly different in those with compared
to those without rash (Table 6-4 page 122).
Fatigue occurs in 90-100% of cases of IM. As discussed we aimed to make an
objective measurement of fatigue, by recording whether individuals could leave
home at the worst point in their illness. In our cohort 9 cases were house bound, and
17 were not. The percentage of CD8+ cells expressing CD244 was significantly
higher in those who were housebound, (p<0.05) compared to those who were not,
(median expression in the housebound group was 89%, and 78% in the group able to
leave home). In addition, the median numbers of CD244/CD8 lymphocytes were
higher in the housebound compared to the non housebound group (3.47 x 106 /ml
compared to 2.87 x 106 /ml respectively), however these differences were not
significant (Figure 6-9 page 125). Expression of the other parameters measured
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including CD8, CD3 and CD244/CD3 subsets were not significantly different
between the two groups (Table 6-4 page 122).








Lymphocyte count NS NS NS NS NS
CD3 % ** NS NS ** NS
CD3 count * NS NS NS NS
CD8 % ** * NS NS NS
CD8 count * NS NS NS NS
CD3CD244/CD3 % * NS NS NS NS
CD3CD244 count * NS NS NS NS
CD3SLAM/CD3 % NS NT NS NS NT
CD3SLAM count NS NT NS NT NT
CD8CD244/CD8 % * NS * NS NS
CD8CD244 count * NS NS NS NS
CD8SLAM/CD8 % NS NT NS NS NT
CD8SLAM count NS NT NS NT NT
** denotes differences between the medians of the groups are statistically significant, p<0.01
* denotes differences between the medians of the groups are statistically significant, p<0.05
NS denotes differences between the medians of the groups are not statistically significant, p>0.05
NT denotes differences between the groups were not tested The definition of the clinical events is
described in the text.
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Mild sore throat Severe sore throat
(b)
Figure 6-7 (a & b) CD8+ T cell lymphocytosis is higher in those with severe
compared to mild sore throat.
(a) The median number of lymphocytes expressing CD8 was significantly higher in
those with severe (n=l 1) compared to those with mild (n=10) sore throat (p<0.05).
The median value for the severe group was 5.18 x 106 /ml for the mild group was
2.89 x 106 /ml. Bars show the median values.
(b) The median number of lymphocytes expressing CD244/CD8 was significantly
higher in those with severe (n=10) compared to those with mild (n=10) sore throat
(p<0.05). The median value for the severe group was 4.64 x 106 /ml and for the mild
group was 2.20 x 106 /ml. Bars show the median values.
NB/lymphocyte counts were not available in all cases. All analysis refer to PBMC.
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Figure 6-8 (a & b) CD8 T cell lymphocytosis is higher in cases of acute IM with
fever than without fever.
(a) The median percentage of lymphocytes expressing CD8 was higher in those with
fever (n=21) compared to those without fever (n=5). The median value for the fever
group was 70% and for the afebrile group was 44%, the difference was significant
(P<0.05).
(b) The median percentage of lymphocytes expressing CD3 was higher in those with
fever (n=20) compared to those without fever (n=5). The median value for the febrile
group was 77%, and for the afebrile group was 66%, however the difference between
the 2 groups was not significant.
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Figure 6-9 (a & b) CD8+ T cell lymphocytosis is higher in those unable
compared to those able to leave home.
(a) The median percentage of CD8 cells expressing CD244 was higher in those who
were house bound (n=8) compared to those who were not (n=17). The median value
for the house bound group was 89% and for the group able to leave home was 78%,
the differences between the 2 groups was significant (P<0.05).
(b) The median numbers of lymphocytes expressing CD244/CD8 was higher in those
who were house bound (n=7) compared to those who were not (n=13). The median
value for the house bound group was 3.47 x 106/ml and for the other group was 2.87
x 106 /ml however the difference between the 2 groups was not significant.
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6.4 Immune activation at diagnosis of IM shows a strong
positive correlation with viral load
Next we investigated the relationship between viral load and immune activation.
Viral load was measured by PCR in the PBMC of 23 cases of IM at diagnosis (Table
5-6 page 107). The range of viral loads was 0 to 49249 EBV genomes per 106
PBMC. Increased viral load correlated directly with increased percentage of both
CD3 (p< 0.05) and CD8 cells (p<0.05) in the peripheral blood at diagnosis of IM,
and moreover increased viral load correlated directly with increased expression of
CD244 on CD8 cells (p<0.05, Figure 6-10). Viral load did not correlate with CD4






















% of lymphocytes expressing CD244CD8
Figure 6-10 The percentage of lymphocytes expressing CD244/CD8 has a direct
correlation with viral load. (P<0.05 and Pearson r=0.41).
In addition, median viral load was significantly higher in those with severe compared
to mild sore throat (p<0.05) (Figure 6-11 page 127). The median viral load in those
with severe throat was 6868 EBV genomes per 106 PBMC, and in those with mild
sore throat was 2722 EBV genomes per 106PBMC.
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Severe sore throat Mild sore throat
Figure 6-11 The viral load (EBV genomes per 106 PBMC) is higher in those with
severe compared to mild sore throat
The difference between the median of the 2 groups was significant (P<0.05) and bars
show median values.
6.5 Changes in CD244/CD8 are more pronounced in IM than
primary VZV infection in adults.
In order to determine whether changes in the CD244/SLAM activation pathway are
specific for primary EBV infection, we analysed CD244/SLAM in T cell subsets of
patients with severe acute VZV infection. The median percentage expression of
CD244 on CD3, CD4, CD8 subsets was raised in acute VZV cases; the range for
CD3 cells was 24-63%, for CD4 cells was 5-23% and for CD8 cells was 53-69%.
However, the median percentage expression was significantly higher in IM than
VZV for both CD3 and CD8 subsets (p<0.05, Figure 6-12 page 128). There was an
indication of an increased percentage expression of SLAM on CD3, CD4, CD8
subsets in VZV cases, but levels of expression were not significantly different from
either control subjects or IM cases. Thus, CD244 is significantly upregulated on T
lymphocytes during acute IM and VZV infection on both CD3 and CD8 subsets, but
activation is more marked during IM than VZV.
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Figure 6-12 The median percentage of CD8 cells expressing CD244 is higher in
IM than in VZV infection
The percentage of CD8 cells expressing CD244 is shown for the 4 cases of VZV and
the median counts for IM cases and controls are also shown. The median percentage
of CD8 cells expressing CD244 was higher in IM than in VZV (p<0.05); the median
expression in IM was 82% and in VZV was 63%.
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7 Expression of SAP in infectious Mononucleosis
In Chapter 6 (page 109) we showed that significant up-regulation of both SLAM and
CD244 on lymphocytes occurs during acute IM. Therefore we decided to monitor
the expression of SAP, the intracellular regulator of this lymphocyte activation
pathway, during acute IM. Immunohistochemistry was used to assess the expression
of SAP in a variety of cells and tissues both from the IM cohort and healthy controls.
As detailed in the methods, intracellular flow cytometry could not be used to monitor
SAP expression due to technical difficulties (Section 3.8.3 page 80).
7.1 Optimisation of single colour immunohistochemistry.
The experiments were undertaken as detailed in the methods (Section 3.9 page 81),
using DAB single staining, however the following optimisation steps were carried
out.
7.1.1 Cytospin Preparation
Optimal results were obtained using fresh PBMCs to make cytospins. However
reasonable results could be obtained using frozen cells if dead cell numbers were
minimized by rapid thawing of the cells. If numbers of dead cells were high, at
approximately greater than 10%, increased background staining occurred. We also
found long term storage of the cytospins, even at -20° C, led to poor staining with
loss of cell integrity, and optimal results were acquired within 3 months of making
the slides.
7.1.2 Antibody Titration
Polyclonal anti-SAP antibody was available commercially, either derived from rabbit
or goat. Both types of antibody were diluted at 1:10, 1:20 and 1:50 in DAKO
antibody diluent, and staining of control sections (PHA stimulated PBMC) was
carried out. Problems with excessive background staining were encountered;
however a 1:20 dilution of goat antibody gave the best results and was used
throughout (Table 7-1 page 130).
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Table 7-1 Results of antibody titration
Dilution of antibody in DAKO
diluent.









1:10 ++ ++ +++ ++
1:20 +/- ++ ++ +
1:50 - + + +
++ = good signal + = moderate signal - undetectable signal
7.2 Expression of SAP in peripheral blood lymphocytes
during acute IM and in controls
7.2.1 Expression of SAP is elevated during acute IM
Expression of SAP in PBMC was analysed by immunohistochemistry in 16 cases of
acute IM and in 17 healthy controls. A negative control slide, without primary
antibody, was included in each experiment, and always gave negative results. A
positive control of either PHA blasts or a known positive sample was used during
optimization experiments.
At the time of diagnosis of IM, the number of PBMC expressing SAP was high with
54-100% of cells expressing SAP, compared to 2-74% of PBMC from controls
(Figure 7-1 page 132). The median values were significantly different between
controls and cases: the median value for cases was 85% compared to the median
values for controls of 33% (p<0.001, Table 7-2 page 131).
7.2.2 SAP expression remains elevated during recovery from acute IM
Expression of SAP in PBMC was analysed in 8 cases over the course of IM, at time
points between 11-139 days following diagnosis (median 24 days). Although SAP
expression fell over the course of the illness, ranging from 41-73 % of PBMC, values
remained significantly raised compared to controls (p<0.01, Table 7-2 page 131 and
Figure 7-2 page 132).
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Table 7-2 Expression of SAP in PBMC
Case or control Group Number of cases % of PBMC expressing SAP
At diagnosis of IM 16 Range 54-100%
Median 85%***
During recovery from IM 8 Range 41-73%
Median 54 %*
Healthy controls 17 Range 2-74%
Median 33%
*** median values were significantly different to control values (p<0.001)
* median values were significantly different to control values (p<0.05)
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Figure 7.1 PBMC from 4 acute IM cases showing
positive staining for SAP (stained brown). The





Figure 7.2 PBMC from acute IM cases and controls showing staining for SAP
(stained brown). The magnification is shown for each image.
a. Healthy control with no antibody (negative control) x 400
b Healthy control x 400
c IM follow up (day 21) x 200
d As image c, x 1000
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7.2.3 Relationship between expression of SAP and expression of CD8,
CD244/CD8 and SLAM/CD8 on lymphocytes in acute IM
In 9 control subjects we did not find a significant relationship between the
percentage of cells expressing SAP and either the percentage of CD8 cells, or the
percentage of CD8 cells expressing either CD244 or SLAM cells in the peripheral
blood. However in the 10 cases analysed at diagnosis of acute IM, there was a
significant correlation between the percentage of CD8 cells expressing CD244 and
the percentage of SAP positive cells in the peripheral blood (Pearson r =0.71, p<0.05
and Figure 7-3 page 134). However, as in the control data, no relationship was found
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% of CD8+ lymphocytes expressing CD244
Figure 7-3 The percentage of CD8+ lymphocytes expressing CD244 correlates
with the percentage of PBMC expressing SAP.
There is a significant correlation between the two parameters (Pearson r=0.71,
p<0.05).
7.2.4 Expression of SAP in tissue from acute IM
Tissue (colon) was available from one case of fulminant IM, case 10 in the XLP
mutation study, (Table 4-1 page 89). Routine diagnostic immunohistochemistry
showed a lymphocytic infiltration within the mucosa, with both B cells (CD20+) and
T (CD3+) cells present. Within the lymphocyte infiltration, approximately 30-50% of
the cells were noted to express EBNA-2 protein (Figure 7.4 page 136), though
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double staining for lymphocyte subtype within the EBNA-2 population was not
undertaken. There was also a large number of EBER positive cells (Figure 7.4 page
136) and SAP was widely distributed (Figure 7.5 page 137). In addition occasional
cells were found to express LMP1.
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Figure 7.4 show expression of EBV antigens in a case of severe
IM, (case 10, chapter 4 ). (a) shows EBER staining (brown) x
200 and (b). Shows EBNA2 staining (brown) x 200. Arrows
indicate a typical positive cell.
Figure 7.5 shows expression of SAP in the colon in severe
IM (case 10, chapter 4). Magnifications are shown for each
image (a) x 200 and (b) x400. Arrows show typical positive
cell.
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7.3 Dual expression of interferon gamma and SAP in
peripheral blood cells from acute IM
Activated CD8+ T cells are able to release TH1 type cytokines and this process is
thought to be critical to the pathogenesis of acute IM. We therefore investigated
whether cells expressing SAP also expressed IFN y during acute IM.
Dual staining for INF y and SAP was carried out on fixed PBMC from 5 cases of
acute IM, 5 healthy controls, 3 cases during recovery from IM, and 5 positive
controls (PHA blasts) (Section 3.9.5 page 82).
In 4/5 cases of acute IM examined, expression of dual positive cells was high, in 1
case expression was low (the definition of high and low staining is described
(Section 3.9.5 page 82)). Of note is that all cells that expressed INF y also expressed
SAP. In 2/3 cases studied during recovery from IM, no dual positive cells were
identified, however in 1 case low numbers of dual positive cells were identified. In 5
healthy controls no dual positive cells were identified. Dual expression of INF y and
SAP was high in 5 out of 5 cases of PHA stimulated control cells; the positive
control (Figure 7.6 page 139).
We therefore confirmed that cells expressing SAP during acute IM, co-express INF
y, and therefore are able to contribute to the pathogenesis of acute IM.
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Figure 7.6 PBMC from control and 3 acute IM cases showing
staining for SAP (stained blue) and INF y (stained brown). The
magnification is shown for each image.
a. PHA blasts x 1000
b Acute IM x 400
c Acute IM x 400
d Acute IM x 1000
A
V
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8 Immune response to primary Epstein-Barr virus
infection: a critical role for natural killer cells
The role of antigen specific CD3+ CD8+ cytotoxic T cells in the control of primary
EBV infection is well established (Section 2.6.8.1 page 34). However, time is
required for the antigen specific immune response to develop and expand. In contrast
innate immune responses, such as NK cells, are thought to be vital early in the
infection process, but data are lacking on the activity ofNK cells during viral
infection in humans. The scale, phenotype and function of the NK cell response
during IM are described in this chapter.
8.1 NK cell numbers are significantly elevated at diagnosis
of IM
NK cell numbers were analysed by flow cytometry at diagnosis, and during recovery
from IM, and compared to data from healthy controls. The NK cell subset was
defined as cells which fell into the lymphocyte gate, which expressed CD56 but did
not express CD3. Of note, all cells which expressed CD56 also expressed CD244.







Figure 8-1 Identification of NK cells by flow cytometry
The flow plot shows how NK and NKT cell subsets were identified in the
lymphocyte population. NK cells were defined as expressing CD56 but not CD3,
NKT cells were defined as expressing CD3 and CD56.
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In patients with acute IM, (N=26 with lymphocyte counts available in 21 cases) NK
cells were significantly elevated in the peripheral blood at diagnosis compared to
controls (N=23, with lymphocyte counts available in 17 cases). Median counts for
IM cases were 0.87 x 106 per ml, with 5-38 % of lymphocytes expressing a NK cell
phenotype. This compared to healthy controls where median counts were 0.14 x 106
per ml with 1-19% of lymphocytes showing an NK cell phenotype, (p=<0.01, Table
8-1 page 141 and Figure 8-2 page 143).

















1 Na 11 1 0.14 11
2 0.9 38 2 0.32 15
3 0.56 21 3 0.07 5
4 0.42 8 4 0.22 17
5 0.9 15 5 0.38 18
6 2.17 20 6 0.06 5
7 1.31 15 7 0.12 8
8 2.0 34 8 0.05 3
9 1.57 22 9 0.15 12
10 2.1 28 10 0.12 10
11 Na 29 11 0.41 14
12 Na 17 12 0.05 5
13 0.87 20 13 0.03 6
14 2.5 20 14 0.35 15
Immune response to primary Epstein-Barr virus infection: a critical role for natural killer cells 141
An analysis of the immune response to primary Epstein- Barr Virus infection and the association with
clinical events
15 1.01 12 15 0.22 11
16 1.1 13 16 0.09 5
17 0.64 10 17 0.22 10
18 0.1 8 18 Na 6
19 0.5 5 19 Na 7
20 0.55 6 20 Na 11
21 0.54 16 21 Na 1
22 0.7 19 22 Na 7




Median 0.87 17% Median 0.14 10%
Range 0.10-2.50 5-38% Range 0.03-0.41 1-19%
Na - data not available
In a subgroup of 11 cases the proportion of lymphocytes expressing NKT cell
markers, was also investigated. There was no significant expansion of NKT cells in
acute IM, with a median of 1% of lymphocytes expressing CD3+CD56+CD244+,
compared to a control median of 2%.
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Figure 8-2 NK cells are raised in the peripheral blood at diagnosis of acute IM.
A scatter plot of NK cell counts x 106 per ml for controls (N=17) (filled squares) and
cases (N = 21) (filled triangles) is shown. Median counts are shown by bars, and for
cases was 0.87 x 106 per ml and for controls was 0.14 x 106 per ml. The difference
between the median values for the 2 groups was statistically significant (p<0.01).
8.2 NK cells remain elevated during recovery from IM
In order to relate the clinical symptoms of IM to changes in NK cell numbers a study
of NK cell numbers in the peripheral blood, was carried out during the course of IM
on a group of 6 patients (cases 1,4, 9, 10, 11 and 12 in Table 5-6 page 107).
As documented, NK cell counts were elevated at diagnosis. At a subsequent review
at the time point closest to 1 month following diagnosis, NK cell counts had fallen
(range 0.14-0.50 x 106 per ml) but remained elevated compared to controls (p<0.01
Figure 8.3 page 144). However, at this time point both the total lymphocyte counts
and CD8+T cell counts for cases had fallen and were not significantly different from
controls (Table 6-1 page 110): median lymphocyte counts for 6 cases of IM were
1.82 x 106 per ml and 1.35 x 106 per ml for controls, with CD8 positive lymphocytes
0.44 x 106 per ml for cases and 0.48 x 106 per ml for controls. 5 out of the 6 cases
studied at this time point continued to be unwell, with symptoms such as enlarged
glands and fatigue (Figure 8-4 page 145). By 6 months after diagnosis NK cell
counts in all cases had fallen to within the range for controls (0.03-0.41 x 106 per
ml), and median counts were not significantly different to controls.
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Days following diagnosis *■ 6month+
Figure 8-3 NK cell counts are raised in the first month following diagnosis of IM
A line graph is shown of NK cell counts from 6 cases of IM at diagnosis to 6 months
post diagnosis. Cases with severe sore throat are shown by an unbroken line and
cases with mild sore throat are shown by a broken line (See section 8.4 page 159).
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Figure 8-4 NK cell counts and key clinical features in 6 cases of IM
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8.3 The CD5&r'9ht cell population is expanded in acute IM
As NK cell numbers were shown to be elevated in acute IM, changes in cell
phenotype, which may contribute to the pathogenesis of IM were investigated.
CD56bnght cells are important producers of regulatory cytokines and may provide a
link between the innate NK cell and acquired CD8 cell response to infection (Cooper
et al., 2001a).
A number of investigators have noted that when analysed by flow cytometry,
expression of CD56 on NK cells can be categorised as bright or dull. Approximately
90% of resting cells express low levels of CD56, and are defined as CD56du" cells
and 10% of resting cells express high levels of CD56, and are defined as CD56bnght
cells (Lanier et al., 1986). However, there is no absolute classification of a CD56bnght
cell, and the fluorescent intensity recorded by the cytometer will depend on certain
machine parameters as well as the fluorescence emitted by the cell. Therefore CD56
expression was analysed both as a single parameter, median fluorescence intensity
(MFI) (Figure 8.5 page 147), and also by recording the percentage of the total NK
cell population which showed high levels of CD56 expression. In order to enable
comparison between different experiments, the voltages, gates and compensation
settings on the flow cytometer were not changed between experiments.
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Figure 8-5 MFI of CD56 on NK cells is raised in IM compared to controls
The histograms show the method of calculation ofMFI expression of CD56 on NK
cells from a subject with acute IM (top plot) and a control subject (bottom plot).
The analyses of intensity of CD56 expression as a single parameter was carried out
first, and a statistically increased MFI of CD56 was found on NK cells from IM
patients (n= 8) compared to controls (n=9) (p<0.001). MFI for cases was 125 and for
controls was 25. Next the proportion ofNK cells in IM expressing a CD56bnght cell
phenotype was analysed, and again this was found to be significantly raised (median
of 17% compared to a control median of 6%) (p< 0.01, Figure 8.6 page 148 and
Figure 8-7 page 149). Unlike studies on cells from healthy donors or cultured NK
cells (Cooper et al., 2001b), a proportion of CD56bnght cells were also found to
concurrently express CD 16 (Figure 8-7 page 149). It is therefore possible that this
population is not an expansion of the CD56bl,ght cell population, but a population of
NK cells which show increased expression of CD56 during acute IM. CD244 is
constituently expressed on NK cells (Nakajima et al., 1999), and there was no
difference in intensity of expression of CD244 on NK cells from IM cases than from
controls (MFI 242 in cases and MFI 223 in controls).
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Figure 8-6 The CD56br,ght cell population is expanded in acute IM.
A Scatter plot of the percentage ofNK cells of CD56bnghtcell phenotype for IM cases
(n=8) and controls (n=9) is shown. Bars show median values of 17% for cases (filled
triangles) compared to 6% for controls (filled squares). The difference between the
median values for the 2 groups was statistically significant (p<0.01).
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Gated on CD3 negative
population
Figure 8-7 The FACS plot shows the expansion of a CD56br,sht cell population in
a typical case of IM compared to a healthy control
The 2 plots on the left are gated on all lymphocytes and the 2 plots on the right are
gated solely on CD3 negative lymphocytes. The arrows identify the NK cell
population which express high levels of CD56 which is expanded in acute IM. A
comparison of the ability of NK cells from cases of IM and controls to kill an EBV
infected cell line
As we had identified a change in NK cell phenotype during acute IM, we next
investigated if this change in phenotype was associated with a change in NK cell
function. NK cells are able to kill cell lines latently infected with EBV (LCLs)
(Blazar et al., 1980), and therefore the ability to kill EBV infected cell lines was
compared between NK cells from acute IM cases and controls.
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8.3.1 Optimization of methods
8.3.1.1 NK cell separation by magnetic beads results in pure NK cell
population.
NK cell separation was carried out using magnetic beads as described in the methods
(Section 3.10 page 84). The cell purity of the resulting NK cell population was
checked by standard FACS analysis on 5 occasions. The NK cell population was
stained using antibodies to CD56 and CD3, and found to routinely contain less than
0.5 percent CD3 positive cells on all occasions (Figure 8-8 page 151). Furthermore,
the population did not contain any B cells (CD 19+), monocytes (CD 14+) or CD4 + T
cells. Following separation a substantial number of cells were present in the NK cell
fraction which could not be identified, and were negative for B, T and NK cell
markers. It was not possible to identify their phenotype further, however it is unlikely
they would alter the subsequent cytotoxicity assay as they did not have a T cell
phenotype. A reduction in the number of cells was found following addition of lysis
buffer, suggesting a proportion may be red cells or red cell aggregates.
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Figure 8-8 NK cell populations are pure post MACS bead separation.
The top plot shows the lymphocyte population pre MACS bead separation and the
bottom plot shows the population post separation. The figures on the right show the
percentage of cells in each quadrant. The cells were stained with CD3FITC (X axis)
and CD56PE (Y axis).
8.3.1.2 NK cell cytotoxicty assay
8.3.1.2.1 Method 1- NK cell killing ofautologous LCL
In the first method used the aim was to compare NK cell cytotoxicity from IM cases
and healthy controls against an autologous LCL. It was decided to use NK cells
directly ex-vivo, rather than clone the cells, as cell culture could lead to changes in
cell phenotype and function. Therefore fresh PBMC were used to set up an LCL, and
the rest of the sample was frozen within 48 hours of the blood being taken. The NK
cell population was separated from the frozen stored PBMC, once the LCL was
established. In the preliminary experiments using healthy controls, the subjects were
re-bled to obtain fresh NK cells at the time of the cytotoxicity assay.
LCLs were grown from 8 healthy controls and 6 cases of IM. The cytotoxicity assay
was carried out as described (Section 3.11 page 85), and on all occasions the target
LCL and NK cells were autologous. A positive control for NK cell killing, the cell
line K562, was included in all experiments.
8.3.1.2.2 LCLs grown forlO days are not killed by NK cells
In 2 control experiments the LCL was used as the target cell line 10 days after EBV
infection and culture. However, at this stage of culture the NK cells failed to lyse the
target LCL, despite effective lysis of K562 cells. In the same 2 donors, at week 7 of
LCL culture, substantial killing of both LCL and K562 occurred.
Table 8-2 NK cell killing of LCL at 10 days and 7 weeks of tissue culture
% cytotoxicity of K562 % cytotoxicity against LCL at 10
days of culture
20:1 10:1 5:1 20:1 10:1 5:1
Control 1 25 17 11 0 0 0
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Control 2 92 100 100 0 0 0
% cytotoxicity of K562 % cytotoxicity against LCL at 7
weeks of culture
20:1 10:1 5:1 20:1 10:1 5:1
Control 1 22 15 23 9 5 3
Control 2 40 41 8 39 55 31
The results are shown above in (Table 8-2 page 151).Therefore in all further
experiments the LCL was grown for at least 5 weeks.
8.3.1.2.3 NK cells separatedfrom cyropreserved PBMC have impaired killing
capacity immediately after defrosting
When LCL growth was established, viable PBMC were rapidly defrosted and the NK
cell fraction was separated and used immediately as effector cells in a standard
cytotoxicity assay.
In the first experiment, NK cells were separated from 1 acute case of IM and 1
healthy control. The cytotoxicity assay was carried out immediately after separation
of NK cells, and no killing of either LCL or K562 occurred (Table 8-3 page 153).
In a further 2 control experiments the NK cells were placed in an incubator for 2
hours at 37° C, before use in the cytotoxicity assay. A 2 hour incubation was chosen
as this allowed the cytotoxicity assay to be completed within 1 day.
A slight improvement in killing occurred with low percentage killing of K562;
however at all ratios killing of less than 10% was recorded. In contrast the median
killing of K562 by fresh NK cells from controls was 40% at ratio of 20:1, 31% at
10:1, and 22% at 5:1 (Table 8-4 page 154) for details of individual control
experiments), and no killing of LCL occurred. In comparison, in a further 2 control
cases in which NK cells were separated and suspended in medium, and then left at
37° C overnight, levels of killing comparable to those obtained from fresh NK cells
occurred (Table 8-3 page 153). Separation of NK cells from fresh PBMC and storage
at 4° C overnight did not affect their ability to lyse target cells.
8.3.1.2.4 NK cells from IM cases storedfor 12 hours clump
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Following the above experiments, NK cells separated from frozen PBMC were
stored overnight at 37° C. However NK cells from IM cases tended to form cell
clumps overnight, and despite use of DNAase it was not possible to obtain enough
NK cells for meaningful cytotoxicity assays.
Table 8-3 NK cell killing capacity of recently thawed and incubated cells
Percentage killing of target cells
NK cells separated from
frozen PBMC
Ratio ofNK cell to K562 Ratio ofNK cell to LCL
(cultured 5-7 weeks)





IM Donor 1 0 0 0 0 0 0




Control 6 9 8 0 0 0




Control NA 34 20 NA NA NA




Control NA 30 18 NA 17 2
Control 40 41 8 39 55 31
NA denotes data unavailable.
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Table 8-4 Percentage of Killing of LCL and K562 cell lines by autologous NK
cells
Controls % Killing of target cell
Ratio ofNK cell to K562 Ratio of NK cell to LCL
20:1 10:1 5:1 20:1 10:1 5:1
NK cells from
fresh PBMC
Control 1 NA 50 27 NA 5 0
Control 2 NA 30 18 NA 17 2
Control 3 68 43 41 54 3 5
Control 4 25 27 1 1 9 5 3






Control 6 41 6 5 1 6 1
Control 7 NA 20 35 NA NA NA
Control 8 NA 33 34 NA NA NA
NA - data not available
8.3.2 Use of MHC class 1 negative EBV infected cell line as universal
target
8.3.2.1 Characterization of 721.221 cell line
As the first method could not be reliably used for IM cases, a second method was
optimized using a MHC class 1 negative EBV infected cell line as universal target
for all controls and IM cases. 721.221 is a mutant EBV latently infected cell line
which does not express MHC 1 (Shimizu et ah, 1988), and is routinely used as a NK
cell target. In order to ensure that the cell line was comparable to an autologous LCL,
the expression of EBV latent antigens was monitored.
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Flow cytometry experiments showed that the cell line was MHC 1 negative, but
MHC 2 positive, and could therefore be used as a target cell for NK cell killing by
any donor (Figure 8.9 page 155). Cytospins preparations from the 721.221 cell line
were stained for the EBV latent antigens LMP, EBNA2 and EBNA 3a, 3b, in
addition to CD 19 (B cell antigen), and all were shown to be expressed by
immunohistochemistry. The cell line was also positive for EBERS using In Situ
hybridization. Immunohistochemistry using anti EBNA 3c antibodies failed, and
antibodies to EBNA 1 were not available. These results confirmed a viral latency 3





Figure 8-9 Cell line 721.221 does not express MHC 1.
The 721.221 cell line was stained with antibodies to both MHC1 and MHC2 and the
expression of the antigens was assessed by flow cytometry. The histograms show
negative expression ofMHC 1 (top histogram) and positive expression of MHC2
(bottom histogram).
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image. All images are magnified x 400
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8.3.2.2 NK cells in IM show an enhanced capacity to kill an EBV
infected cell line
NK cells were separated from 9 controls and 8 cases of IM and used as effector cells
with the 721.221 cell line as the target, in a standard chromium release cytotoxicity
assay. All NK cells were obtained from fresh PBMC, and used either directly or
stored overnight at 4° C.
Fresh NK cells from acute IM showed an enhanced ability to lyse the 721.221 cell
line compared to NK cells from controls, at ratios of 20:1 (median 8 % for controls
and 32 % for cases), 10:1 (median 6% for controls and 20 % for cases) and 5:1
(median 5 % for controls and 14.5 % for cases). The differences in median
percentage killing between controls and cases were statistically significant at both
20:1 and 5:1 (p<0.05), and just failed to reach significance at 10:1 (p= 0.06). A
representative experiment is shown in Figure 8.11 page 157 and the results from
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Figure 8-11 NK cells from IM patients have enhanced cytotoxic capacity against
an EBV infected cell line
The percentage specific lysis of 721.221 target cells by NK effector cells at ratios of
effector to target cells of 5:1,10:1 and 20:1 are plotted. A representative experiment
from the results on the 8 IM and the 9 control experiments is shown.
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Table 8-5 Percentage killing of K562 and 721.221 cell lines by NK cells
Acute IM % Killing of target cells
Ratio ofNK cell to K562 Ratio of NK cell to 721.221
20:1 10:1 5:1 20:1 10:1 5:1
Case 1 33 26 23 19 20 16
2 42 43 27 36 46 26
3 33 13 20 28 50 65
4 Na 16 10 Na 9 9
5 38 29 19 33 25 20
6 3 4 2 3 3 3
7 35 20 14 35 20 13
8 39 16 4 32 17 11
Range 3-42 4-43 2-27 3-36 3-50 9-65
Median 35 18 16.5 32* 20# 14.5*
*Median values were significantly different to control values (p<0.05)
# Median values were of borderline difference to control values (p=0.06)
% Killing of Target Cells
Healthy
Ccntrols
Ratio of NK cell to K562 Ratio ofNK cell to 721.221
20:1 10:1 5:1 20:1 10:1 5:1
Control 1 19 14 8 12 7 6
2 21 16 11 19 11 8
3 Na 1 3 1 2 2
4 Na Na Na 4 3 5
5 Na Na Na 8 5 4
6 54 40 27 66 53 36
7 1 1 1 2 1 1
8 29 18 12 14 12 5
9 6 9 8 1 Na Na
Range 1-54 1-40 1-27 1-66 1-53 1-36
Median 20 14 8 8 6 5
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8.4 Percentage of NK cells in the peripheral blood is higher
in those with mild compared to severe sore throat
The results of the functional studies on NK cells from IM cases suggest NK cells can
eliminate EBV infected B cells, and therefore would have a protective role in
primary EBV infection. In order to investigate this further we analysed levels of NK
cells in peripheral blood in relation to clinical outcome.
As previously documented severity of sore throat was recorded in 26 students and
classified as either mild (14 subjects) or severe (12 subjects) (Table 5-6 page 107).
The percentage of NK cells in the PBMC was significantly higher in the mild
compared to the severe group (p<0.05, Figure 8.12 page 159). The range ofNK cells
for the mild group was 8-38 %, with a median of 19.5%, and the range for severe
group was 5-28 %, with a median of 13.5%. (The range for the control group was 1-
19%, median 10%, see Figure 8.12 page 159). The number of NK cells was higher in
the mild compared to the severe group - median of 0.87 x 106 /ml compared to 0.80






















mild sore throat severe sore throat
Figure 8-12 The percentage of NK cells in peripheral blood in acute IM is
higher in those with mild compared to severe sore throat
A plot is shown of the percentage of lymphocytes ofNK cell phenotype in the
peripheral blood at diagnosis of IM for those with mild (N=14) (filled squares)
compared to severe sore throat (N=12) (filled triangles). The bars show the median
values of 19.5% for the mild sore throat group and 13.5% for the severe sore throat
group (p< 0.05).
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The relationship between a number of other clinical parameters and NK cells was
also investigated. Fever was experienced by 21 out of 26 cases, and the median
percentage of NK cells in the PBMC was higher in those without (20%) compared to
those with fever (15%). However no significant statistical difference was found
between the 2 groups, possibly because the group without fever was so small.
Likewise, NK cell numbers in the peripheral blood were higher in those without
fever (1.14 x 106/ml), compared to those with fever (0.87 x 106/ml), but again no
significant statistical difference was found between the 2 groups. A rash occurred in














Figure 8-13 The percentage of NK cells in peripheral blood in acute IM is
higher in those with rash than those with no rash
Plots are shown of both the percentage (upper plot) and numbers of lymphocytes
(lower plot) of NK cell phenotype in the peripheral blood at diagnosis of IM for
those with rash (N=5) (filled squares) compared to those with no rash (N=20) (filled
triangles). The median percentage of NK cells was significantly higher at 29% in
those with rash, compared to 15% in those without rash (p<0.05). The number ofNK
cells in the peripheral blood was also markedly higher in the group with rash, at 1.45
x 106/ml compared to 0.70 x 106/ml to those without rash, however changes were
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not significant. FBC were not available in all cases. Median values are shown by the
bars.
The median percentage ofNK cells in the peripheral blood in the group with rash
was significantly higher at 29% compared to 15% in those without rash (p<0.05,
Figure 8.13 page 160). The number ofNK cells in the peripheral blood was also
markedly higher in the group with rash, at 1.45 x 106/ml compared to 0.70 x 106/ml
to those without rash, however changes were not statistically significant, and there
were only 2 cases in the group with rash.
Physical activity and fatigue were also recorded in the IM cohort. At diagnosis of
IM, 17 of the 26 cases were able to leave home and 9 were house bound. Both the
percentage and number of NK cells were lower in the housebound group (median
values for the housebound group were 13% and 0.6 x 106 /ml, compared to 17% and
0.9 x 106 /ml for the group able to leave home). However, no significant statistical
difference was found between the 2 groups. Assessment of ability to attend
university was also made. 17 of the 26 cases either were not able to attend at all or
attended part time, 6 cases continued to attend full time, and 3 cases were on holiday
so were excluded from the analysis. No difference was found between the 2 groups
either with respect to median number of NK cells or median percentage of NK cells
in the peripheral blood. The median number of NK cells in the full time attendees
was 0. 94 x 106 /ml compared to 0.90 x 106/ml in the part time attendees, with
median percentage of 17.5% and 16% respectively.
8.5 In acute IM, NK cells show an inverse correlation with
EBV load
Next we investigated the relationship between EBV load and NK cell numbers at
diagnosis of IM. Viral load was measured by PCR in the peripheral blood
mononuclear cells of 23 IM cases. The range of viral loads was 0 to 49249 per 106
PBMC, and increased viral load correlated inversely with the percentage of NK cells
in the peripheral blood, the pearson correlation coefficient ® was - 0.44 with
corresponding p value of <0.05 (Figure 8.14 page 162). In a subgroup of 19 cases in
whom lymphocyte counts were available, there was a trend to an inverse correlation
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Figure 8-14 At diagnosis of IM the percentage ofNK cells in the peripheral
blood shows an inverse correlation with viral load
A plot is shown of EBV load per 106 PBMC against percentage of NK cells in the
lymphocyte population at diagnosis of acute IM. The Pearson correlation coefficient
® was - 0.44 with corresponding p value of <0.05.
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9 Discussion
Primary EBV infection presents a wide spectrum of clinical manifestations ranging
from subclinical infection to fulminant disease, which is rapidly fatal (XLP). IM is
caused by delayed primary infection with EBV and is thought to be
immunopathological in nature, due to an exaggerated CD8+ T cell response to viral
antigens presented on infected B lymphocytes. This CD8+ T cell response is now
well characterised, and is antigen specific with large clonal expansions of cytotoxic T
cells reactive with predominantly lytic viral antigens (see Section 2.6.8.1 page 34).
However the mechanisms underlying this intense immune activation and in particular
its relationship to the clinical symptoms of IM, are not clearly understood. In
addition it is not known why the majority of individuals undergo silent
seroconversion, with IM limited to around fifty percent of those who seroconvert as
young adults. A number of possible explanations have been proposed. These include
variability of infecting dose, genetic diversity leading to alterations in the dynamics
of the immune response such as cytokine polymorphisms, and factors in T cell
development such as affinity maturation (Silins et al., 2001). Another factor may be
changes in the immune response with age.
Recent progress in our understanding of fatal IM has identified a lymphocyte
activation pathway in which cell surface CD244 and SLAM are regulated by SAP,
the gene mutated in XLP. Since absence of a functional SAP protein in XLP leads to
fatal IM, the level of control of immune activation by SAP is likely to be critical in
determining the outcome of primary EBV infection in healthy individuals. A large,
ongoing epidemiological study on IM in the Edinburgh student population (Crawford
et al., 2002), allowed access to blood samples from subjects with acute IM and
follow up samples on a subset of these for the present study.
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9.1 Characteristics of the IM Cohort
Over 2 years we recruited 2012 first year students at admission to university to the
MRC seroepidemiological study, and at this time around 25% were seronegative for
EBV, both by serological and PCR testing. The seronegative individuals were asked
to report to the university health service with clinical illness suggestive of IM. In
total 137 cases of IM were diagnosed at the health centre over this period, and 56
cases were recruited, therefore we recruited 41% of all cases. The age range was 18-
26, and around half the cases were male and half female. When compared to the
epidemiological studies carried out in the 1960's, our cohort has a higher rate of sero
prevalence to EBV. This is likely to be due to a more diverse social mix in university
students and an increase in sexual activity in adolescence. Unlike the previous
studies, our study included female students. Interestingly, we found female students
had a higher seroprevalence of EBV at this age (Crawford et al., 2002), and therefore
their inclusion would raise the overall prevalence of EBV in the cohort. The reason
for this difference in seropositivity in men and women is unclear. One possibility is
that the quantity of EBV a seronegative subject receives during sexual intercourse is
higher from sperm, than from vaginal secretions, thus women, as the receptive sexual
partner are more likely to seroconvert following intercourse with a seropositive
partner. However, this hypothesis is only plausible if sexual transmission is an
important mode of EBV spread. Alternatively, adolescent females frequently have
sexual partners older than themselves, who in turn are more likely to be EBV
positive as seropositivity increases with age.
The results of the clinical assessment have not been fully analysed, however our
impression at this stage is that the clinical features have not changed markedly since
the work on IM in the 1960's. The typical features continued to be sore throat
experienced by over 95%, lymphadenopathy experienced by nearly 100%, and fever
experienced by 75% of our cohort. Anorexia and headache were also common,
experienced by around 78% and 66% respectively, and rash occurred in 10%. In
addition the clinical course of the illness remains similar, with a short prodrome, of a
median of 6 days followed by as severe period of a median of 7 days, followed by a
prolonged recovery period. The median length of illness from the beginning of the
prodrome was 32 days. Of interest, in the 1960's cases were often hospitalised for
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several weeks (Sawyer et al., 1971), and though this does not occur now, a large
number of cases suffered fatigue which led to significant impact on university
studies. Unfortunately 4 out of the 56 cases studied either dropped down a year or
left university following IM.
One of our aims was to make an objective assessment of disease severity at
diagnosis. In order to do this we needed to identify clinical features that were
common, varied with degree of illness, and could be recalled and recorded
objectively. We found sore throat was the most useful parameter; it was both widely
experienced and simple to grade. Furthermore we found sore throat was a reasonable
surrogate marker of disease severity. For example experience of fever was easy to
elucidate from the cases, but not a good marker for the spread of disease severity as it
occurred in the vast majority of cases. However, the 5 cases that did not have fever
had mild sore throat, confirming sore throat is a good surrogate marker of disease
severity.
Analysis of physical function and fatigue was best assessed by ability to leave home;
it is a simple fact to recall and does not require any further quantification. 9 out of
the 26 cases were unable to leave home, and 1 of these cases had no fever and only
mild sore throat whereas 2 of these cases had mild sore throat but fever. Thus there is
a link between severity of clinical features and ability to leave home, but this was not
absolute.
The high incidence of IM in the student population meant the GP's had a low thresh-
hold for carrying out diagnostic serology. Consequently we identified a number of
cases that had very mild illness. For example, nearly 20% (6 out of 26 cases) of the
immune activation cohort managed to continue to attend university full time during
their illness. One of the important conclusions from these data is that IM has a
spectrum of illness from silent seroconversion, through mild illness to the more
typical clinical course and finally those with severe IM.
Dr Macsween will report on the clinical aspects of the study in more detail in her
MD thesis.
Discussion 165
An analysis of the immune response to primary Epstein- Barr Virus infection and the association with
clinical events
9.2 Immune activation study
A detailed analysis of the immune response and expression of the
CD244/SLAM/SAP pathway in T cells was made in 26 cases of IM. In agreement
with earlier studies discussed in the introduction (Section 2.6.8.1 page 34), we found
a lymphocytosis in 85% of cases of acute IM at the time of diagnosis which mainly
consisted of CD8+ T cells although NK cell numbers were also significantly
elevated. In addition, several studies have documented the expression of T cell
activation markers such as HLA DR and CD25 on CD8+ T cells in peripheral blood
in IM (Tomkinson et ah, 1987; Callan et al., 1996; Hoshino et al., 1999).
We have demonstrated that CD8+ T cells also show upregulation of the
CD244/SLAM activation pathway. Thus, significantly increased numbers of CD8 T
cells expressed cell surface CD244 and SLAM, and although absolute numbers of
CD4 T cells were not raised, their level of activation as assessed by CD244
expression was also significantly increased. Earlier studies have shown that the
activated T cells in IM secrete a variety of inflammatory cytokines (see Section
2.6.8.2 page 36), which are thought to be responsible for the clinical symptoms of
IM. Our results now indicate that activation of CD4+ and CD8+ T cells through the
CD244 and SLAM pathway is involved in this process. The change in activation
status of CD4 + T cells in particular may be pivotal to directing the cytokine profile
seen in IM by their ability to regulate the TH1/TH2 balance (Dong and Flavell,
2001).
Full recovery from IM is the norm, but the clinical course is often prolonged.
Having found that the CD244/SLAM pathway is activated in IM T cells, we were
interested to see whether this could be a key event in determining the disease pattern
in IM by linking T cell activation with clinical events and duration of illness. Our
results show that the prolonged clinical features are not simply a reflection of
increased T cell numbers, as the lymphocytosis present at diagnosis fell rapidly, and
by day 16 all T cell subsets were within the normal (control) range. However, the
analysis also showed that, despite normal cell counts, T cells maintain expression of
the activation markers CD244 and SLAM for prolonged periods following diagnosis.
At around one month after diagnosis 5 out of 5 cases remained unwell, and in each
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case expression of CD244 and SLAM on CD8 T cells was elevated. Moreover, those
who had a more protracted clinical course continued to show increased expression of
the activation markers on CD8 T cells even at 40 days post diagnosis. This work is
in agreement with Bharadwaj et al who also identified T cells with an activated
phenotype (CD38 positive) during recovery from IM (Bharadwaj et al., 2001).
Interestingly, even at an early stage of the disease process, we found that SAP
expression was markedly increased in PBMC, thus maintaining control of the
activation process. This contrasts with the situation in XLP where the loss of SAP
function allows uncontrolled T cell activation and overproduction of inflammatory
cytokines, usually with fatal consequences. Further evidence for the role of SAP in
the pathogenesis of IM, was provided by the identification of the co-expression of
SAP and INF y in PBMC from acute IM.
As discussed, sore throat is a good marker of disease severity in IM. Symptoms vary
from mild pharyngitis to a complete inability to swallow, and occasionally airway
obstruction requires emergency surgical intervention. We graded the degree of sore
throat at diagnosis as either mild or severe and found that those with severe sore
throat had a significantly higher number of both CD8+ T cells, and CD8+ T cells
expressing CD244. A small number of cases in our cohort did not experience fever,
and again we found lower numbers of both CD8 and CD244/CD8 T cells in the
group with less severe symptoms. In the same group of patients ability to leave home
during acute IM had a weaker association with T cell activation, a finding that may
reflect the pathology of fever and sore throat compared to the mechanisms
underlying the fatigue affecting an individual's ability to leave home. Both fever and
swelling with ulceration of the pharynx are a direct consequence of immune
activation and cytokine release, whereas ability to leave home may reflect infection
severity but also psychological response to illness.
Additionally some variables such as ability to attend university at the time of
diagnosis were more difficult to quantify accurately and compare between
individuals. We found students work load varied both between different courses and
year of course. Therefore someone with the same degree of illness might manage to
attend a small number of lectures in a week but not an all day field trip.
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Of the immune parameters investigated numbers of CD8+T cells and CD244+CD8+
T cells had the strongest correlations with clinical features. SLAM positive subsets of
T cells had a weaker link with clinical features and this suggests that CD244 subsets
have a more significant role in the pathogenesis of IM. As CD3+ T cells are largely
composed of CD8+ T cells in IM, the correlations found between CD3+T cell
subsets and clinical features are explained by this CD8+ component.
We used a quantitative PCR method to measure the level of viral DNA in PBMC
and over 90 % of cases had a detectable level of virus. These results are similar to
Hopwood et al and Berger et al who detected EBV viral DNA in around 90% of IM
cases studied (Hopwood et al., 2002). In addition Berger found levels of virus fell
over time following diagnosis (Berger et al., 2001). We were interested in the
relationship between viral load and clinical disease. We found that the percentages
of both CD8+ and CD8+/CD244+ T cells correlated with the level of viral DNA in
PBMC (viral load). Moreover, in 23 cases investigated the level of cell associated
virus was higher in those with severe compared to mild sore throat (Figure 6-11 page
127). Therefore our data supports the hypothesis that higher viral loads are associated
with increased immune activation and increased severity of outcome of infection,
and by inference silent seroconversion would be linked to lower viral load. In
contrast, in a small number of cases, Silins et al found similar levels of viral DNA in
peripheral blood cells from those with silent and clinical seroconversion (Silins et al.,
2001).
Since defective SAP function in XLP confers a specific inability to control EBV
infection (Section 2.7.8 page 45), we were interested to find out whether activation
of the CD244/SLAM/SAP pathway was in any way a specific feature of primary
EBV infection. We therefore analysed expression of these molecules in PBMC from
adults with primary VZV infection. We found that expression of CD244 was
significantly enhanced in VZV cases compared with healthy controls, but that the
changes were significantly more pronounced in IM despite the fact the VZV cases
were more unwell with 3 out of 4 cases requiring hospital admission. (None of the
26 cases of IM in the immune activation cohort required hospital admission). One
reason for this difference may be that VZV is directly cytopathic, with the virus itself
causing cell damage and thus clinical features such as necrotic skin lesions (Arvin,
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2003). Therefore in contrast to EBV the severity of clinical illness is not likely to be
related to the degree of immune activation.
9.3 The NK cell response in IM
In contrast to the acquired immune response, little is known about innate immune
responses during IM. Previous investigators have identified elevated NK cells and
gamma delta T cell numbers, but information on function was hampered by
difficulties in identifying a true NK cell population. However, identification of an
NK cell defect in individuals with XLP highlights the importance of these cells in the
control of primary infection (see section 2.10.6 page 61). Moreover, there is
increasing evidence from experimental systems of a major role for NK cells in
control of herpes virus infections (reviewed in Arase and Lanier, 2002). The best
evidence comes from the demonstration of susceptibility to mouse CMV being
linked to an activating NK cell receptor. At present, data from human infections are
limited. We analysed the scale, phenotype and function of the NK cell response in
the same cohort of 26 cases of IM.
We found a significant increase in NK cells at diagnosis of IM, with raised cell
numbers and an elevated percentage of NK cells within the lymphocyte population.
Furthermore, in a subgroup of patients from whom serial samples were available, we
showed that median NK cell numbers remained elevated over the first month of the
illness but had reverted to normal levels by 6 months post diagnosis. This finding
contrasts with lymphocyte counts and CD8 + T cell numbers that rapidly returned to
control levels. These data are in agreement with earlier studies showing elevations
of CD16+ lymphocytes in IM (Tomkinson et al., 1987). We did not find an
expansion of NKT cells in acute IM, however the characterisation of NKT cells
remains difficult, and use of an alternative marker such as Val4-Jal8/v(31 lmay be
useful (Prussin and Foster, 1997; Lee et al., 2002).
In addition to the increase in NK cell numbers found in IM, we also identified a
marked change in NK cell phenotype, including a significant increase in the
proportion of CD56bnght cells in the peripheral blood. It should be noted that, as the
total numbers of NK cells are raised there were increased numbers of both CD56bllght
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and CD56dim subsets, but with an expansion of the proportion of the CD56bnght
subset in cases compared to controls. These CD56bnght cells are potent producers of
immunoregulatory cytokines, and recent studies by Fehniger et al, identified them as
the dominant NK cell subset in human lymph nodes. They show that CD56bnght cells
release cytokines such as INF y which can stimulate antigen specific T cells
(Fehniger et al., 2002). Activated T cells then release IL-2, which in turn activates
CD56bnght cells to become highly cytotoxic and also stimulates the production of
more INF y. This stimulatory loop thus provides an important link between the
innate and adaptive immune responses. In the context of primary EBV infection,
where initial infection of B cells occurs in the lymphoid tissue of the oropharnyx
(mainly in tonsil), the level of interaction between activated CD56bnght cells and EBV
specific T cells may be key to determining clinical outcome. It is possible that the
increased numbers of CD56bnght cells which we detected in peripheral blood
represent a spill-over from the primary site of infection, but clearly it would be
interesting to study NK and T cell subsets, along with cytokine gene expression, in
tonsils from early EBV infections. The co-expression of CD 16 on CD56bngh> NK
cells has not been previously described, and its significance is unclear.
The functional studies revealed that freshly isolated NK cells from IM blood show an
enhanced ability to kill an EBV infected B cell line, and we suggest that this is a key
factor in control of the early infection. In primary infection EBV establishes a pool
of infected B cells in oropharyngeal lymphoid tissue both by driving their
proliferation and by inducing the production of viral progeny, which can infect
bystanding B cells. Infected B cells from this site enter the blood stream and
disseminate throughout the body. In healthy individuals the immune system
eventually exerts control over this infection and a state of viral latency is established.
EBV specific cytotoxic T cells are believed to be key to the resolution of primary
infection. However, these cells appear to develop slowly since there is an incubation
period of around 30 days before the typical immunopathological symptoms of IM
develop. Thus there is a window of opportunity for uncontrolled B cell proliferation
and viral replication, and it is during this period that the cytotoxic activity ofNK
cells is likely to be crucial. Moreover, Parham (Parham, 2003) has recently suggested
that early control of infection by the innate immune system, and NK cells in
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particular, may result in resolution of infection prior to symptom onset. This
argument is especially relevant to primary EBV infection where the pathology of
symptomatic infection, IM is driven by the acquired immune response to the virus
rather than the virus directly. Another interesting possibility is that NK cell
phenotype and function is related to age and cell function in infants may allow better
control of early viral infection.
The importance ofNK cells in control of primary infection is supported by our
analysis of disease severity in relation to NK cell responses. In contrast to CD8+ T
cell responses, where higher numbers of cells were linked to more severe illness;
higher percentages of NK cells were found in the peripheral blood of those with
milder illness. Additionally, we found an inverse correlation between percentage of
NK cells and amount of EBV load in the peripheral blood (Section 8.5 page 161).
However, we have also found a positive correlation between the percentage of
CD8+T cells in the peripheral blood and viral load. Therefore it is not clear whether
both CD8+T cell and NK cell responses independently influence viral production, or
whether CD8+ T cells are the driving force and lower percentages ofNK cells in the
peripheral blood are simply a reflection of higher percentages of CD8+T cells. Our
results are only an indication of the relationship between the factors at the point of
diagnosis, and it would be useful to monitor the 3 factors in a larger number of cases
over the course of the illness. Interestingly in the 6 cases in which we monitored NK
cell counts over time, those with more severe illness as assessed by sore throat
severity all had lower NK cell counts than those with mild sore throats (Figure 8-4
page 145).
There was not a clearcut relationship between NK cell counts and physical function
such as ability to attend university. This may reflect that NK cell function is most
critical in early stages of disease pathology, and so links with the first physical
symptoms such as sore throat, and not with later and prolonged features such as
impaired physical function. In summary we have provided evidence that NK cells
are a critical component of the control of primary EBV infection in adults with IM.
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Interestingly, our work has parallels in a mouse model of CMV infection, where
increased NK cell cytotoxicity has been identified very early in viral infection, and
was mediated by virus induced IFN a and IFN P (Orange and Biron, 1996).
9.4 XLP mutation analysis
We screened 10 cases of putative XLP for mutations in the four coding exons of the
SAP gene, using PCR based sequencing techniques, and found no mutations. The
most likely explanation for this is that the cases are in fact sporadic fulminant IM.
The cases were all males who had been suspected on clinical grounds of having
severe EBV related disease, in the majority of cases presenting with severe fatal IM.
Clinical data was very limited in a number of cases, with only 2 of the cases having a
family history, and in several of the cases the evidence to suggest a diagnosis of XLP
was fairly limited. However, at the time of identification of the XLP gene, it was
important to establish whether mutations in SAP were linked to other conditions in
which severe EBV infection occurs. In other reported series 50-60% of those with a
clinical diagnosis of XLP have been found to have a mutation. Another explanation
is that mutations may be present in parts of the gene that have not been sequenced
such as the promotor regions. This work reinforces the importance of establishing
good diagnostic criteria for a condition before attempting to find putative genes
linked to disease causation.
Since the identification of the XLP gene, a great deal of progress has been made in
our understanding of the pathogenesis of the disorder, and the critical role of SAP in
control of lymphocyte activation. It is now clear that clinical XLP can occur without
EBV infection, but the virus continues to be the most well recognised trigger. Why
this should be so is still not known. One hypothesis is that NK cells are vital to the
control of primary EBV. Thus the loss of control of NK cell activation due to
mutations in SAP in XLP patients, may lead to a failure of appropriate NK cell
killing via an interaction of CD244 on the NK cell and CD48 on EBV infected B
cells. However, NK cells appear to be important to the control of other viral
infections such as CMV, and CMV is not a common trigger for XLP.
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Another intriguing possibility is suggested by recent work from a mouse model of
XLP. Mice with mutations in the SAP/SH2D1A gene were found to have an inability
to develop full humoral immunity following viral infection, as their B cells failed to
switch immunoglobulin isotype (Crotty et al., 2003). Interestingly, this was thought
to be due to lack of appropriate CD4+T cell help, rather than an overt defect in B
cells, as SAP is predominately expressed in T cells rather than B cells. This failure to
switch immunoglobulin isotype would explain the hypogammaglobulinamia which is
a characteristic feature of XLP. Critically, resolution of primary EBV infection and
change to latent infection requires a switch in B cell phenotype from a proliferating
B cell blast into a B memory cell. This switch to a memory cell phenotype is
associated with a down regulation in the immune response, as the immune
stimulating EBV antigens presented on the proliferating blast are down regulated.
Thus if the mouse model reflects what occurs in human XLP patients, EBV infected
B cells would be unable to undergo this change in phenotype. Interestingly this is
probably not directly due to a defect in the B cells as SAP does not appear to be
expressed in B cells, but due to defective CD4+ T cell help. Therefore the EBV
infected blast, cannot switch to a memory phenotype and so provides a continuous
immune stimulus for lymphocyte proliferation that is characteristic of XLP.
It has been suggested that SAP expression may differ between individuals or with
age (Klein and Klein, 1998), and this could explain the age related variation in
response to primary EBV infection. The work we have carried out so far is not
extensive enough to clarify this, although we did notice considerable variation in the
numbers of PBMC expressing SAP between healthy donors. It would certainly be
interesting to investigate SAP expression and immune activation pathways in infants,
but there are considerable ethical difficulties in carrying out studies in healthy
children.
However we are looking for polymorphisms in the SAP gene, which might underlie
the variation in SAP expression which we have documented, and which in turn might
explain the variable clinical response to primary infection in adults. Another
possibility that might underlie a genetic susceptibility to clinical primary EBV
infection is differences in the NK cell KIR family of receptors.
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The KIR family ofNK cell receptors is known to be one of the most polymorphic
regions of the human genome, and several investigators have suggested that this
genetic diversity is driven by common viral infections (Arase and Lanier, 2002). At
present it is not clear whether certain KIR haplotypes are linked to disease
susceptibility; but it would certainly be interesting to investigate this possibility in
relation to clinical outcome of primary EBV infection.
Some of the difficulties we have in understanding the pathogenesis of IM would be
helped by an animal model of IM, such as the rhesus monkey model developed by
Wang (Wang, 2001). In humans we can compare immunological and virological
characteristics between individuals with different clinical responses to infection, and
from this build up an understanding of the relationship between them, as we have
done in this study. However, there are limitations to this approach, which can
establish correlations, but further information would be gained in a system which
allowed controlled manipulation of the factors. For example it would be useful to
quantify the changes in virus specific CD8 cells that occurred over the clinical course
of the illness in animals infected with varied doses of virus. Another useful study
would be to monitor the course of disease in animals depleted of NK cells.
The role of CD4+T cells in the control of primary EBV infection has not yet been
fully elucidated. Therefore another useful addition to the study would be to monitor
CD4+T cells, ideally EBV antigen specific T cells, and relate these findings to
clinical features and viral load. Gamadia and colleagues have recently identified the
early development of antigen specific CD4+ T cell responses as a key difference in
the immune response in those that undergo silent as opposed to clinically overt CMV
infection post transplant (Gamadia et al., 2003). Parallels may occur in primary EBV
infection and it would be interesting to investigate whether mild primary EBV
infection is associated with increased number of virus specific CD4 + T cells.
We suggest that activated T cells expressing CD244 modulate the clinical features of
IM, but control of activation is maintained by concurrent increased expression of
SAP. However, before this occurs NK cells have a critical role in both eliminating
infected B cells and augmenting this antigen specific T cell response via release of
immunomodulatory cytokines. The magnitude of the NK cell response may
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ultimately determine whether primary EBV infection has a subclinical or clinical
outcome.
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10 Future perspectives
It is clear from the data presented in this thesis that the scale of the acquired immune
system is critical to the clinical outcome of primary EBV infection. Additionally, the
data supports a complementary role for NK cells in control ofEBV infected cells and
possibly a link between the 2 components of the immune system. A number of
questions are raised by this data.
Is there a functional difference between CD56bnght cells and CD56dim cells in acute
IM?
Flow cytometric sorting of CD56bnght cells and CD56dim cells in acute IM and
controls, followed either by RT-PCR studies or immunohistochemical staining of
cytospins, would allow assessment of the cytokine profile of each cell type. In
addition, information on serum levels of cytokines, both those involved in NK cell
activation (such as type l interferons) or released from NK cells (INF y), would
clarify the cytokine networks important in NK cell control of EBV.
What is the molecular interaction between NK cells and EBV infected cells?
At present we know little of the molecular details of the interaction between NK cells
and EBV infected cells. We do know that CD244 and CD48 interact in vitro; little is
known of the functional importance of this in vivo. This could be investigated further
by assessing NK cell mediated cytotoxicity of a cell line 1106MEL (Porgador et al.,
1997) transfected (using vaccinia constructs) with individual EBV lytic and latent
genes. Alternatively, monoclonal antibody blocking studies could be carried out
using the model of NK mediated killing of an EBV infected cell line we have
developed (Section 8.3.2.2 page 157). Antibodies to EBV lytic and latent antigens,
as well as antibodies to NK cell surface receptors could be added to the system, and
any inhibition of killing monitored.
Do NK cells have a role in the prevention/treatment of EBV associated tumours?
This could be investigated further in the (SCID) mouse model of BLPD by
monitoring tumour response in mice treated with autologous human NK cell
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infusions. Alternatively, NK cell numbers, function and phenotype could be
monitored in transplant recipients and in parallel their EBV DNA load in the
peripheral blood and incidence of BLPD development.
Does NK KIR receptor usage vary between silent and overt seroconvertors to EBV?
At the end of the MRC study DNA will be available from cases (over 50 in each
group) that have silently seroconverted, cases who have developed IM and
persistently seronegative individuals. It would be useful to investigate differences in
KIR usage between these different groups, and this could be carried out using the
PCR-SSP method recently developed by Uhrberg et al (Uhrberg et al., 1997; Gomez-
Lozano and Vilches, 2002).
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Visit Number Number MRC/ Date of Visit
Date of Birth Doctor
Clinical assessment - Visit 1
Date of first symptoms (incl "prodrome")
Date ofmost severe symptoms
Duration ofmost severe symptoms (days)
Unwell for how long (days)
Presenting features and how long experienced for at
time of presentation to GP









Are you able to attend all your timetabled classes Yes/No
Total hours timetabled per week





Total hours missed due to illness
Is the amount of studying that you do in your own
time normal for you at present?
Yes/No
Are you able to undertake your normal social life? Yes/No
Are you able to undertake your normal exercise
pattern ?
Yes/No
Do you have a part-time job? Yes/No
Hours per week
If yes, give dates absent, or "none" for no time off
1
Physical features
Sore throat Have you experienced
this ever during your
illness
No, not at any point
during illness
Unable to swallow saliva YES/NO
Unable to swallow liquids YES/NO
Unable to swallow soft diet YES/NO


















Do you have any other medical
conditions, the glandular fever
has affected?
Alcohol - units in last week
Alcohol - usual per week
Admitted to hospital / seen in A+E / out-patients?





Temperature student will be given chart and









Spleen size Not palpable Tip Fingers below costal margin
Liver Not palpable Edge Fingers below costal margin
Palpable glands YES/NO cervical Right left both
supraclavicular Right left both
Submandibular Right left both
axilliary Right left both
inguinal Right left both
Tonsils enlarged YES /NO Grade 12 3
Visit Number Number MRC/ Date of Visit
Date of Birth Doctor
3
